Molecular analysis of the HIV-therapy associated lipodystrophy-syndrome by Stankov, Metodi Vasilev
 Molecular analysis of the 
 HIV-therapy associated lipodystrophy-syndrome 
 
 
 
 
 
 
 
 
Der Naturwissenschaftlichen Fakultät der Gottfried Wilhelm Leibniz Universität 
Hannover 
 
zur Erlangung des Grades 
 
Doktor der Naturwissenschaften 
Dr. rer. nat 
 
 
genehmigte Dissertation  
von 
Metodi Vasilev Stankov, Dipl. Mol. Biol. 
geboren am 24.01.1971 in Sofia, Bulgarien 
2007 
 2
 
Referent:  Prof Dr.rer.nat. Walter Müller 
Coreferent:  Prof. Dr. Georg M.N. Behrens 
Day of Promotion: 09.02.2007 
 3
ABBREVIATIONS .......................................................................................................... 7 
ABSTRACT.................................................................................................................... 11 
ZUSAMMENFASSUNG ............................................................................................... 13 
1 INTRODUCTION ....................................................................................................... 15 
2 REVIEW OF THE LITERATURE ............................................................................. 16 
2.1 HAART associated lipodystrophy syndrome ........................................................... 16 
2.1.1 Morphological alterations ...................................................................................... 16 
2.1.2 Metabolic alterations.............................................................................................. 16 
2.1.3 Factors associated with the development of HAART-associated lipodystrophy .. 16 
2.1.4 Proposed pathophysiological mechanisms of lipodystrophy syndrome ................ 17 
2.1.4.1 Retinoic acid binding protein-1 (CRABP-1) mediated inhibition of adipocyte 
differentiation.................................................................................................................. 17 
2.1.4.2 Lamin A/C disturbances ..................................................................................... 17 
2.1.4.3 Local changes in glucocorticoid concentrations................................................. 17 
2.1.4.4 PI induced peripheral adipocyte apoptosis in HIV patients with lipodystrophy 18 
2.1.4.5 PI inhibited differentiation.................................................................................. 18 
2.1.4.6 NRTI induced mitochondrial toxicity................................................................. 18 
2.1.4.6.1 Depletion of mtDNA ....................................................................................... 18 
2.1.4.6.2 Depletion of mRNA......................................................................................... 20 
2.1.4.6.3 Disturbances of the nucleotide pool................................................................. 21 
2.1.4.6.4 Mutations ......................................................................................................... 22 
2.1.4.6.5 Physical interference........................................................................................ 22 
2.1.4.7 Cytokines and adipocytokines ............................................................................ 22 
2.1.4.8 HAART induced selective autonomic neuropathy ............................................. 24 
2.2 Adipose tissue ........................................................................................................... 24 
2.2.1 Functions................................................................................................................ 24 
2.2.1.1 Secretory function............................................................................................... 24 
2.2.1.2 Metabolic function.............................................................................................. 25 
2.2.2 Adipose tissue heterogeneity and plasticity........................................................... 26 
2.2.3 Origin of adipocytes............................................................................................... 26 
2.2.4 Adipocyte differentiation....................................................................................... 26 
2.3 Adipocyte and HAART ............................................................................................ 32 
2.3.1 Effects of PI ........................................................................................................... 32 
2.3.2 Effects of NRTI ..................................................................................................... 33 
 4
2.3.2.1 Effects of NRTI on adipogenesis........................................................................ 33 
2.3.2.2 Effects of NRTI on mtDNA................................................................................ 33 
2.3.2.3 Effects of NRTI on mitochondria (besides mtDNA depletion) .......................... 34 
2.3.3 Other factors contributing to mitochondrial dysfunction in WAT ........................ 34 
2.4 Metabolic complications........................................................................................... 34 
2.4.1 Insulin resistance.................................................................................................... 34 
2.4.2 Dyslipidemia.......................................................................................................... 35 
3 AIMS OF THE STUDY .............................................................................................. 36 
4 MATERIALS AND METODS ................................................................................... 37 
4.1 MATERIALS............................................................................................................ 37 
4.2 METODS.................................................................................................................. 51 
4.2.1 DNA Isolation........................................................................................................ 51 
4.2.2 Total RNA Isolation............................................................................................... 52 
4.2.2.1 Total RNA Isolation from lipid tissues............................................................... 52 
4.2.2.2 Total RNA isolation from no lipid tissues and cells ........................................... 52 
4.2.3 Reverse Transcription ............................................................................................ 53 
4.2.4 Real-Time PCR...................................................................................................... 54 
4.2.5 ELISA .................................................................................................................... 57 
4.2.6 Cell lines ................................................................................................................ 59 
4.2.7 Oil Red O staining ................................................................................................. 63 
4.2.8 Mitochondrial functions......................................................................................... 63 
4.2.8.1 Membrane potential ............................................................................................ 63 
4.2.8.2 Mitochondrial mass............................................................................................. 64 
4.2.9 Propidium iodide staining...................................................................................... 64 
4.2.10 Enzyme activities................................................................................................. 65 
4.2.11 Cloning................................................................................................................. 69 
4.2.12 Animals................................................................................................................ 72 
4.2.13 Drug administration ............................................................................................. 73 
4.2.14 Assessment of body fat mass distribution............................................................ 73 
4.2.15 Collection of tissues............................................................................................. 73 
4.2.16 Glucose tolerance test (GTT)............................................................................... 73 
4.2.17 3H thymidine Assay ............................................................................................. 74 
4.2.18 Statistical methods ............................................................................................... 74 
5 RESULTS .................................................................................................................... 75 
 5
5.1 Relationship of mitochondrial DNA depletion and respiratory chain activity in 
preadipocytes treated with nucleoside-analogue reverse transcriptase inhibitors .......... 75 
5.1.1 Influence of NRTI on adipocyte morphology, differentiation, and triglycerol 
accumulation................................................................................................................... 75 
5.1.2 Molecular analysis of adipocyte differentiation. ................................................... 75 
5.1.3 Effect of NRTI on adiponectin production ............................................................ 77 
5.1.4 Effect of NRTI on mtDNA content in non-proliferating cells............................... 79 
5.1.5 Effect of NRTI on mtDNA content in differentiating or proliferating preadipocytes
........................................................................................................................................ 79 
5.1.6 Effect of NRTI on mtDNA content in HUH 7 cell line......................................... 80 
5.1.7. Association of mtDNA depletion with respiratory chain function ....................... 82 
5.1.8 Effect of NRTI on mtDNA content in human subcutaneous fibroblasts ............... 83 
5.1.9 Association of mtDNA depletion with respiratory chain function in.................... 84 
5.1.10 NRTI effect on mitochondrial mass and function in primary human fibroblasts 85 
5.1.11 Effect of NRTI on mtDNA content in human primary preadipocytes ................ 87 
5.1.12 Association of mtDNA depletion with respiratory chain function in human 
primary preadipocytes..................................................................................................... 89 
5.2 Zidovudine inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells
........................................................................................................................................ 89 
5.2.1 AZT perturbs adipocyte mass through an effect on differentiation-dependent TG 
accumulation. .................................................................................................................. 89 
5.2.2 Mitotic clonal expansion is affected by AZT. ....................................................... 90 
5.2.3 Precursors proliferation is affected by AZT. ......................................................... 91 
5.2.4 Effects of AZT on adipogenic marker expression. ................................................ 93 
5.2.5 Impaired differentiation is confirmed by decrease in adipokines expression and 
secretion. ......................................................................................................................... 93 
5.2.6 AZT effect on adipocyte viability.......................................................................... 94 
5.3 Adipocyte viability and function but not preadipocyte differentiation is 
compromised by IDV...................................................................................................... 96 
5.3.1 IDV affects adipocyte mass but does not affect differentiation-dependent 
accumulation of TG. ....................................................................................................... 96 
5.3.2 IDV does not affect mitotic clonal expansion ....................................................... 96 
5.3.3 Effects of IDV on adipogenic marker expression.................................................. 98 
5.3.4 IDV perturbs adipocyte function ......................................................................... 100 
 6
5.3.5 IDV promotes loss of adipocyte viability ............................................................ 100 
5.3.6 In vivo analyse of HAART on adiponectin production. ...................................... 102 
5.4 Lipoatrophy and ubiquitous mtDNA depletion in mice following long-term NRTI 
traement ........................................................................................................................ 102 
6.4.1 Effects of AZT and d4T on fat amount and distribution in treated mice............. 102 
5.4.2 Effect of d4T and AZT on of body weight acquisition, in young male C57BL/6 
mice............................................................................................................................... 104 
5.4.3 Effect of d4T and AZT on water and food consumption..................................... 104 
d4T and AZT ................................................................................................................ 104 
5.4.4 Effects of therapeutic drug levels d4T on mtDNA content in different tissues... 104 
5.4.5 Effect of d4T on adipokine production................................................................ 105 
5.4.6 Effect of AZT and d4T on mouse insulin sensitivity........................................... 106 
6 DISCUSSION............................................................................................................ 107 
REFERENCES ............................................................................................................. 118 
RESEARCH CONTRIBUTIONS ................................................................................ 142 
PERSONAL DATA...................................................................................................... 144 
ACKNOWLEDGEMENTS.......................................................................................... 146 
Declaration on the dissertation ..................................................................................... 147 
 
Key words:  lipodystrophy, HIV, highly active antiretroviral therapy (HAART) 
Schlagwörter: lipodystrophie, HIV, hochaktiven antiretroviralen therapie (HAART) 
 7
 
ABBREVIATIONS  
ATP Adenosine triphosphate 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
AMPK Adenosine monophosphate kinase 
A-2-P L-Ascorbic acid 2-phosphate 
sesquimagnesium salt hydrate 
 
aP2 Fatty acid binding protein 
Akt (PKB) Protein kinase B 
AZT Zidovudine  
BSA Bovine serum albumin 
BCA Bicinchoninic acid 
C/EBP CCAAT/enhancer-binding protein  
CPT1 Carnitine palmitoyltransferase 1 
CHD Coronary heart disease 
CCCP Carbonyl cyanide m-
chlorophenylhydrazone 
 
CD36 Transporter of fatty acids 
d4T Stavudine 
DHEA Dihydroepiandrosterone 
dTTP Deoxythymidine triphosphate 
dCTP Deoxycytosine triphosphate 
dUTP Deoxyuridine triphosphate 
dsDNA Double-stranded DNA 
DMSO Dimethyl sulfoxide 
DMEM Dulbecco's modified eagle medium  
 8
dNTP Deoxyribonucleotide triphosphate 
DOC Dissolved organic carbon 
ddC Zalcitabine 
ELISA Enzyme-linked immunosorbent assay 
EDTA Ethylenediaminetetraacetic acid 
Earle's BSS Earle's balanced salt solution  
EGTA Ethylene glycol bis(β-aminoethyl ether)-
N,N,N’,N-tetraacetate 
 
ERK MAP-kinase 
ECM Extracellular matrix 
FAS  Fatty acid synthase  
FFA Free fatty acids  
FBS Fetal bovine serum 
FACS Fluorescence activated cell sorting 
FP Prostaglandin F receptor 
FCS Fetal calf serum 
GH Growth hormone 
HAART Highly active antiretroviral therapy 
HDL High-density lipoprotein 
HIV Human immunodeficiency virus  
HBV Hepatitis B virus 
HSL Hormone sensitive lipase  
HCV Hepatitis C virus 
IFN Interferon 
IDV Indinavir 
IL Interleukin  
IBMX 3-Isobutyl-1-methylxanthine 
 9
IPTG Isopropyl-β-D-thiogalactopyranosid 
IR Insulin resistance  
IGF Insulin-like growth factor 
JNK MAP kinase 
LPL Lipoprotein lipase  
LDH Lactate dehydrogenase 
LB Luria-Bertani 
LDL Low density lipoprotein  
LRP Low-density lipoprotein receptor–like 
protein 
 
mtDNA Mitochondrial DNA  
mRNA Messanger RNA  
MRC Mitochondrial respiratory chain 
MTR Mito Tracker Red 
NNRTI Nonnucleoside reverse transcriptase 
inhibitor 
 
NFV Nelfinavir 
NRTI Nucleoside reverse transcriptase inhibitor  
NADH Reduced nicotinamide adenine 
dinucleotide 
 
OD Optical density 
PI Protease inhibitor 
PPAR Peroxisome proliferator-activated receptor 
PAI1 Plasminogen activator inhibitor-1 
PBMC Peripheral blood mononuclear cell 
PCR Polymerase chain reaction  
PBS Phosphate buffered saline 
PEP K-phosphoenolpyruvate 
 10
pref Preadipocyte factor 
PS Penicillin/streptomycin 
PEPCK Phosphoenolpyruvate carboxykinase 
PDGF Platelet-derived growth factor 
PG  Prostaglandin 
Rpm Revelations per minute 
PK Pyruvate kinase 
RTV Ritonavir 
ROS Reactive oxygen species 
RA Retinoic acid 
RT Reverse transcription 
SREBP Sterol regulatory element-binding protein 
SQV Saquinavir 
SDS Sodium dodecyl sulfate 
SCD  Stearoyl-CoA desaturase 
SAT Subcutaneous adipose tissue 
TNF Tumor necrosis factor 
TNF-R Tumor necrosis factor-reseptor 
TZD Thiazolidinedione 
TG Triglycerides 
TK Thymidine kinase 
TGF Transforming growth factor 
WAT White adipose tissue 
X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside 
  
 
 11
ABSTRACT 
The advent of highly active antiretroviral therapy (HAART) including protease 
inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI) in different 
combinations has significantly reduced the morbidity and mortality of HIV-infected 
patients. Unfortunately, HAART has been associated with severe adverse events such as 
fat redistribution, dyslipidaemia, insulin resistance and diabetes mellitus. The aetiology 
of this so called lipodystrophy syndrome appears to be multifactorial. It has been 
hypothesised to consist of drug effects on adipocyte proliferation and differentiation, 
alteration in adipokine and cytokine expression as well as impairment of mitochondrial 
functions. Specifically, mitochondrial DNA (mtDNA) depletion has been proposed as 
an important factor leading to peripheral lipoatrophy in HIV-patients receiving 
antiretroviral therapy. 
We aimed in this study: 1) to explore the molecular mechanisms of the effects of 
different HAART drugs on different in vitro models of adipose tissue metabolism and 
physiology; 2) to investigate the effect of PI and NRTI on adipocyte proliferation, 
differentiation, viability and adipokine production; 3) to assess nucleoside-analogue 
reverse transcriptase inhibitor (NRTI)-mediated mtDNA depletion and to correlate 
mtDNA depletion with the activity of the respiratory chain complexes; 4) to investigate 
the effect of NRTI treatment on mtDNA content of various organs and tissues in a 
murine model as well as to establish a murine model of lipodystrophy. 
3T3-L1 cell line, primary human subcutaneous fibroblasts and preadipocytes 
were exposed to different concentration of PI Indinavir (Crixivan®) and Ritonavir 
(Norvir®) and to NRTI including AZT (Retrovir®), d4T (Zerit®) and ddC (Hivid®) at 
different developmental stages for up to two months. Groups of C57BL/6 mice were 
treated with d4T, AZT or vehicle (5-20 mice per group) for up to 15 weeks with daily 
human doses adjusted for murine body surface area. MtDNA contend was determined 
by Real-Time PCR in liver, muscle, heart, brain, and fat tissue.  
AZT and d4T impaired adiponectin production in vitro at therapeutic Cmax 
concentrations. Susceptibility of preadipocytes to mtDNA depletion was depending on 
cell proliferation and differentiation and mtDNA depletion occurred only after exposure 
to high drug concentration. Under these conditions, d4T led up to 80 % mtDNA 
depletion in both dividing and differentiating preadipocytes whereas AZT had some 
effect only in the latter. Despite mtDNA depletion by NRTI, activities of the respiratory 
chain complexes were found to be unimpaired. High doses of AZT impaired 
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differentiation process through inhibition of clonal expansion. Preadipocyte 
proliferation, clonal expansion and differentiation were unaffected by IDV. This drug 
contributed to adipose tissue atrophy of the in vitro model through promotion of 
adipocyte cell death. Over a time period of 15 weeks animals receiving d4T had less of 
both peripheral as well as central fat. Neither d4T nor AZT had and effect on insulin 
sensitivity. Analysis of mtDNA content revealed depletion of mtDNA in organs 
including the brain (-20%) and fat tissue (-27%) but the most profound and significant 
depletion was evident in muscle (-56%), liver (-64%), and heart (-45%). 
Our results suggest that adipocyte proliferation and/or differentiation is required 
for significant mtDNA depletion. At the same time, these data do not support the 
hypothesis that mtDNA depletion leads to impairment of the respiratory chain function 
in adipocytes. Instead, we provide evidence that AZT contributes to atrophy by 
inhibiting clonal expansion rate and ultimately reducing the overall differentiation 
capacity. We conclude from our studies that IDV and perhaps other PI are able to affect 
cell viability of the 3T3-L1 cell line model of differentiation. This is the first study to 
show fat loss and hypoadiponectinema in mice after treatment with thymidine-
analogues. d4T can cause fat loss without significant mtDNA depletion in fat tissue or 
insulin resistance in mice. 
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ZUSAMMENFASSUNG 
Seit dem Beginn der hochaktiven antiretroviralen Therapie (HAART), die oft aus 
Kombinationen von Proteaseinhibitoren (PI) und nukleosidalen Reversetranskriptase-
Inhibitoren (NRTI) besteht, ist es zu einem signifikanten Rückgang der Morbidität und 
Mortalität von HIV-Patienten gekommen. Leider kann diese Therapie mit 
unerwünschten Nebenwirkungen, wie z.B. Fettverteilungstörungen, Dyslipidämien, 
Insulinresistenz und Diabetes mellitus, verbunden sein. Die Ätiologie dieses sog. 
Lipodystrophie-Syndroms ist offenbar multifaktoriell. Verschiedene Hypothesen gehen 
davon aus, dass sich die Medikament negativ auf die Adipozytendifferenzierung und -
proliferation, die Expression von Adipokinen und Zytokinen sowie die 
Mitochondrienfunktion auswirken. Besonders der Verlust von mitochondrialer DNA 
(mtDNA) ist als wichtiger Faktor für den peripheren Fettverlust antiretroviral 
behandelter HIV-Patienten postuliert worden. 
In dieser Studie sollten die molekularen Mechanismen verschiedener HIV-Medikamente 
auf den Fettstoffwechsel in in vitro Modellen untersucht werden. Zweitens sollte der 
Effekt von PI und NRTI auf die Proliferation, Vitälität und Adipokinproduktion von 
Adipozyten analysiert werden. Drittens sollte die mtDNA-Depletion durch NRTI 
quantifiziert und mit der Aktivität der Atmungskettenkomplexe korreliert werden. 
Schließlich sollte in einem Mausmodell der Effekt einer NRTI-Behandlung auf den 
mtDNA-Gehalt in verschiedenen Organen bestimmt und ein Mausmodell zur 
medikameteninduzierten Lipoatrophie etabliert werden. 
3T3-L1 Zellen, humane Fibroblasten aus dem Subkutangewebe und Präadipozyten 
wurden mit verschiedenen Medikamentenkonzentrationen zu unterschiedlichen 
Entwicklungsphasen mit den PI Indinavir (Crixivan®) und Ritonavir (Norvir®) bzw. mit 
den NRTI AZT (Retrovir®), d4T (Zerit®) und ddI (Hivid®) für bis zu zwei Monaten 
inkubiert. Darüber hinaus wurden C57BL/6 Mäuse (5-20 Tiere per Gruppe) mit d4T, 
AZT oder Plazebo für bis zu 15 Wochen mit Dosierungen behandelte, die den beim 
Menschen verwendeten Medikamentenmengen entsprechen. Anschließend wurde 
mittels Real-Time-PCR in den Organen der Tiere (Leber, Muskel, Herz, Gehirn und 
Fettgewebe) der Gehalt an mtDNA bestimmt.  
Bei therapeutischen Cmax Konzentrationen inhibierten AZT und d4T die Produktion 
von Adiponektin in vitro. Die Depletion von mtDNA in Adipozyten war von ihrer 
Proliferation oder Differenzierung abhängig und trat nur bei höheren 
Medikamentenkonzentrationen auf. Unter diesen Bedingungen führte d4T zu einer 80% 
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mtDNA Depletion in proliferierenden oder differenzierenden Präadipozyten. AZT hatte 
nur einen nur schwachen Effekt auf den mtDNA-Gehalt differenzierender Adipozyten. 
Trotz dieser mtDNA Depletion ließen sich keine Funktionsbeeinträchtigungen der 
Atmungskettenkomplexe objektivieren. Hohe Konzentrationen von AZT reduzierten 
durch eine Inhibition der klonalen Expansion die Differenzierung von Präadipozyten. 
Die Proliferation, klonale Expansion und Differenzierung von Präadipozyten war durch 
Indinavir unbeeinträchtigt, jedoch kam es durch dieses Medikament zu einem 
vermehrten Zelltod der Adipozyten. Mäuse, die über 15 Wochen mit d4T behandelt 
wurden, wiesen weniger peripheres und zentrales Fett auf. Die mtDNA war in diesen 
Tieren im Gehirn (-20%) und im Fettgwebe (-27%), besonders aber im Skelettmuskel (-
56%), in der Leber (-64%) und im Herzmuskel (-45%) vermindert. 
Zusammenfassend deuten die Ergebnisse darauf hin, dass mtDNA Depletion in 
Adipozyten von ihrer Proliferation und/oder Differenzierung abhängig ist. Andererseits 
fanden sich keine Hinweise dafür, dass diese mtDNA Depletion notwendigerweise zu 
einer mitochondrialen Dysfunktion und mit eingeschränkter Atmungskettenaktivität 
führt. AZT trägt wahrscheinlich durch eine Inhibition der klonalen Expansion von 
Präadipozyten bei zur Lipoatrophie. Indinavir, wie vielleicht auch andere PI, verringern 
zusätzlich die Vitalität von Adipozyten. Schließlich gelang es in dieser Arbeit erstmals, 
ein Tiermodell für medikamenteninduzierte periphere Lipoatrophie und 
Hypoadiponektinämie ohne Zeichen der Insulinresistenz zu entwickeln. 
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1 INTRODUCTION 
Clinical use of highly active antiretroviral therapy (HAART) including protease 
inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI) in different 
combinations has significantly reduced the mortality of AIDS patients. NRTI target the 
HIV enzyme reverse transcriptase that in the cytoplasm of the infected cell, reverse 
transcribes the viral RNA genome into double-stranded cDNA. The double-stranded 
cDNA migrates to the nucleus where it is integrated into the cell genome, becoming a 
provirus. NRTI differ from physiological nucleosides only by a minor modification in 
the ribose molecule and act as alternative substrate. Incorporation of NRTI induces 
abortion of DNA synthesis. Until now, all classical HAART regimens have contained 
two NRTI. PI inhibit the enzyme HIV protease which cuts the viral gag-pol polyprotein 
into its functional subunits. Inhibition of HIV protease leads to non-infectious virus 
particles. Combination of NRTI and PI for the first time led to efficient and sustained 
viral suppression and leads to significant immunologic reconstitution. Unfortunately, 
HAART has been associated with severe adverse events such as: fat redistribution, 
dyslipidaemia, insulin resistance and diabetes mellitus. The so called HAART 
associated lipodystrophy syndrome has been suspected to have a multifactorial 
aetiology. This aetiology probably includes: inhibition of adipocyte differentiation, 
alteration of mitochondrial functions, altered leptin and adiponectin production and 
altered cytokine expression. Adipose tissue appears to play a central role in HAART 
associated alterations of lipid metabolism and insulin sensitivity. 
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2 REVIEW OF THE LITERATURE 
 
2.1 HAART associated lipodystrophy syndrome 
HAART associated lipodystrophy syndrome can include the following clinical 
characteristics (1-22): 
2.1.1 Morphological alterations 
• Loss of subcutaneous fat (arms, legs and buttocks) 
• Accumulation of visceral fat 
• Dorsocervical fat pads (Buffalo hump) 
• Breast enlargement (in females) 
2.1.2 Metabolic alterations 
• Insulin-resistance 
• Diabetes mellitus 
• Elevated serum triglycerides (TG) 
• Elevated low-density lipoprotein (LDL)-cholesterol 
• Elevated very low-density lipoprotein (VLDL)-cholesterol 
• Elevated apolipoprotein B and E 
• Reduced high-density lipoprotein (HDL)-cholesterol 
2.1.3 Factors associated with the development of HAART-associated lipodystrophy 
Main factors 
• HIV infection is suspected to play a role in the lipid alterations (23) 
• The use of PI is mainly associated with visceral fat accumulation and metabolic 
alterations (5;12;24-27) 
• The use of NRTI is mainly associated with peripheral fat wasting (9;12;21;28)  
Additional factors 
• Duration of antiretroviral treatment (3;12;22;29) 
• Nadir of CD4 T cells (29) 
• Age (3;29) 
• Nutrition (12) 
• Elevated TG at baseline (12;22) 
• Elevated C-peptide levels (22) 
• Nutritional status (12) 
• HCV co-infection (30;31) 
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2.1.4 Proposed pathophysiological mechanisms of lipodystrophy syndrome 
 
2.1.4.1 Retinoic acid binding protein-1 (CRABP-1) mediated inhibition of 
adipocyte differentiation 
The catalytic domain of HIV-1 protease has been found to be highly homologous to the 
lipid-binding domain of low-density lipoprotein receptor-like protein (LRP) and to the 
retinoic acid-binding domain of cellular retinoic acid binding protein 1 (CRABP-1) 
(13). Retinoic acid isomerizes in cis-9-retinoic acid and activates the nuclear retinoid X 
receptor-α - PPARγ complex. This complex is involved in the regulation of adipocyte 
proliferation and differentiation (32). As CRABP-1 carries retinoic acid, its PI induced 
inhibition may result in ultimate alterations in the process of adipocyte proliferation and 
differentiation (33). Many in vitro studies however disproved this hypothesis. There is 
no structural similarity between the three-dimensional crystal structure of CRABP-1 and 
HIV-1 protease (34). PI bind directly to neither retinoid X receptor-α nor PPARγ 
(35;36). 
 
2.1.4.2 Lamin A/C disturbances 
Phenotypic similarities between HAART lipodystrophy and familial partial 
lipodystrophies have been found in certain aspects. Defects in lamin A/C are considered 
to be the reason for autosomal dominant familial partial lipodystrophies (37). Mutations 
in 1-acylglycerol-3-phosphate O-acyltransferase-2 from other site is the genetic feature 
of autosomal recessive congenital generalized lipodystrophy. Therefore PI-induced 
alteration in the expression and maturation of these or some other homologous genes 
has been hypothesized to be involved in the pathogeneses of HAART lipodystrophy 
(38). 
 
2.1.4.3 Local changes in glucocorticoid concentrations 
HAART lipodystrophy syndrome presents some similarities in body fat redistribution 
with Cushing’s syndrome which led to the hypotheses of eventual participation of the 
hypothalamicpituitary-adrenal axis (39;40). Although some studies argue agains this 
hypotheses as a mechanism of HAART induced fat redistribution, cortisol could be 
locally produced in adipose tissue after 11β-hydroxysteroid dehydrogenase type 1 
conversion of cortisone (41). The expression levels of this enzyme and of glucocorticoid 
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receptors are significantly higher in omental versus subcutaneous fat (42;43), which is 
consistent with the idea that although in patients on HAART serum and urine cortisol 
concentrations are normal, locally increased glucocorticoid levels may be responsible 
for regional adiposity, even without hypercortisolism. Whether or not this mechanism 
contributes to HAART lipodystrophy syndrome currently is not very clear. 
 
2.1.4.4 PI induced peripheral adipocyte apoptosis in HIV patients with 
lipodystrophy 
Histopathologically subcutaneous adipose tissue has been characterized as 
nonencapsulated mature adipose tissue (44). The presence of fibrotic changes excludes 
neoplastic or dysplastic pathology. HAART lipodystrophy has been characterized with 
subcutaneous adipocyte apoptosis (45). Loss of peripheral adipocytes could lead to 
increased fat accumulation in visceral adipocytes with subsequent IR and may partially 
explain the occurrence of lipodystrophy syndrome (13). 
 
2.1.4.5 PI inhibited differentiation 
Certain groups hypothesized that PI effects on sterol regulatory element-binding 
protein-1 (SREBP-1) may interfere with the process of adipocyte differentiation 
(46;47). In contrasts to these in vitro PI studies, a recent human study demonstrated that 
four weeks of IDV has no effect on adipogenic transcription factors expression in 
subcutaneous adipose tissue of healthy HIV-negative volunteers (48). 
 
2.1.4.6 NRTI induced mitochondrial toxicity 
It has been shown that NRTI inhibit the DNA polymerase-γ thereby leading to 
inhibition of mtDNA synthesis resulting in mitochondrial DNA (mtDNA) depletion 
(49). NRTI induced mtDNA depletion may be a reason for a decrease in mitochondrial 
gene expression and ultimate impairment of function as mtDNA encodes 13 
polypeptides, which are subunits of the respiratory chain (MRC) with active role in the 
process of oxidative phosphorylation. Subcutaneous fat samples from patients with 
lipodystrophy demonstrate mtDNA depletion (50-53). 
 
2.1.4.6.1 Depletion of mtDNA 
Both treated and therapy naïve HIV positive patients have been demonstrated to have 
lower mtDNA in comparison to healthy controls (54-59). Pathologies related to 
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mitochondrial toxicity such as hepatic steatosis, myopathy and lactic acidosis occur in 
HIV-positive patients and have been associated with NRTI-induced mtDNA depletion 
(49;60;61). Numerous studies documented mtDNA depletion and mitochondrial ultra-
structure abnormalities in NRTI treated patients (50-53). The fact that some patients 
with inborn mitochondrial diseases present with fat redistribution, directed the attention 
to the eventual role of mitochondrial toxicity in the process of fat redistribution (62;63), 
although marked differences of the phenotypic alteration are evident. Accumulating 
reports about the association of lipoatrophic changes with mtDNA depletion 
(50;51;64;65) led to the hypothesis that, NRTI induced white adipose tissue mtDNA 
depletion may play a role in lipodystrophy pathogenesis (49). Possible mechanisms for 
mtDNA depletion have been provided by in vitro analyses demonstrating direct NRTI 
inhibition of mitochondrial polymerase γ enzyme(51;66-71). Additionally to these in 
vitro experiments the model has been supported by some animal studies (72-76). 
According to DNA polymerase-γ hypothesis NRTI induce a shift in the balance of intra-
mitochondrial pool of native nucleotides that affects the activity of DNA polymerase-γ 
and results in subsequent decrease in mtDNA, mtRNA and the expression of electron 
transport proteins encoded by mtDNA with ultimate effect on cell energetics. Assuming 
that adipose tissue would react in the way other tissues react to the above mentioned 
changes, OXPHOS deficiency in adipocytes may bring reduction of fatty acid synthesis, 
decrease in fatty acid oxidation and apoptosis (77). On the other hand the initiation of 
mtDNA replication depends on an RNA-primed DNA synthesis activity (78). It is 
tempting to hypothesise that at this point NRTI may inhibit DNA polymerase γ reverse 
transcription activity as well. In a principle situation a mtDNA decrease bellow a certain 
threshold for a definite period of time should results in an impairment of electron 
transport and ATP synthesis(79;80). Reduced ATP syntheses in the liver for example, 
requires a reduction of mtDNA below a threshold of about 20–30% of the normal 
mtDNA content (81). Whether this ‘threshold hypotheses’ applies also for adipocytes is 
currently not known. In comparison between lipoatrophic, non-lipodystrophic HIV-
positive patients and HIV-negative control the first group turned out to have 36% and 
43% less mtDNA in the subcutaneous fat than the second and the third group, 
respectively (51). However, at present it is still under discussion whether or not mtDNA 
depletion is involved in the pathogenesis of the HAART induced clinical symptoms and 
DNA polymerase-γ hypothesis alone seems insufficient to explain the lipodystrophy 
syndrome (82). Some studies describing HAART-related mitochondrial toxicity do not 
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find mtDNA depletion. Additionally, there is increasing discrepancy and controversy 
concerning the effect of NRTI-induced mtDNA depletion on mitochondrial function. 
Although some studies in HAART patients correlated positively mtDNA levels and 
mitochondrial activities (83-85) there are many that were unable to establish such 
correlation. The discrepancy has been deepened by recent study in lipodystrophic 
patients demonstrating preservation of multiple mitochondrial enzyme activities despite 
mitochondrial depletion (86). Some of the difficulties to establish correlation come from 
the fact that mitochondrial dysfunction and in particular OXPHOS deficiency can be 
compensated through certain mechanisms such as mitochondrial proliferation (79;87). 
Such proliferatory compensation has already been reported in adipose tissue of patients 
with lipoatrophy (50;88). No correlation has been found in a study paralleling mtDNA 
depletion, cytochrome c oxidase gene expression and enzyme activity (89). 
Contradictory results have been obtained from studies that were able to show an 
association of mtDNA depletion in blood cells of patients with hyperlactataemia and 
lipoatrophy (56;59;90), as others have failed to demonstrate such an effect (91-
93).Taken together these studies suggest additional mechanisms, and several hypotheses 
have been proposed that oxidative damage of mtDNA could contribute to peripheral fat 
loss (94;95). Others suspected NRTI direct inhibition of mitochondrial respiration (96) 
as well as inhibition of ADP/ATP translocase (97), adenylate kinase (98), NADH 
oxidase (99), protein glycosylation (100) and a ‘bystander effect’ (101). 
 
2.1.4.6.2 Depletion of mRNA 
The cause-effect link between mtDNA depletion and mtRNA transcription has been 
questioned by some non-HAART-studies demonstrating normal transcription despite 
severe mtDNA depletion (102;103). This raised the concern that mtDNA depletion does 
not necessarily affect the quantity of mtRNA. On the other hand in peripheral blood 
mononuclear cells (PBMC) from HAART treated patients, decrease in mitochondrial 
gene expression was observed even without mtDNA depletion (89). Direct influence of 
NRTI on mitochondrial gene expression and/or inhibition of mtRNA syntheses has been 
suspected in these cases (104;105). NRTI may directly inhibit the activity of mtRNA 
polymerase or affect the regulation of mitochondrial transcription co-factors (as for 
some of them the regulation is through the process of phosphorylation) and thereby 
disturb the whole process of transcription (106). NRTI may influence nucleotide 
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syntheses and eventually ribonucleotide synthesis in a similar way. The above 
mentioned effects of NRTI would potentially result in altered mtRNA levels. 
 
2.1.4.6.3 Disturbances of the nucleotide pool 
NRTI cellular and mitochondrial internalization, transport, homeostasis and 
phosphorylation are critical steps in their effect on cell metabolism. Their intra-
mitochondrial concentration is absolutely critical for their effect on mtDNA replication 
and transcription, but measurement of intracellular and intra-mitochondrial 
concentrations of NRTI and their metabolites is hampered by technical issues. Although 
it is clear, that NRTI pharmacological effects are exerted by their triphosphates it is 
more and more believed that their toxicological effects are exerted by some of their 
other forms as well. There are three steps in the phosphorilation of most of NRTI, 
particularly the thymidine analogues. Thymidine kinase (TK1, and TK2) phosphorylates 
NRTI to NRTI-MP and then to NRTI-DP. NRTI-DP is phosphorylated to NRTI-TP by 
nucleoside diphosphate kinase (107-110). The balance phosphorylation 
/dephosphorylation is maintained by phosphatases and if disrupted could impact 
mtDNA replication. A critical relation exists between endogenous deoxyribonucleotide 
triphosphate (dNTP) and NRTI triphosphate pools. NRTI act as competitive inhibitors 
and/or chain terminators (111-113) in order to inhibit both HIV-reverse transcriptase 
and mammalian DNA polymerase-γ (113-115). Competitive inhibition results from the 
competition of NRTI and endogenous nucleotides at the nucleotide-binding site of DNA 
polymerase-γ leading to inhibition of mtDNA replication. MtDNA abnormalities have 
been documented in patients with inherited thymidine phosphorylase deficiencies 
(116;117) suggesting that eventual imbalances in the mitochondrial nucleotide pool may 
result in mtDNA disturbances. A wide variety of nucleic acid pathways depend on the 
endogenous nucleoside/nucleotide pools and could be affected if NRTI disrupt the 
balance. AZT in its non-phosphorylated form has been shown to inhibit thymidine 
phosphorylation in certain organs which eventually may disrupt the substrate supply of 
deoxythymidine triphosphate (dTTP) for mtDNA replication (118-120). The proper 
function of MRC is very important for the synthesis of pyrimidine nucleotides (121) and 
if disrupted may result in decrease in ATP production with subsequent impairment of 
pyrimidine synthesis and phosphorylation (122). Uridines ability to rescues in vitro 
mtDNA depletion induced by the pyrimidine analogues such as d4T, AZT, and ddC 
supports this hypotheses (57;123)  
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2.1.4.6.4 Mutations  
Apart from the quantity, mtDNA quality is also a very important feature of this genetic 
information. In the process of cell aging mitochondrial DNA mutations accumulate 
gradually (62;79;80). This accumulation is explained with the fact that mitochondrial 
DNA is much more vulnerable than nuclear DNA. As mitochondria are powerful source 
of reactive oxygen species (ROS), mtDNA is exposed to very strong oxidative stress. 
Oxidative phosphorylation is based on the negative membrane potential. This negative 
membrane potential at the matrix side leads to high concentration of lipophilic cations 
inside mitochondria and makes drugs that are lipophilic cations prone to damage this 
region. In connection to HAART some groups reported mtDNA mutations in patients 
blood (124), others found mtDNA deletions (125;126) and still others suggested NRTI 
impairment of mitochondrial energy-production, cellular redox misbalance and affected 
mtDNA integrity(127). 
 
2.1.4.6.5 Physical interference 
Interestingly, AZT has been found to induce in vitro reduction in mitochondrial 
membrane potential even without mtDNA depletion (128) and to have a short term 
effect on the MRC (76) and ATP production (127). These observations led to the 
speculation that NRTI interfere physically with the membrane structure. ddC increased 
the production of reactive oxygen species (ROS) and decreased ATP in a murine model 
long before any detectable mtDNA depletion (129). 
 
2.1.4.7 Cytokines and adipocytokines  
Misbalanced cytokine expression has been suggested to play a role in the pathogeneses 
of peripheral lipoatrophy. Although in the normal course of HIV progression the 
number of Tumor necrosis factor-α (TNF-α) producing T cells progressively decreases 
through apoptosis (130), HAART alleviates this natural process and leads to their 
accumulation (131). HAART has been associated with dysregulation of TNF-α 
producing T cells, and this association has been very persuasive in the settings of 
lipodystrophy syndrome. As the physiological regulation of TNF-α synthesis involves 
apoptosis, the increased potential of TNF-α production of some CD4 and CD8 T cells 
helps them to escape activation-induced apoptosis, which explains their HAART 
associated accumulation. The amount of TNF-α CD8 T cell precursors has been 
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associated with TG, cholesterol and apoB/Apo-A1 ratio in the setting of HAART 
lipodystrophy (131). In vitro TNF-α affects mitochondria, impairs the function of MRC, 
and increases ROS production (132;133). The mechanism has been hypothesised to be 
either TNF-α binding to its cell surface receptor or to a 60 kD protein of the inner 
mitochondrial membrane (134). Although TNF-α overexpression in mice was 
associated with some heart mtDNA damage, suggesting impaired capacity of mtDNA 
repair or increase in ROS formation, to date there is no confirmation that direct 
interaction of mitochondrial components and TNF-α is responsible for any kind of 
mitochondrial dysfunction (135). 
In vitro models of preadipocyte differentiation demonstrated antiadipogenic effect of 
inflammatory cytokines. Changes in adipose tissue as in the state of obesity or 
lipoatrophy are associated with altered cytokine and adipocytokine secretion. Similar 
alterations are observed in HAART lipodystrophy. Expression profiles of fat biopsies 
from lipodistrophic HAART treated patients revealed increase in TNF-α and IL-6 
expression. The increased expression of these cytokines was positively correlated with 
cell apoptosis (136). Certain TNF-α gene polymorphisms have been also associated 
with lipodystrophy establishing once more the link between this cytokine and the 
pathology (137). TNF-α is able to directly inhibit the autophosphorylation of insulin 
receptors (138). It has been suggested that TNF-α inhibitory effect on adipogenesis is 
mediated by TNF-α-R1 which activates ERK pathway (139). In vitro TNF-α is able to 
inhibit the expression of PPARγ and C/EBPα(140), as well as GLUT4 and lipoprotein 
lipase (LPL), which very well correspond to the induced inhibition of differentiation 
(141). TNF-α-induces lipolysis through TNF-α-R1, JNK and p44/42 mediated 
activation of MAPK family (142). In HIV as in other viral infections plasma interferon-
α (IFN-α) levels have been found to increase (143;144). Plasma concentrations of IFN-α 
in HAART patients are much higher than in controls and have been associated with 
lipodystrophy (145;146). The immune function of interferons is to provide resistance to 
viral infections and to regulate the immune response (147). On the other hand IFN-α 
possesses a very complex metabolic function in the regulation of lipid metabolism: it 
reduces TG clearance, suppresses LPL activity, and stimulates lipolyses and liver 
lipogenesis. It also influences glucagon, cortisol and noradrenaline metabolism, which 
makes the involvement of IFN-α in lipodystrophy syndrome highly probable 
(39;40;42;43;148;149). Last but not least the expression of critical adipokines such as 
leptin and adiponectin has been found to be reduced under HAART (46;136;150-152). 
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2.1.4.8 HAART induced selective autonomic neuropathy  
Adipose tissue is innervated both by sympathetic as well as parasympathetic nerves. 
Activation of these nerves decreases or increases fat accumulation. It has been 
hypothesized that selective autonomic neuropathy may be the reason for the fat 
redistribution in HAART-lypodistrophy (153). Indeed, in the hypothalamic area, 
sympathetic and parasympathetic nuclei are organized in a way that, they separate 
different sets of neurons towards intra-abdominal and subcutaneous fat (154). HAART 
neurotoxicity in some particular sets of neurons may result in selective fat loss or/and 
fat accumulation in certain parts of the body (155). 
 
2.2 Adipose tissue 
Studying the mechanism of adipocyte differentiation helps understand the cellular and 
molecular mechanisms of adipose tissue development and behaviour in physiological 
and pathophysiological states and may be an important tool in the development of 
therapeutic strategies for the treatment and prevention of adipose pathology. 
 
2.2.1 Functions 
 
2.2.1.1 Secretory function 
Mature adipocytes store energy under hormonal control. They secrete a wide variety of 
factors that play a role in processes such as appetite regulation, vascular diseases and 
immunological reactions. Adipocytes have been characterized as endocrine as well as 
paracrine/autocrine cells. White adipose tissue (WAT) not only plays a role in numerous 
physiological processes, but autoregulates its own growth and development. Adipocyte 
secreted hormone leptin participates in the regulation of body fat mass. Eventual 
decrease/increase in fat stores is accompanied by corresponding decrease/increase in 
leptin levels followed by a subsequent increased/decrease in food intake (156;157). 
Leptin is able to modulate insulin effects at the level of liver (158). It modulates 
adrenocortical steroidogenesis (159) and the ovary steroid production (160). Leptin is 
involved in haematopoietic and immune system development as well as in the processes 
of reproduction (161-164). Both human and murine obesity have been characterized 
with high levels of leptin. Another adipocyte secreted hormone is adiponectin (165). 
Adiponectin plasma blood levels have been positively correlated with adipose content 
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(166). There are two receptors AdipoR1 and R2 (167). In murine models adiponectin 
enhances free fatty acids (FFA) oxidation at the level of muscle (168). Patients with 
type 2 diabetics demonstrate low adiponectin levels (169). Adiponectin is considered to 
predominantly promote the effect of insulin. Adipocytes secret TNF-α, which contribute 
to the development of IR, inhibits adipocyte differentiation and has a negative impact on 
the specific adipocyte genes expression (138;170-177). Adipocytes secret immune 
system-related proteins such as acylation stimulation protein (ASP), which results from 
the interaction of complement factors (D, B and C3) (178). This factor stimulates 
glucose transport and TG synthesis (179-181). Some adipocyte secreted proteins have a 
vascular function. Angiotensinogen regulates the blood supply of adipose tissue and the 
efflux of FFA (182;183). Angiotensin II a derivative of angiotensinogen stimulates 
mature adipocytes to produce prostacyclin. This is considered to be a 
paracrine/autocrine mechanism to promote adipocyte differentiation (184). Angiotensin 
II influences positively the process of lipogenesis and modulates adipocyte lipid 
synthesis and subsequent storage (185). Another factor with vascular function is 
plasminogen activator inhibitor type 1 (PAI-1 ) (183). Subcutaneous fat has lower levels 
of PAI-1 than intra abdominal. PAI-1 levels have been found to be increased in obesity 
(186;187).  
 
2.2.1.2 Metabolic function 
In addition to their secretory and endocrine functions adipocytes take part in energy 
metabolism as well. WAT, depending on the situation, synthesises and accumulates 
and/or degrades TG (188). Lipid accumulation is either through direct uptake of 
circulating lipoprotein-TG particles after LPL hydrolyses or through de novo synthesis 
from glucose. LPL hydrolyses lipoprotein-TG particles into FFA and with the help of 
fatty acid binding proteins they are transported into the adipocyte. GLUT4 transport the 
glucose for the de novo synthesis of TG. First pyruvate and glycerol-3-phosphate are 
synthesised. Pyruvate takes part in the formation of acetyl-CoA. Acetyl-CoA 
carboxylase (ACC) controls the conversion of acetyl-CoA into malonyl-CoA. Fatty acid 
synthase (FAS) takes part in the formation of long chains of fatty acids. Insulin controls 
these anabolic pathways. Hormone sensitive lipase (HSL) hydrolyzes TG into FFA and 
monoacylglycerol. Monoacylglycerol is also finally converted into glycerol. Lipolysis is 
controlled hormonally by noradrenaline and adrenaline when the insulin levels are low 
(189).  
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2.2.2 Adipose tissue heterogeneity and plasticity 
WAT varies in volume and cell number. Anabolic or catabolic conditions may influence 
the size of adipocytes and induce either hypertrophy or hypotrophy (190;191). The 
number of adipocytes depends on preadipocyte proliferation and differentiation as well 
as on cell loss. Differentiation has been found to take place even in adult mammals 
(192). In adults differentiation is age and fat depot volume dependant. The volume of 
the fat depot depends on lipolytic factors (catecholamines, GH and TNF-α) and on 
lipogenic factors (insulin and glucocorticoids). The Adipocyte number depends on 
preadipocyte proliferation, differentiation, dedifferentiation and apoptosis(74;188;193). 
In vitro adipocyte apoptosis has been demonstrated to be induced by TNF-α (194) and 
growth factor deprivation. On the other hand insulin prevents this process (195). 
Different fat depots react on a different way to factors such as GH, insulin, 
catecholamines, IL-6 and TNF-α (196). 
 
2.2.3 Origin of adipocytes 
Adipocyte lineage derives from embryonic stem cell precursors. These precursors have 
the potential to differentiate into several mesodermal cell types (myocytes, osteoblasts, 
chondrocytes and adipocytes). The precise molecular mechanism of the commitment to 
adipocyte lineage is not very clear. WAT development starts at birth and depends on the 
species and the fat depot (197-200). Different fat pads demonstrate a wide variety of 
molecular and biochemical differences (43;201-205). Fat cell size and fat cell number 
increase after birth and adipogenesis persists throughout the whole life (206-209). In 
vitro experiments demonstrate that fat cell precursors isolated from adult WAT can still 
be differentiated (210-216). 
 
2.2.4 Adipocyte differentiation 
 
2.2.4.1 Models of differentiation 
In order to dissect the molecular and cellular events characterizing differentiation 
scientists need good models. Preadipose cell lines and isolated primary preadipocytes 
are already committed to the adipocyte lineage. 3T3-F442A and 3T3-L1 are the most 
widely used cell lines (217-219). Ob17 cells generated from (ob/ob) mice are another 
cell model (220). Mature adipocytes can be generated through in vitro differentiation of 
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embryonic stem cells (ES) (221). It is worth mentioning that in vitro-differentiated 
adipocytes possess many of the characteristics of the in vivo adipocytes (222;223). Of 
course primary cultures have to be used to validate results from preadipose cell lines, 
they are diploid and reflect better the in vivo situation. Although adipocyte primary 
cultures have the disadvantage that they are comprised of heterogeneous stromal 
vascular preadipose cells, 100% differentiation is possible under proper stimulation 
(216;224;225). At proliferation stage both preadipocyte lines and primary preadipocytes 
are fibroblasts like cells. In order to acquire the biochemical and morphological 
characteristics of mature adipocyte they require proper stimulation. Although very often 
different adipocyte cell models require different stimulation, there are some cell lines 
that are stimulated in the same manner as the primary precursors. For example 3T3-L1 
cell line and primary human preadipocytes require the same stimulation: insulin, 
glucocorticoids and 3-isobutyl-1-methylxanthine (IBMX) (203;213;214;216;224;226-
229). 
 
2.2.4.2 Process of differentiation 
The beginning of preadipocyte conversion requires them to exit the cell cycle. 
Acquisition of an adipocyte phenotype is characterized by early, intermediate, and late 
markers of differentiation as well as progressive TG accumulation. These changes are 
predominantly achieved at the transcriptional level, and in rare particular cases at the 
level of posttranscriptional regulation (230;231). Differentiation process consists of: 
activation of genes necessary for differentiation and repression of genes inhibiting 
adipogenesis. Most of the information about the changes in gene expression during 
different stages of adipocyte differentiation has been derived from preadipose cell lines. 
To date there is only limited information about the molecular events accompanying 
primary preadipocyte differentiation.  
 
2.2.4.2.1 Growth arrest  
It is believed that in both primary preadipocytes and preadipose cell lines, 
differentiation requires growth arrest(232). Transcription factors such as C/EBPα and 
PPARγ are involved in the process of growth arrest. C/EBPα contributes through its 
antimitotic activity (233), it increase mRNA and protein levels of p21/SDI-1 and thus 
inhibits the cell growth (234). PPARγ is able to induce growth arrest in fibroblasts most 
probably in cooperation with C/EBPα (235). It has been hypothesised that although 
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C/EBPα and PPARγ expression levels increase in the process of differentiation, they are 
already high enough in preadipocytes to induce growth arrest.  
 
2.2.4.2.2 Clonal expansion  
The continuation of differentiation process after preadipocyte growth arrest depends on 
the availability of appropriate mitogenic and adipogenic signals. Preadipose cell lines 
undergo one or two rounds of DNA replication and cell division after growth 
arrest(232). It has been shown that inhibition of DNA synthesis at this stage inhibits the 
differentiation into fat cells(236-238). The drug rapamycin is able to inhibit the process 
of clonal expansion. This inhibition interferes with the subsequent adipocyte 
differentiation confirming the critical role of clonal expansion in 3T3-L1 differentiation 
model. Isolated primary human preadipocytes differentiate without cell division, giving 
rise to the speculation that probably they have already undergone this critical clonal 
expansion in vivo (239). Clonal expansion is characterized with temporal increase in the 
levels of the phosphatase inhibitor HA2. If constitutive expressed during clonal 
expansion this inhibitor blocks differentiation. Constitutive expressions during later 
stages of differentiation doesn’t have this effect (240).  
 
2.2.4.2.3 Early changes in gene expression  
Growth arrest and clonal expansion are accompanied with changes in the pattern of 
gene expression. The expression of LPL increases spontaneously at confluence 
(192;215;236;238;241-243). This factor is secreted by mature adipocytes and controls 
lipid accumulation (244;245). The early phases are characterised with a temporal 
increase in C/EBPβ and C/EBPδ expression (246-248). An increase in the not adipocyte 
specific PPARδ expression precedes that of PPARγ (249). Although PPARγ expression 
reaches its maximum in mature adipocytes, it increases already somewhere about day 
second after the hormonal induction of differentiation (246;250). The early induced 
C/EBPβ and C/EBPδ expression decreases at the moment when C/EBPα expression 
increases followed by a rise in the expression of a wide variety of adipocyte-specific 
genes (246;248;251). SREBP-1c is also induced in early differentiation process. 
SREBP-1c takes part in cholesterol metabolism and influences adipocyte gene 
expression (252-254). Preadipocyte factor-1 (pref-1) which maintains the preadipocyte 
phenotype, decreases during differentiation (255-257). Adipocyte differentiation is 
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characterised with drastic changes in shape, morphology and adipocyte-specific gene 
expression. Expression of genes such as actin and tubulin decreases (258). The 
occurring changes in cytoskeletal and Extracellular matrix (ECM) components 
eventually affect the expression and action of PPARs and/or C/EBPs.  
 
 
 
Figure A Progression of 3T3-L1 preadipocyte differentiation. The major identified events of 
preadipocyte differentiation are presented chronologically. Areas labelled by gene names represent 
periods of gene expression during the differentiation program. The distinct stages of differentiation (very 
early, early, intermediate and late) are also provided (259). 
 
2.2.4.2.4 Terminal Differentiation 
Acquisition of insulin sensitivity and increase in de novo lipogenesis are characteristic 
features of terminal differentiation. This stage presents marked increase in mRNA, 
protein level and activity of many enzymes involved in TG metabolism: ATP citrate 
lyase, glycerol-3-phosphate acyltransferase, malic enzyme, fatty acid synthase, acetyl-
CoA carboxylase, stearoyl-CoA desaturase, glycerol-3-phosphate dehydrogenase (260-
262). The syntheses of certain factors such as perilipin (protein associated with lipid 
droplets), fatty acid binding protein (aP2) and transporter of fatty acids (CD36) 
increases (262-266). The occurring increase in insulin sensitivity is accompanied with 
concomitant increase in glucose transporters and the amount of insulin and adrenergic 
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receptors (267-271). Adipocytes secrete a lot of factors such as adiponectin, leptin, 
adipsin, monotubulin, PAI -1 and angiotensinogen II (185;187;242;272-275). The 
expression of many genes such as leptin, GLUT4, stearoyl-CoA desaturase (SCD1), aP2 
and phosphoenolpyruvate carboxykinase (PEPCK) is under the control of PPARγ and 
C/EBPα (276-280). A process called dedifferentiation has also been suggested. During 
this process adipocytes reacquire preadipocyte characteristics (173;175;281). However 
to date it is not clear, whether or not reversion to a preadipose phenotype exists in vivo. 
 
2.2.4.2.5 Factors influencing differentiation 
GH promotes differentiation and turns preadipocytes sensitive to the mitogenic effects 
of insulin-like growth factor-I (IGF)-I which are necessary for clonal expansion (282-
284). GH is also hypothesised to be involved in adipose conversion through the 
promotion of antimitogenic state (282;285). GH possesses lipolitic activity and 
eventually antiadipogenic. IGF-I from other site plays a role in the differentiation of 
3T3-L1 preadipocyte as well as primary cultures (216;286-289). Insulin and growth 
factors activated serine/threonine kinase Akt (PKB) also takes part in differentiation 
process. Akt is a downstream factor of phosphatidylinositol 3-kinase pathway. 
Constitutive expression of Akt in 3T3-L1 preadipocytes has been shown to induce 
spontaneous differentiation even in the absence of differentiation stimulus 
(Dexamethasone(DEX)/IBMX/insulin) (290). Growth factors and cytokines are mostly 
inhibitors of differentiation. Transforming growth factor (TGF)α for example has been 
shown to inhibit differentiation (291;292). EGF I has also been characterised as an 
inhibitor of differentiation (292-294). Contradictory reports exist concerning the effect 
of platelet-derived growth factor (PDGF) ranging from inhibition to stimulation of 
differentiation (288;295-297). TGFβ has been found to indisputably inhibit 
differentiation process (210;294;298-300). Other inhibitors of differentiation are 
interleukin-1β and interferon-γ (301-303). TNF-α is a negative regulator of LPL and 
inhibitor of adipocyte differentiation (173;174) Its antiadipogenic activity may be due to 
its downregulation of C/EBPα and PPARγ expression, and upregulation of myc 
expression (171;304-307). The effect of the superfamily of nuclear hormone on 
adipocyte differentiation is not very clear. In principle they act through binding to 
intracellular hormone receptors. DEX (a synthetic glucocorticoid) is a component of the 
routine differentiation cocktail (203;210;211;213;214;308-311). Glucocorticoids induce 
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expression of C/EBPδ followed by the formation of C/EBPδ-C/EBPβ heterodimer and 
ultimately expression of PPARγ (247). Interestingly, at supraphysiological 
concentrations they inhibit adipocyte differentiation (213;312). Retinoic acids (RA) 
inhibit C/EBPβ expression with subsequently inhibition of C/EBPα and PPARγ 
expression (250;313;314). On the other hand 3,3',5-triiodothyronine effect on 
preadipocyte differentiation is restricted to Ob17 cell line and it has no effect on other 
models (213;214;225;227;228;288;315-317). 
Adipocytes as well as preadipocytes are able to produce prostaglandins (PGs) (318;319) 
with various functions. Prostaglandin E2 has been shown to have an antilipolytic effect. 
PGF2α and PGI2 have been characterized to act as modulators of differentiation process. 
Prostaglandin D2 functions as an adipogenic signals with a stimulatory effect on 
differentiation (246;320). Prostacyclin (PGI2) function as an adipogenic effector as well 
(294;321;322) with clear activatory effect on PPARs (246;323;324). On the other hand 
prostaglandin F2α inhibits differentiation (294;319;325-328) and prostanoid receptor 
(FP) is also involved in the inhibition of differentiation (328;329). PGE2 and PGD2 have 
no clearly defined role in the process of preadipocyte differentiation (176;329). 
Concerning the effect of cAMP on adiposity differentiation we have to mention that 
IBMX is used in vitro as a differentiation stimulus. IBMX increases the expression of 
C/EBPβ (330). And although it is suspected that IBMX acts through stimulation of 
cAMP accumulation (331;332) the mechanism of its action is still unknown. 
Some studies demonstrated that pref-1, which is an EGF repeat-containing 
transmembrane protein, is able to inhibit adipocyte differentiation (333). It has been 
hypothesised that pref-1 links the cell interior to the differentiation signals from the 
extracellular environment (256;257;334). In mature adipocytes pref-1 is almost 
undetectable. Its expression is downregulated by FCS and it is suspected that pref-
1inhibits adipocyte differentiation through unique mechanism (333). 
There is a link between exogenous hormones and transcriptional regulators. In contrast, 
knowledge of the molecular mechanisms regarding the effect of the ECM on adipocyte 
differentiation is lacking. The molecular mechanisms of ECM effect on adipocyte 
differentiation are very important for our understanding of how is differentiation really 
going in tissues. ECM components as well as cell adhesion molecules modify the 
interaction between cells and environment and affects differentiation and migration. 
ECM alters cell situation and exposes the cell surface to different factors of the 
environment (335). Components of ECM interact with growth factors (336). Some 
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authors hypothesised cytoskeleton connection between nuclear matrix and ECM (337). 
To date there is not much information about how ECM influences adipocyte 
differentiation. During adipocyte differentiation, there are changes in cytoskeletal 
components, cell morphology, and the type of secreted ECM components (338). 
 
2.3 Adipocyte and HAART 
 
In vivo studies in HIV patients have three main disadvantages: 
• Complexity 
• Simultaneous use of several anti-retroviral drug classes 
• Difficulty in obtaining tissue material 
 
In vitro studies: 
• Can be performed with well characterized adipocyte cell lines (3T3-L1 or 
3T3F442A) to investigate drug effects on individual differentiation steps and 
events. 
• Clarify the influence of individual molecules on adipocyte functions 
• Are easy to perform, however, do not always parallel the in vivo situation 
 
2.3.1 Effects of PI 
In vitro PI have been found to affect adipogenesis, adipocyte functions, insulin 
sensitivity and adipocyte apoptosis. In terms of insulin sensitivity it has been shown that 
short nelfinavir (NFV) incubation, inhibits insulin signalling (339;340), and that IDV 
has a rapid and reversible inhibitory effect on GLUT4, independent of insulin signalling 
(339;341;342). As several PI have been found to inhibit in vitro adipocyte 
differentiation (35;36;343-345), some groups proposed that PI interfere with SREBP-1 
maturation (47;346) with subsequent effect on expression of genes such as PPARγ, 
C/EBPα and FAS (47;346;347). For example, IDV inhibits in vitro the expression LPL 
and FAS, both downstream factors of SREBP-1 (344). On the other hand some PI were 
suggested to impair in vitro lamin A/C maturation leading to disruption of nuclear 
architecture. The disrupted nuclear architecture has been hypothesised to induce 
SREBP-1 nuclear dislocation and ultimately adipocyte dysfunction (38). 
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2.3.2 Effects of NRTI 
 
2.3.2.1 Effects of NRTI on adipogenesis 
Subcutaneous abdominal adipose tissue from lipoatrophic HAART treated patients 
contains higher percent of small adipocytes in comparison to control fat and 
demonstrates decreased expression of the adipogenic transcription factors C/EBPβ, 
C/EBPα, PPARγ and SREBP-1c (348). The in vitro experiments targeting elucidation of 
the above mentioned changes in adipose tissue brought however some contradictory 
results. One group demonstrated no effect of d4T on 3T3-L1 lipid accumulation even in 
combination with some PI (346), when other showed that d4T and didanosine (ddI) 
affect the lipid accumulation and increase the rate of adipocyte cell death in 3T3-F442A 
adipocytes without effect on differentiation process and insulin sensitivity (349). A third 
group however found NRTI to interfere with 3T3-F442A adipocytes differentiation 
(345). In both cell lines d4T and AZT intracellular phosphorylation has been confirmed 
(350). 
Some increase in the level of adipocyte apoptosis in subcutaneous adipose tissue from 
HAART patients has been reported (351) which could be a result from HAART-induced 
cytokine overexpression and/or mitochondrial toxicity. 
 
2.3.2.2 Effects of NRTI on mtDNA 
Numerous pathological alterations related to mitochondrial toxicity such as hepatic 
steatosis, myopathy and lactic acidosis have been diagnosed in HAART treated patients 
and have been predominantly associated with NRTI-induced mtDNA depletion 
(49;60;61). In vitro studies demonstrated that d4T concentrations near Cmax for 4 days 
reduce the mtDNA content in CEM cells by 50% (352) and 25 days d4T (36 µM) 
incubation reduce the mtDNA content of HepG2 hepatoma cells by half (353). Some 
inborn mitochondrial diseases have been associated with fat redistribution although not 
similar to the HAART associated one (62;63). As mtDNA depletion and mitochondrial 
ultra-structure abnormalities have been found in NRTI treated patients (50-53), NRTI 
induced WAT mtDNA depletion has been suggested to play a role in lipodystrophy 
pathogenesis (49). Some studies correlated (51), but others did not, the lipoatrophy with 
subcutaneous fat mtDNA depletion, suggesting that mtDNA depletion may not be the 
main mechanism of NRTI induced lipoatrophy (50;53). Several studies found normal 
mtDNA levels in HAART treated patients with lipodystrophy (126;354-356). So far the 
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link between NRTI-induced mtDNA depletion and impairment of oxidative 
phosphorylation (OXPHOS) hasn’t been established. Eventual OXPHOS deficiency in 
adipocytes could be accompanied by reduction in fatty acid synthesis, decrease in the 
oxidation of fatty acids and apoptosis (77). Some studies suggest that mitochondrial 
dysfunction like impaired OXPHOS may be compensated through mechanisms such as 
mitochondrial proliferation (79;87). Such compensation has been reported in adipose 
tissue of lipoatrophic HAART treated patient (51;88).  
 
2.3.2.3 Effects of NRTI on mitochondria (besides mtDNA depletion) 
It is considered that NRTI may cause mtDNA oxidative damage (95;357). Furthermore 
some heteroplasmic mtDNA point mutations as well as multiple deletions in mtDNA 
have been reported in connection to NRTI treatment (124;355;356). On the other hand 
NRTI have been also related to direct inhibition of mitochondrial respiration (96). 
Another mechanism contributed to NRTI adverse effects on mitochondria is inhibition 
of ADP/ATP translocase (97). Some in vivo alteration in fatty acid and lipid metabolism 
unrelated to mtDNA content have been also documented (74;81). 
 
2.3.3 Other factors contributing to mitochondrial dysfunction in WAT 
TNF-α has been found to be able to affect mitochondrial function and to cause mtDNA 
damage. On the other hand the protease inhibitor RTV has been reported to induce 
mtDNA damage in human endothelial cells (358). Diabetes has also been involved in 
mtDNA damage as different tissues of diabetic patient presented mtDNA damage such 
as mtDNA depletion and multiple mtDNA deletions (359-361). 
 
2.4 Metabolic complications 
Although HAART has enormously improved the prognosis and survival of HIV 
infected patients, it has been associated with metabolic complications like IR, 
dyslipidemia, and fat redistribution and the term HAART-lipodystrophy syndrome has 
been introduced to in order to describe these pathological complications. 
 
2.4.1 Insulin resistance 
IR and impaired glucose tolerance are among the major metabolic abnormalities in 
HAART-lipodystrophy syndrome (362;363). These alterations have been associated 
with atherogenic lipid profiles which contribute to an independent risk of cardiovascular 
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disease (364). Even diabetes has been reported in association with the therapy (149). 
Disturbances in glucose homeostasis are very often accompanied by fat redistribution in 
HAART treated patients (149;365). In vitro studies demonstrated direct effect of some 
PI on insulin sensitivity(366). However, recent new results surprisingly demonstrated 
increased glucose uptake from subcutaneous adipose tissue (SAT) from lipoathrophic 
patients on a PI based regimen (367). This observation is not in line with hypothesis in 
which lipoatrophy is induced through PI generated blockade of insulin-stimulated 
glucose uptake in adipose tissue. This increased glucose uptake in subcutaneous fat of 
lipoatrophic patients may even compensate for the fat loss. Nevertheless the whole 
picture is that in the settings of HAART-induced lipodystrophy, IR correlates with 
decrease in subcutaneous and increase in intra abdominal fat (368;369), and there are 
plenty of studies confirming such correlation (149;368;370-372). The apparent increase 
in lipolysis and the inability of insulin to decrease FFA under such conditions argue in 
favour of eventual IR at the level of adipose tissue as well (373;374). Even genetic 
forms of lipoatrophy (Beradinelli-Seip syndrome) present IR (348).  
 
2.4.2 Dyslipidemia 
Lipid disturbances are commonly seen in HIV-infected patients with alterations like 
hypertriglyceridemia reported even before the introduction of HAART (144). Decreased 
TG clearance in combination with increased syntheses of VLDL in the liver were also 
commonly reported (375). In the era of HAART hypertriglyceridemia has been 
associated with PI use and has been induced by RTV in HIV-negative individuals (26). 
The HAART-associated lipodystrophy has been also associated with 
hypertriglyceridemia, and decrease of high-density lipoprotein (HDL) and increase in 
LDL cholesterol (362-364). Fat redistribution itself is frequently accompanied with 
hypertriglyceridemia and low HDL (149;365). The combination of high LDL together 
with low HDL is a constellation well known to be associated with an increased risk of 
coronary heart disease (CHD). 
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3 AIMS OF THE STUDY  
 
The aims of our study were to address the following issues: 
 
Do NRTI and PI affect adipocyte morphology, differentiation and TG accumulation?  
 
Is the gene expression during adipogenesis altered as a result of antiretroviral drugs 
effect on in vitro models of differentiation? 
 
Do NRTI deplete mtDNA content in adipocyte cell line models, adipocyte primary 
cultures and in vivo murine models? 
 
What influence does adipocyte developmental stage have on NRTI-induced mtDNA 
depletion? 
 
Does mtDNA depletion correlate with impairment of respiratory chain enzyme activity, 
mitochondrial membrane potential and cell viability? 
 
Do antiretroviral drugs affect circulating concentration of adiponectin and its expression 
in adipocyte and murine models? 
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4 MATERIALS AND METODS 
4.1 MATERIALS 
4.1.1 PCR  
DNeasy Tissue Kit (50)  Qiagen, Hilden 
RNeasy Lipid Tissue Mini Kit (50) Qiagen, Hilden 
RNeasy Protect Mini Kit (50)  Qiagen, Hilden 
Omniscript RT Kit (200)  Qiagen, Hilden 
QuantiTect SYBR Green PCR Kit (1000) Qiagen, Hilden 
QIAshredder Kit (50)  Qiagen, Hilden 
RNeasy-Free DNase set (50)  Qiagen, Hilden 
RNase A  Qiagen, Hilden 
Taq PCR Core Kit (250 U)  Qiagen, Hilden 
BCA™ Protein Assay Kit  PIERCE 
TA Cloning® Kit with pCR®2.1  Invitrogen, USA 
Taq PCR Core Kit (250 U)  Qiagen, Hilden 
 
4.1.2Primers All the primers are given in the 5’ to 3’ direction 
Real time PCR  
Actb;D:11461   
FORWARD PRIMER TGT TAC CAA CTG GGA CGA CA 
REVERS PRIMER GGG GTG TTG AAG GTC TCA AA 
LPL;ID:16956  
FORWARD PRIMER TGT CAG CTG GCT ACA CCA AG 
REVERS PRIMER GGT CAG ACT TCC TGC TAC GC 
C/EBPα;ID:12606  
FORWARD PRIMER TGG ACA AGA ACA GCA ACG AG 
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REVERS PRIMER TCA CTG GTC AAC TCC AGC AC 
 
C/EBPβ;ID:12608  
FORWARD PRIMER ACT TCA GCC CCT ACC TGG AG 
REVERS PRIMER GGC TCA CGT AAC CGT AGT CG 
PPARγ;ID:19016  
FORWARD PRIMER CGA GTC TGT GGG GAT AAA GC 
REVERS PRIMER GGA TCC GGC AGT TAA GAT CA 
Adiponectin; ID:11450  
FORWARD PRIMER GGA ACT TGT GCA GGT TGG AT 
REVERS PRIMER CCA AGA AGA CCT GCA TCT CC 
Tfrc; ID:22042  
FORWARD PRIMER TCC GCT CGT GGA GAC TAC TT 
REVERS PRIMER ACA TAG GGC GAC AGG AAG TG 
Primers for nested PCR  
GH; ID: 2688  
FORWARD PRIMER GGT CTC CAG CGT AGA CCT TG 
REVERS PRIMER CAA TCC TCC AGG CCT TTC TC 
FORWARD PRIMER GCA TCC ACT CAC GGA TTT CT 
REVERS PRIMER AAG AGA AGG AGA GGC CAA GC 
mtDNA; NC_001807  
FORWARD PRIMER GAG GAG ACA AGT CGT AAC ATG G 
FORWARD PRIMER GTG CAC TTG GAC GAA CCA G 
REVERS PRIMER GGG TTT GGG GCT AGG TTT AG 
mtDNA; AY172335  
FORWARD PRIMER CCG TCA CCC TCC TCA AAT TA 
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REVERS PRIMER GGG CTA GGA TTA GTT CAG AGT G 
GH; ID: 14599 
 
 
FORWARD PRIMER CTG GCT GCT GAC ACC TAC AA 
REVERS PRIMER TCC CCT ACC CCA TAG TTT CC 
Primers for cloning  
GH; ID: 2688  
FORWARD PRIMER TAC AGG TAA GCG CCC CTA AA 
FORWARD PRIMER GTC CTG TGG ACA GCT CAC CT 
REVERS PRIMER AAG AGA AGG AGA GGC CAA GC 
mtDNA; NC_001807  
FORWARD PRIMER AAG GTG TAG CCC ATG AGG TG 
FORWARD PRIMER ACC ACC TCT TGC TCA GCC TA 
REVERS PRIMER GGC AGG TCA ATT TCA CTG GT 
 
4.1.3 ELISA  
Mouse Adiponectin/Acrp30 Quantikine ELISA Kit  R&D Systems, Wiesbaden 
Human Adiponectin/Acrp30 Quantikine ELISA Kit  R&D Systems, Wiesbaden 
Mouse Leptin Quantikine ELISA Kit   R&D Systems, Wiesbaden 
Human LeptinQuantikine ELISA Kit  R&D Systems, Wiesbaden 
 
4.1.4 Media  
F-12 Nutrient Mixture  GIBCO, Eggestein  
Hepes  GIBCO, Eggestein 
Newborn calf serum  GIBCO, Eggestein 
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Foetal calf serum PAA Laboratories GmbH 
DMEM  GIBCO, Eggestein 
Trypsin EDTA  GIBCO, Eggestein 
HBSS  GIBCO, Eggestein 
NEAA  GIBCO, Eggestein 
H2O DNAse, RNAse Free  GIBCO, Eggestein 
MEM  GIBCO, Eggestein 
 
4.1.5 Buffers and solutions  
Primary preadipocytes  
Buffer I HANKS 
 
Buffer II 500ml HANKS 
25ml 10%BSA 
Filter sterilized 
 
Primary preadipocyte cell culture 
medium (500ml) 
DMEM/F12 428ml. 
FBS 50 ml (final conc. 10%) 
P/S 100U/100mg/ml 
A-2-P 500µl (500mg+10mlPBS) 
 
Differentiation medium for 
primary human preadipocytes 
Primary cell culture medium 500ml 
DEX 9,5ml (1mg in 1ml ethanol and 1:50 with 
DMEM) 
IBMX 5,5ml (100mg in 10ml pure ethanol) 
Indomethacin 895µl (20mg in 1ml pure ethanol) 
Insulin 50µl (10mg in 1ml acetic acid) 
 
3T3-L1 propagation medium 90% DMEM containing 
4 mM L-glutamine 
1.5 g/L sodium bicarbonate 
4.5 g/L glucose 
P/S 100U/100mg/ml 
and 10% FCS 
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3T3-L1 differentiation medium 3T3-L1 propagation medium 
520 µM IBMX 
1 µM DEX 
167 nM insulin 
8 µg/ml biotin 
 
HUH 7 propagation medium 90% MEM (Eagle) containing 
2 mM L-glutamine 
Earle's BSS 
1.5 g/L sodium bicarbonate 
0.1 mM NEAA 
1.0 mM sodium pyruvate 
P/S 100U/100mg/ml 
and 10% FCS 
 
Hep G2 propagation medium 90% MEM (Eagle) containing 
2 mM L-glutamine 
Earle's BSS 
1.5 g/L sodium bicarbonate 
0.1 mM NEAA 
1.0 mM sodium pyruvate 
P/S 100U/100mg/ml 
and 10% FCS 
 
C2C12 propagation medium 90% DMEM containing 
4 mM L-glutamine 
1.5 g/L sodium bicarbonate 
4.5 g/L glucose 
P/S 100U/100mg/ml 
and 10%; FCS 
 
Enzyme activities  
 
Hepes buffer 110 mM NaCl 
2.6 mM KCl 
1.2 mM KH2PO4 
1 mM CaCl2 
1.2 mM MgSO4 7H2O 
25mM Hepes 
pH 7.4 
 
Complex I  
Modified buffer  Baker water 
50mM KCl 
60mM Saccharose 
50mM Triethanolamin-HCl 
2mM MgCl2 
1mM EDTA 
pH 8 
 42
 
100mM NADH 70mg/1ml modified buffer 
 
100µM Cytochtrom C  20mg/330µl water 
 
Rotenone 0,1mg/1ml ethanol 
 
Complex II+III  
 
50mM KH2PO4 680,5mg/100ml Baker water 
 
250mM NaN3 0,0163g/1ml Baker water 
 
100µM Cytochtrom C 20mg/330µl water 
 
Rotenone 0.1mg/1ml ethanol 
 
1M Succinate (acid) 1.18g/10ml Baker water 
 
Antimycin 0,001g/1ml ethanol  
 
Complex IV  
10mM KH2PO4 0,1365g/100ml Baker water 
pH 7 adjusted with KOH  
 
D-Cytochrome C 0,01g Cytochtrom C 
1trace ascorbic acid 
3ml KH2PO4-buffer 
Dissolve and dialyse for 3X6h 
 
100mM K-ferricyanide 32,92g/1l Baker water 
 
Complex V  
Modified buffer 500ml Baker water  
50mM KCl 
60mM Saccharose 
50mM Triethanolamin-HCl 
2mM MgCl2 
1mM EDTA 
 
MgATP (200mM) 0,6g ATP in 3ml 500mM MgCl2-Baker water 
(Adjust pH 8 with KOH ) 
 
50mM PEP 0.103g/5ml Baker water 
(Adjust pH 7 with KOH ) 
 
100mM NADH 0,07g/1ml modified buffer 
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LDH 1100U/mg 
 
PK  
50mM EGTA 0,95g/50ml H2O 
(Adjust pH 8 with KOH) 
 
KCN 0,02/Modiffied buffer 
 
Oligomycin 10mg/1ml ethanol 
 
Citrate synthase  
Tris buffer (0,1M Tris-HCL) 1,6g/100ml Baker water 
(pH 8 adjust with KOH) 
 
Oxaloacetate 1,32mg/1ml Baker water 
 
Acetyl-CoA 5mg/350µl Baker water 
 
Cloning  
LB (Luria Bertani) medium 1.0% Tryptone  
0.5% Yeast Extract 
1.0% NaCl 
pH 7.0 
 
LB agar plates LB medium  
15 g/L agar before autoclaving 
 
pCR®2.1, linearized 25 ng/μl in 10 mM Tris-HCl, 1 mM 
EDTA, pH 8 
 
10X PCR Buffer 100 mM Tris-HCl, pH 8.3 (at 42°C) 
500 mM KCl 
25 mM MgCl2 
0.01% gelatin 
 
10X Ligation Buffer 60 mM Tris-HCl, pH 7.5 
60 mM MgCl2 
50 mM NaCl 
1 mg/ml bovine serum albumin 
70 mM β-mercaptoethanol 
1 mM ATP 
20 mM dithiothreitol 
10 mM spermidine 
 
50 mM dNTPs 12.5 mM dATP 
12.5 mM dCTP 
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12.5 mM dGTP 
12.5 mM dTTP 
(adjusted to pH 8.0) 
 
T4 DNA Ligase 4.0 Weiss units/μl 
 
Sterile Water Deionised, autoclaved water 
 
Control DNA Template 0.1 μg/μl in 10 mM Tris-HCl, 1 mM 
EDTA, pH 8 
 
Control PCR Primers 0.1 μg/μl each in 10 mM Tris-HCl, 
1 mM EDTA, pH 8 
 
S.O.C. Medium 2% Tryptone 
0.5% Yeast Extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose (dextrose) 
 
pUC19 Control DNA 10 pg/μl in 5 mM Tris-HCl, 
0.5 mM EDTA, pH 8 
 
Glycerol stocks Medium 
15% glycerol 
 
Oil Red O stock solution 300 mg of Oil Red O powder 
100 ml of 99% isopropanol 
 
Oil Red O working solution 3 parts Oil Red O stock solution 
2 parts deionised water 
 
NRTI and PI solutions All drugs were dissolved in DMSO. 
The highest concentration of the solvent used in 
the incubation experiments (DMSO 0.1%) did 
not affect cellular viability and preadipocyte 
differentiation. 
 
4.1.6 Chemicals  
DNA ladder  Invitrogen, USA 
H2O DNAse, RNAse Free  Invitrogen, USA 
AZT (3′-Azido-3′-deoxythymidine) Sigma-Aldrich, Munich 
AZT pills GlaxoSmithKline-GmbH 
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D4T (2′,3′-Didehydro-3′-
deoxythymidine ) 
 
Sigma-Aldrich, Munich 
D4T pills Bristol-Myers Squibb GmbH 
IDV Merck Sharp&Dohme 
TNF-α Provided by Prof. D. Neumann, 
Pharmacology, MHH 
 
IBMX (3-Isobutyl-1-methylxanthine) Sigma-Aldrich, Munich 
Insulin  Sigma-Aldrich, Munich 
d-Biotin  Sigma-Aldrich, Munich 
D-Lactose  Sigma-Aldrich, Munich 
Uridine  Sigma-Aldrich, Munich 
Dexamethasone  Sigma-Aldrich, Munich 
DdC (2′,3′-Dideoxycytidine) Sigma-Aldrich, Munich 
Oil Red O  Sigma-Aldrich, Munich 
MitoProbe JC-1  Molecular Probes, Eugene, OR, USA 
MitoTracker Red 580  Molecular Probes, Eugene, OR, USA 
Annexin V  Molecular Probes, Eugene, OR, USA 
Trypan blue ICN Biomedicals, Aurora, USA 
Propidium iodide Sigma-Aldrich, Munich 
Hoechst 33342 Sigma-Aldrich, Munich 
PEP (K-phosphoenolpyruvate)  Sigma-Aldrich, Munich 
Cytochrome C  Sigma-Aldrich, Munich 
Antimycin A  Sigma-Aldrich, Munich 
Oligomycin B Sigma-Aldrich, Munich 
Rotenone Sigma-Aldrich, Munich 
Acetyl CoA  Sigma-Aldrich, Munich 
Camptothecin  Sigma-Aldrich, Munich 
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D-Pantothenic acid  Sigma-Aldrich, Munich 
Amphotericin B  Sigma-Aldrich, Munich 
Collagenase  Sigma-Aldrich, Munich 
2-Deoxy-D-glucose  Sigma-Aldrich, Munich 
Glucose 40 Braun Braun, Melsungen, Germany 
Cytochalasin B  Sigma-Aldrich, Munich 
Rapamycin  Sigma-Aldrich, Munich 
NADH (Nicotinamide adenine 
dinucleotide, reduced) 
 
Roche 
PK (Pyruvate Kinase)  Roche 
L-Lactatdehydrogenase  Roche 
FGF (Fibroblast Growth Factor) Promocell 
2,6-Diisopropylphenol  Sigma-Aldrich, Munich 
Amobarbital Sodium salt  Sigma-Aldrich, Munich 
Butilated hydroxyanisole Sigma-Aldrich, Munich 
Carbonyl cyanide  Sigma-Aldrich, Munich 
6 hydroxy-2,5,7,8-tetramethylchroman 2 
carboxylic acid  
 
Merck, Darmstadt 
Carboxy H2-DCFDA  Molecular Probes 
L-Ascorbic acid  Sigma-Aldrich, Munich 
Indomethacin  Sigma-Aldrich, Munich 
MgATP  Sigma-Aldrich, Munich 
BSA (Albumin from bovine serum) Sigma-Aldrich, Munich 
PBS (Phosphate buffered saline) Biochrom, Berlin AG 
Trypsin-EDTA GIBCO, Eggestein 
Biocoll separating solution Biochrom, Berlin AG 
PS (penicillin streptomycin)  Biochrom, Berlin AG 
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KH2PO4 (Potassium phosphate 
monobasic) 
 
Sigma-Aldrich, Munich 
CaCl2 (Calcium chloride) Sigma-Aldrich, Munich 
MgSO4 (Magnesium sulphate) Sigma-Aldrich, Munich 
Sucrose (β-D-Fructofuranosyl-α-D-
glucopyranoside) 
 
Sigma-Aldrich, Munich 
Ethidium Bromide Sigma-Aldrich, Munich 
Agarose Invitrogen, USA 
MgCl2 (Magnesium chloride) Sigma-Aldrich, Munich  
Formalin (formaldehyde) Sigma-Aldrich, Munich 
CCCP (Carbonyl cyanide 3-
chlorophenylhydrazone ) 
 
Sigma-Aldrich, Munich 
KOH (Potassium hydroxide) Sigma-Aldrich, Munich 
EDTA (Ethylenediaminetetraacetic acid) Sigma-Aldrich, Munich 
NaN3 (Sodium azide) Sigma-Aldrich, Munich 
Succinate  ICN Biomedicals, Aurora, USA  
Acetic acid Sigma-Aldrich, Munich 
Ethanol  J.T. Baker 
KCN (Potassium cyanide) Sigma-Aldrich, Munich 
EGTA Ethylene glycol-bis (2-
aminoethylether)-N,N,N′,N′-tetraacetic 
acid  
 
Sigma-Aldrich, Munich 
Tris-HCl (TRIS hydrochloride) Sigma-Aldrich, Munich 
Oxaloacetate  Merck, Darmstadt 
DOC (dissolved organic carbon) Sigma-Aldrich, Munich 
Baker water  J.T. Baker 
TCA (Trichloroacetic acid) Sigma-Aldrich, Munich 
IPTG (Isopropyl β-D-1-
thiogalactopyranoside ) 
 
Sigma-Aldrich, Munich 
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Ampicillin  Sigma-Aldrich, Munich 
Kanamycin  Sigma-Aldrich, Munich 
X-Gal (5-Bromo-4-chloro-3-indolyl β-
D-galactopyranoside)  
 
Sigma-Aldrich, Munich 
Glycerol  Sigma-Aldrich, Munich 
Tryptone  Sigma-Aldrich, Munich 
Yeast Extract  Sigma-Aldrich, Munich 
NaOH (Sodium hydroxide)  Sigma-Aldrich, Munich 
Agar  Sigma-Aldrich, Munich 
Gelatin  Sigma-Aldrich, Munich 
β-mercaptoethanol  Sigma-Aldrich, Munich 
DTT (dithiothreitol)  Sigma-Aldrich, Munich 
Spermidine  Sigma-Aldrich, Munich 
Isopropanol  J.T. Baker 
 
4.1.7 Consumables  
Conical Filter Paper Whatman GmbH, Germany 
Cell culture dishes Becton Dickinson, Heidelberg 
Tubes Greiner, Frickenhausen 
Cell culture flasks Greiner, Frickenhausen 
96 well-round bottom plates  Greiner, Frickenhausen 
96 well-sharp bottom plates ICN Biomedicals, Aurora, USA 
24 well cell culture plates Corning Costar, Sigma-Aldrich, Munich 
12 well cell culture plates Corning Costar, Sigma-Aldrich, Munich 
6 well cell culture plates Corning Costar, Sigma-Aldrich, Munich 
Petri-dishes Sarstedt, Nümbrecht 
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Syringes Braun, Melsungen, Germany 
Needles Braun, Melsungen, Germany 
One touch test strips Bayer, Germany 
Sticking plastic film for the plates  Nunc, Wiesbaden  
PS (Polyester)-tubes (0,6ml) Greiner, Frickenhausen 
Sterile filter (Easy flow TM) Becton Dickinson, Franklin, USA 
Safe Lock tube 1,5ml Eppendorf, Hamburg 
PCR tubes Eppendorf, Hamburg 
Optical 96-well reaction plates Applied Biosystems, USA 
Optical Adhesive Cover Starter Kit Applied Biosystems, USA 
Pipette tips 1000µL Eppendorf, Hamburg 
Pipette tips 200µL Eppendorf, Hamburg 
Pipette tips 100µL Eppendorf, Hamburg 
Pipette tips 10µL Eppendorf, Hamburg 
Optical tape BioRad, Hercules, USA 
Safe Skin Purple Nitrile Kimberly-Clark, Roswell, USA 
Safe Skin Satin Plus Kimberly-Clark, Roswell, USA 
FACS Flow 20l Becton Dickinson, Heidelberg 
Cryo-Box  NeoLab, Heidelberg 
Cryo Tube Roth, Karlsruhe 
 
4.1.8 Equipment  
iCycler BioRad, Hercules, USA 
Thermocycler Biometra, Goettingen 
Counter (MicroBeta) PerkinElmer 
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Cell harvester Inotech, Rockvill, MD 
Gel Doc 2000 BioRad, Hercules, USA  
Lamina Air Flow (Gelaire)  Flow Laboratories Gmbh, Germany 
Centrifuge 5415C Eppendorf, Hamburg 
Multifuge 3s-r Heraeus, Osterode 
Verifuge3,2RS Heraeus, Osterode 
Centrifuge (AvantiTM30) Beckman-Coulter, Krefeld 
Centrifuge J2-21 Beckman-Coulter, Krefeld 
Vortex (Stuart) Bibby Sterilin LTD, Staffordshire, UK 
Shaker GFL (Gesellschaft fur Labortechnik mbH) 
Photometer UV-1202 Shimadzu Europa GmbH, Duisburg 
Spectrophotometer 8453 Hewlett-Packard 
Photometer  Labsystems Multiskan PLUS, Helsinki  
Scales Sartorius Gmbh, Göttingen  
Ascensia Elite Sensor Glucometer Bayer, Germany 
FACSCalibur Becton Dickinson, Heidelberg 
Pipette research 1000 Eppendorf, Hamburg 
Pipette research 200 Eppendorf, Hamburg 
Pipette research 100 Eppendorf, Hamburg 
Pipette research 10 Eppendorf, Hamburg 
Pipette research 2,5 Eppendorf, Hamburg 
Microscope Carl Zeiss, West Germany 
Microscope Carl Zeiss, West Germany 
Incubator PLP,Heraeus, Australia 
Water bath Jurgens, Burgwedel 
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Hand counter Omnilab, Bremen 
Dual Timer Omnilab, Bremen 
 
4.1.9 Cell lines and animals  
C2C12 LGC Promochem GmbH, Germany 
HUH 7 Gift from Herpetology and 
Gastroenterology  
 
3T3-L1 LGC Promochem GmbH, Germany 
Hep G2 LGC Promochem GmbH, Germany 
Primary fibroblasts Isolated from human 
Primary preadipocytes Isolated from human 
One Shot® TOP10F´ Chemically 
Competent E. coli  
 
Invitrogen, USA  
One Shot® TOP10 Chemically 
Competent E. coli 
 
Invitrogen, USA 
C57BL/6 mice Charles River Laboratories, USA 
 
4.2 METODS 
4.2.1 DNA Isolation 
DNA isolation was done using DNeasy Tissue Kit (50) Cat. No 69504 (QIAGEN 
GmbH, Deutschland) following the manufactures procedure. Briefly, total cellular DNA 
purification was achieved without organic extraction or ethanol precipitation, but using 
silica-gel-membrane technology. Selective binding of DNA to the DNeasy membrane 
took place after cell lyses. Proteinase K was used in the initial sample lyses. 
Contaminants and enzyme inhibitors (proteins and divalent cations) were removed by 
centrifugation. DNA binds selectively the DNeasy membrane and contaminations go 
through. Two wash steps removed the left over contaminations and enzyme inhibitors. 
Finally DNA was eluted. DNA A260/A280 ratio was between 1.7 - 1.9. The isolated 
fragments are between 100bp and 50 kb in size. 
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4.2.2 Total RNA Isolation 
4.2.2.1 Total RNA Isolation from lipid tissues 
Total RNA was isolated using RNeasy Lipid Tissue Mini Kit (50) Cat. No74804 
(QIAGEN GmbH, Deutschland) following the manufactures procedure. Briefly, in this 
kit phenol/guanidine-based lysis is combined with silica-gel membrane purification of 
total RNA. QIAzol Lysis Reagent consists of single-phase solution of guanidine 
thiocyanate and phenol. This solution is designed to improve fatty tissues lysis and 
inhibit RNases. After samples homogenization with QIAzol Lysis Reagent (QIAGEN 
GmbH) chloroform was added and the homogenate separated by centrifugation into 
organic and aqueous phases. Proteins are in the lower (organic phase) and to the 
interphase, DNA is in the interphase and RNA is in the upper (aqueous phase). Ethanol 
was added to the upper, aqueous phase to ensure appropriate binding conditions. Total 
RNA binds the membrane of the RNeasy Mini Spin Column making possible, phenol 
and the other contaminations to be washed away. RNase-free water was used for the 
elution of total RNA. With this method all RNA molecules that are longer than 200 
nucleotides were isolated. RNAs such as 5.8S rRNA, 5S rRNA, and tRNAs which are 
<200 nucleotides were not isolated.  
 
4.2.2.2 Total RNA isolation from no lipid tissues and cells 
Total RNA from no-lipid tissues and cells was isolated using RNeasy Protect Mini Kit 
(50) Cat. No 74124 (QIAGEN GmbH, Deutschland) following the manufactures 
procedure. Briefly, this is a combination of microspin technology and selective binding 
properties of a silica-based membrane. Guanidine-thiocyanate-containing buffer (which 
inactivates RNases) was used for denaturation, lyses and homogenization. Total RNA 
binds to the membrane of RNeasy Mini spin column and ethanol provides appropriate 
binding conditions leaving the contaminations to be washed away. RNA was then eluted 
in water. The membrane binds RNA molecules longer than 200 nucleotides. RNAs such 
as 5.8S rRNA, 5S rRNA, and tRNAs which are <200 nucleotides were not isolated. 
Reliable gene expression analyses require RNA stabilization as an absolute 
prerequisite. Specific and nonspecific RNA degradation as well as transcriptional 
induction occur after harvesting the samples, which leads to significant changes in the 
gene expression pattern. RNA later RNA Stabilization Reagent (QIAGEN GmbH, 
Deutschland) is new technology for preservation of the gene expression pattern. After 
submerging in RNA later RNA Stabilization Reagent, it permeates the tissues and 
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stabilizes and protects RNA. With Stabilization Reagent the cellular RNA remains 
intact and undegraded even at elevated temperatures. RNA later RNA Stabilization 
Reagent was used only for tissue samples, as it does not stabilize RNA in animal cells, 
whole blood, plasma and serum. 
RNA concentration was determined by the spectrophotometric absorbance at 260 
nm (A260). The relationship between absorbance and concentration (A260 reading of 1 
= 40 µg/ml RNA) determined for an extinction coefficient calculated for RNA in water 
was used. The principle of photometry requires readings between 0.15 and 1.0 in order 
to have significant results. Photometric absorbance is the same for DNA and RNA. 
DNA contamination results in higher A260 values. RNA purity was estimated by the 
ratio of absorbance values at 260/280 nm. RNA had an A260/A280 ratio of 1.9– 2.1. 
Protein contaminations result in lower ratio. For RNA purity the absorbance was 
measured in 10 mM Tris·Cl, pH 7.5. 
 
4.2.3 Reverse Transcription 
Reveres transcription of mRNA was done using Omniscript RT Kit (200) Cat. No 
205113 (QIAGEN GmbH, Deutschland) following the manufactures procedure. Briefly, 
Real-Time PCR requires reverse transcription of mRNA when quantifying RNA. Using 
oligo-dT primers that specifically hybridize to the poly-A tail of mRNAs, RNA was 
transcribed into single-stranded cDNA. The multifunctional enzyme reverse 
transcriptase has 3 distinct enzymatic activities, which in vivo in retroviral infections 
allow transcription of the single-stranded RNA genome into double-stranded DNA:  
• RNA-dependent DNA polymerase (reverse transcriptase). Transcribes cDNA 
from an RNA template (reverse transcription). This activity is used to synthesize 
cDNA. 
• Hybrid-dependent exoribonuclease (RNase H). Specifically degrades only the 
RNA in RNA:DNA hybrids. It affects RNA that is hybridized to cDNA with no 
effect on pure RNA. RNase H activity during reverse transcription improves the 
sensitivity of subsequent PCR. 
• DNA-dependent DNA polymerase 
In vitro activity 1 and 2 are utilized to produce single-stranded cDNA  
A negative control was used to test for DNA contamination. Genomic DNA cannot be 
completely eliminated for certain genes. There are pseudogenes and genes lacking 
introns. To detect DNA contamination a control reaction with no reverse transcription 
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was performed. The control RT reaction contained template RNA and all other 
components, except reverse transcriptase enzyme. An aliquot of this reaction was used 
in the PCR.  
 
4.2.4 Real-Time PCR 
Expression analyses as well as gene quantification were performed using QuantiTect 
SYBR Green PCR Kit (1000) Cat. No 204145 (QIAGEN GmbH, Deutschland) 
following the manufactures procedure and instructions. Briefly, the primers were 
designed using free available computer software Primer3, Steve Rosen & Helen 
Skaletsky, 2000 ( www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi ) and 
following the general guidelines for PCR Primer: GC content about 40–60%; primer 
length of 18–30 nucleotides; to use an annealing temperature of an average 5°C below 
Tm; primer pairs to be with similar Tm values; the length of the PCR product to be < 
300 bp; to avoid sequences of 3 or more Cs or Gs at the 3' end; to avoid a 3'-end T 
which gives greater tolerance of mismatch; to avoid mismatches between the target-
template sequence and primer 3' end; to reduce primer-dimer formation so that not to 
allow for complementarities of more than two bases at 3' ends of primer pairs; to avoid 
complementarity’s sequences between the primers pair within the primer sequence. For 
gene expression analyses one half of the primer was designed to hybridize to the 3' end 
of one exon and the other half to the 5' end of the adjacent exon, so that the primers 
anneal to cDNA, but not to genomic DNA. In all cases when it was impossible, Real-
Time PCR primers were designed to flank a region that contains introns and in this case 
the products were not amplified from genomic DNA under our reaction conditions, as 
they were much longer. All the expression analyses were done under the following 
reaction conditions: 
 
Final Extension 
42 Number of Cycles 
72C 30 sec Extension 
55C 30 sec Annealing 
94C 15 sec Denaturation 
 3-step cycling 
95C 15 minInitial activation step 
Temp Time 
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Primer stock solutions were made by dissolving lyophilized primers in TE. The working 
solutions contained 10 pmol/µl. All the primer solutions were stored at –20°C. Quality 
check for the primers was performed on a denaturing polyacrylamide gel and estimated 
by the appearance of a single band. 
In the Real-Time PCR reaction SYBR Green I dye was used. SYBR Green I dye 
binds to the minor groove of double-stranded DNA (dsDNA). SYBR Green I excitation 
and emission maximums are correspondingly at 497 and 520 nm. Once bound to 
dsDNA, the fluorescence of SYBR Green I greatly increases and that’s how product 
accumulation during Real-Time PCR is detected. At denaturation step, DNA becomes 
single-stranded and SYBR Green is free in solution, therefore produces little 
fluorescence. At annealing the primers hybridize to the target sequence leading to the 
syntheses of a dsDNA to which SYBR Green I binds. At elongation phase as PCR 
primers are extended more and more DNA becomes double-stranded and then a 
maximum amount of SYBR Green I binds. Signal could also be generated from 
nonspecific dsDNA (spurious PCR products, primer-dimers). The specificity of the 
Real-Time PCR reaction is determined entirely by the specificity of the primers pairs as 
SYBR Green fluorescence depends mainly on the presence of dsDNA, which means 
that any double-stranded products generated during the reaction are detected by the 
instrument. Primer-dimer formation, extension of primers bound to non-target DNA 
sequences and other spurious PCR products are not initially distinguishable from the 
target amplicon as the increase in fluorescence detected in these cases is not due to an 
increase in the concentration of the target PCR product. Proper primer design minimizes 
the effects of any unwanted reactions. During the optimization of the assay, PCR 
products were analyzed on a gel to check for the product of interest and for correlation 
between the gel and fluorescence data. 
Absolute amount of the target nucleic acid of interest was determined using 
external standards. These standards contained sequences that are the same as, or differ 
only slightly from the target sequence, and their primer binding sites are always 
identical to the target sequence. This ensured equivalent amplification efficiencies of 
standard and target molecules, which is essential for absolute quantification. A standard 
curve (plot of CT values/crossing points of different standard dilutions against log of 
amount of standard was generated using a dilution series of the standards. Amplification 
of the standard dilution series and of the target sequence was carried out in separate 
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tubes. Comparing the CT of unknown amounts of target with the standard curve allowed 
calculation of the initial amount of target used in Real-Time PCR. It was important to 
select an appropriate standard for the type of nucleic acid to be quantified. 
The relative quantification performed, determines the ratio between the amount of 
target and a reference molecule in the samples. The reference molecule (housekeeping 
gene) was chosen in such a way so that its expression level to be almost constant. When 
using an RNA standard for gene expression analyses, the variable efficiency of reverse 
transcription had been taken into account. The target and the reference were amplified 
with comparable efficiencies. Amplification efficiencies in addition to the setup of the 
PCR reaction itself depend on factors as: pipetting, instrumentation, presence of 
inhibitors, effect of RT reaction volume. Target and reference amounts were quantified 
by using standard curves for both genes. All wells defined as standards were used for 
the generation of a standard curve. The CT values were plotted against the log of the 
template ‘amount’ to generate a straight line. CT values for the samples and the 
standard curve were then used to calculate the absolute or relative amount of starting 
template in experimental samples. One standard curve for the target gene and one 
standard curves for the reference molecule (housekeeping gene) were prepared by 
diluting the reference sample in 5-fold dilutions. The amount of unknown target fell 
within the range of the standard curve points. Reactions were carried out in triplicate. 
No template control was used for detection of contaminations. No template control 
contained all the components of the reaction, but no template. To determine 
amplification efficiency, Real-Time PCR with a dilution series of the sequence of 
interest, was performed. Standard curve was constructed using the obtained CT values. 
The amplification efficiency (E) was calculated using the following equation: 
E = 10 (–1/S) – 1 (S is the slope of the standard curve) 
Well factors were used in the iCycler to compensate for any system or pipetting 
differences. 
Data analyses were performed according to the recommendations provided by the 
manufacturer of the iCycler detection system. Data were produced in the form of 
amplification plots where the number of cycles was plotted against fluorescence. The 
threshold cycle (CT) was used to calculate the starting template amount in each sample.  
The noise level in early cycles is the baseline. Normally it is between cycles 3-15 
because there is still no detectable increase in fluorescence. The baseline was subtracted 
from the PCR products fluorescence. The threshold is a value in log-linear range of the 
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PCR above the baseline. The threshold is set using a logarithmic amplification plot, 
because in this case the log-linear range of the curve is easy to identify. The cycle at 
which the amplification plot crosses the threshold is the threshold cycle (CT). 
Melting curve analyses was performed. This option is built into the software of 
iCycler. The temperature was increased very slowly from a 65ºC to 95ºC. All PCR 
products are double stranded at low temperatures; SYBR Green I dye binds to them and 
gives high fluorescence. At high temperatures denaturation takes place and there is a 
rapid decrease in fluorescence. When the temperature was increasing the fluorescence 
was measured and plotted against the temperature. At higher temperatures there was a 
rapid decrease in fluorescence as nonspecific and specific PCR products reached their 
melting temperatures. 
 
4.2.5 ELISA 
Mouse adiponectin 
Mouse adiponectin quantification was performed using Mouse Adiponectin/Acrp30 
Quantikine ELISA Kit Cat# MRP300 (R&D Systems) and following the manufactures 
procedure. Briefly, this assay employs the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for mouse adiponectin has been pre-coated 
onto a microplate. Standards, control, and samples were pipetted into the wells and any 
mouse adiponectin present was bound by the immobilized antibody. After washing 
away any unbound substances, an enzyme-linked polyclonal antibody specific for 
mouse adiponectin was added to the wells. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution was added to the wells. The enzyme 
reaction yielded a blue product that turned yellow when the stop solution was added. 
The intensity of the colour measured is in proportion to the amount of mouse 
adiponectin bound in the initial step. The sample values were then read off the standard 
curve. 
 
Human adiponectin 
Human adiponectin quantification was performed using Human Adiponectin/Acrp30 
Quantikine ELISA Kit Cat# DRP300 (R&D Systems) and following the manufactures 
procedure. Briefly, this assay employs the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for adiponectin had been pre-coated onto a 
microplate. Standards and samples were pipetted into the wells and any adiponectin 
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present was bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked monoclonal antibody specific for adiponectin was added 
to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells and colour developed in proportion to the 
amount of adiponectin bound in the initial step. The colour development was stopped 
and the intensity of the colour was measured. 
 
Mouse leptin 
Mouse leptin quantification was performed using Mouse Leptin Quantikine ELISA Kit 
Cat# MOB00 (R&D Systems) and following the manufactures procedure. Briefly, this 
assay employs the quantitative sandwich enzyme immunoassay technique. An affinity 
purified polyclonal antibody specific for mouse leptin had been pre-coated onto a 
microplate. Standards, controls, and samples were pipetted into the wells and any mouse 
leptin present was bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for mouse leptin 
was added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells. The enzyme reaction yielded a blue 
product that turned yellow when the stop solution was added. The intensity of the colour 
measured was in proportion to the amount of mouse leptin bound in the initial step. The 
sample values were then read off the standard curve.  
 
Human leptin 
Human leptin quantification was performed using Human Leptin Quantikine ELISA Kit 
Cat# DLP00 (R&D Systems) and following the manufactures procedure. Briefly, this 
assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for leptin had been pre-coated onto a microplate. 
Standards and samples were pipetted into the wells and any leptin present was bound by 
the immobilized antibody. After washing away any unbound substances, an enzyme-
linked monoclonal antibody specific for leptin was added to the wells. Following a wash 
to remove any unbound antibody-enzyme reagent, a substrate solution was added to the 
wells and colour developed in proportion to the amount of leptin bound in the initial 
step. The colour development was stopped and the intensity of the colour was measured. 
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4.2.6 Cell lines 
Hep G2 
Hep G2 was from ATCC® Number HB-8065. This is a human hepatoma derived cell 
line with epithelial morphology. For subculturing, culture medium was removed and 
discarded, the cell layer briefly rinsed with 0.25% (w/v) trypsin- 0.53 mM EDTA 
solution to remove all traces of serum that contains trypsin inhibitor. Then 2.0 to 3.0 ml 
of trypsin-EDTA solution added to flask and the cells observed under an inverted 
microscope until cell layer was dispersed (usually within 5 to 15 minutes). In order to 
avoid clumping it’s advisable not to agitate the cells by hitting or shaking the flask 
while waiting for the cells to detach. Cells that are difficult to detach may be placed at 
37°C to facilitate dispersal. As a next step 6.0 to 8.0 ml of complete growth medium 
were added and cells aspirated by gently pipetting. Appropriate aliquots of the cell 
suspension were added to the new culture vessels and the cultures incubated at 37°C. 
The normally used subcultivation ratio was 1:6 with a medium renewal twice per week. 
For preservation complete growth medium supplemented with 5% (v/v) DMSO was 
used as a freezing medium. The frozen cells were stored in the liquid nitrogen vapour 
phase. Propagation was done at 37°C in 90% minimum essential medium (Eagle) with 2 
mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 
mM non-essential amino acids, and 1.0 mM sodium pyruvate, and 10% fetal bovine 
serum. 
 
HUH 7 
HUH 7 was gift from the Department of Gastroenterology, Hepatology and 
Endocrinology at MHH. This is a human hepatoma derived cell line with epithelial 
morphology. For subculturing, culture medium was removed and discarded, the cell 
layer briefly rinsed with 0.25% (w/v) trypsin- 0.53 mM EDTA solution to remove all 
traces of serum that contains trypsin inhibitor. Then 2.0 to 3.0 ml of trypsin-EDTA 
solution added to flask and the cells observed under an inverted microscope until cell 
layer was dispersed (usually within 5 to 15 minutes). In order to avoid clumping it’s 
advisable not to agitate the cells by hitting or shaking the flask while waiting for the 
cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate 
dispersal. As a next step 6.0 to 8.0 ml of complete growth medium were added and cells 
aspirated by gently pipetting. Appropriate aliquots of the cell suspension were added to 
the new culture vessels and the cultures incubated at 37°C. The normally used 
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subcultivation ratio was 1:7 to 1:10 with a medium renewal twice per week. For 
preservation complete growth medium supplemented with 5% (v/v) DMSO was used as 
a freezing medium. The frozen cells were stored in the liquid nitrogen vapour phase. 
Propagation was done at 37°C in 90% minimum essential medium (Eagle) with 2 mM 
L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM 
non-essential amino acids, and 1.0 mM sodium pyruvate, and 10% fetal bovine serum.  
 
C2C12 
C2C12 was from ATCC® Number CRL-1772. This is a mus musculus derived cell line 
with fibroblast morphology. C2C12 is a subclone (produced by H. Blau, et al.) of the 
mouse myoblast cell line established by D. Yaffe and O. Saxel. (376). The C2C12 cell 
line differentiates rapidly, forming contractile myotubes and producing characteristic 
muscle proteins (377). When subculturing, the cells were never allowed to become 
confluent as this may deplete the myoblastic population in the culture. Myotube 
formation is enhanced when the medium is supplemented with 10% horse serum instead 
of fetal bovine serum. For subculturing, culture medium was removed and discarded, 
the cell layer briefly rinsed with 0.25% (w/v) trypsin- 0.53 mM EDTA solution to 
remove all traces of serum that contains trypsin inhibitor. Then 2.0 to 3.0 ml of trypsin-
EDTA solution added to the flask and the cells observed under an inverted microscope 
until cell layer was dispersed (usually within 5 to 15 minutes). In order to avoid 
clumping it’s advisable not to agitate the cells by hitting or shaking the flask while 
waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to 
facilitate dispersal. As a next step 6.0 to 8.0 ml of complete growth medium were added 
and cells aspirated by gently pipetting. Appropriate aliquots of the cell suspension were 
added to the new culture vessels normally inoculation of 1.5 X 105 to 1.0 X 106 viable 
cells/75 cm2 and the cultures incubated at 37°C with a medium renewal every two to 
three days. For preservation complete growth medium supplemented with 5% (v/v) 
DMSO was used as a freezing medium. The frozen cells were stored in the liquid 
nitrogen vapour phase. Propagation was done at 37°C in 90% dulbecco's modified 
Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate 
and 4.5 g/L glucose, 90% and 10% fetal bovine serum. 
 
3T3-L1 
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3T3-L1 was from ATCC® Number CL-173. This is a mus musculus derived cell line 
with fibroblast morphology. 3T3-L1 is a continuous substrain of 3T3 (Swiss albino) 
developed through clonal isolation. The cells undergo a pre-adipose to adipose like 
conversion as they progress from a rapidly dividing to a confluent and contact inhibited 
state. Culture was never allowed to become completely confluent and was subcultured 
before 80% confluence or when cells reached 5 to 6 X104 viable cells/sq cm. For 
subculturing, culture medium was removed and discarded, the cell layer briefly rinsed 
with 0.25% (w/v) trypsin- 0.53 mM EDTA solution to remove all traces of serum that 
contains trypsin inhibitor. Then 2.0 to 3.0 ml of trypsin-EDTA solution added to flask 
and the cells observed under an inverted microscope until cell layer was dispersed 
(usually within 15 to 25 minutes). In order to avoid clumping it’s advisable not to 
agitate the cells by hitting or shaking the flask while waiting for the cells to detach. 
Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. As a next 
step 6.0 to 8.0 ml of complete growth medium were added and cells aspirated by gently 
pipetting. Appropriate aliquots of the cell suspension were added to the new culture 
vessels, normally an inoculum of 2 to 3 X 103 cells/sq cm. The normally used 
subcultivation interval was every three days with medium renewal 2 to 3 times per 
week. For preservation complete growth medium supplemented with 5% (v/v) DMSO 
was used as a freezing medium. The frozen cells were stored in the liquid nitrogen 
vapour phase. Propagation was done in 90% dulbecco's modified Eagle's medium with 4 
mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose 
and 10%; bovine calf serum. Cells were maintained at 37°C in 95% atmosphere air and 
5%; carbon dioxide (CO2). As a requirement for growth conditions the cells were grown 
in plastic flasks as they do not grow well on some types of glass surfaces. During 
differentiation protocol committed preadipocytes have to withdraw from cell cycle 
before undergoing adipose conversion. For preadipose cell lines as well as for primary 
preadipocytes, growth arrest is required for adipocyte differentiation and is normally 
achieved through contact inhibition when confluence of cells is reached (333;378). For 
differentiation, cells were incubated two days after confluence when a saturation density 
of approximately 50000 cells per sq cm was reached (designated day 0) in DMEM-FCS 
supplemented with a mixture of hormones composed of 520 µM IBMX, 1 µM DEX and 
167 nM insulin for 72 h. Cells were then incubated in DMEM-FCS and 167 nM insulin 
for another 72 h, after which they were maintained in DMEM-FCS with a medium 
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change every 72 h. Cell culture media were supplemented with 100U/100mg/ml 
penicillin/streptomycin and 8 µg/ml biotin. 
 
Preadipocyte primary culture 
For isolation of primary human preadipocytes Buffer I and Buffer II were used. Both 
buffers were filter sterilized. To prepare the collagenase 20mg were dissolved in 10 ml 
Buffer I and filter sterilized. The fat tissue was dissected and minced on a Petri dish 
(about 5ml tissue). Then it was pipetted into 10ml collagenase solution in a 50ml vials 
and vortexed (to reach total volume of about 15ml). The 50ml vial was put into shaking 
water bath at 90 cycles/minute and incubated for 1h. As a next step the solution was 
homogenized by vortexing and separated into two 50ml vials, which were then filled up 
with buffer I and centrifuged 5min/4°C/800rpm. Then the upper fat part was transferred 
into another 50ml vial, the middle part thrown away and the pellet added to the upper 
part in the 50ml vial. Next the 50ml vial was filled up with buffer II and centrifuged 
10min/4°C/1500rpm. After centrifugation the supernatant and the floating fat were 
thrown away and the vial with the pellet filled up with buffer II and centrifuged 
10min/4°C/1500rpm. The supernatant was thrown away and the pellet resuspended in 
primary cell culture medium. The medium was changed every 24-48h. For subculturing, 
culture medium was removed and discarded, the cell layer briefly rinsed with 0.25% 
(w/v) trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains 
trypsin inhibitor. Then 2.0 to 3.0 ml of trypsin-EDTA solution added to flask and the 
cells observed under an inverted microscope until cell layer was dispersed (usually 
within 20 to 30 minutes). As a next step, 10ml of primary cell culture medium was 
added followed by centrifugation at 10min/4°C/1500rpm. Appropriate aliquots of the 
cell suspension were added to the new culture vessels. The normally used subcultivation 
ratio was 1:2. Propagation was done in primary cell culture medium. For differentiation, 
differentiation medium for primary human preadipocyte was used. For preservation 
complete primary cell culture medium supplemented with 5% (v/v) DMSO was used as 
a freezing medium. The frozen cells were stored in the liquid nitrogen vapour phase. 
 
Human primary skin fibroblasts 
Human primary skin fibroblasts were provided by Dr. Thomas Lücke from Department 
for Pediatric Kidney and Liver Diseases and Metabolic Disorders, Hannover Medical 
School, Hannover; Germany. Propagation, preservation and cell culture medium were 
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as explained for 3T3-L1 preadipocytes. Subculturing was performed by splitting culture 
before confluence.  
 
4.2.7 Oil Red O staining  
Oil Red O staining was performed following the protocol from Cambrex Bio Science.  
I order to fix adipogenic culture, media was aspirated and the plate was rinsed with 2 ml 
of sterile PBS. Then PBS was aspirated and 2 ml of 10% formalin added, followed by 
1/2h incubation. To prepare Oil Red O stock solution 300 mg of Oil Red O powder was 
dissolved in 100 ml of 99% isopropanol. For the working solution 3 parts Oil Red O 
stock solution were mixed with 2 parts deionised water and left to stay 10 minutes at 
room temperature (stable for 2 hours). Finally Oil Red O working solution was filter 
sterilized. To stain the adipogenic culture formalin was removed and 2 ml of sterile 
water added in order to rinse the cells. The water was removed and 2 ml of 60% 
isopropanol added and incubated for 5 minutes. Then the isopropanol was removed and 
2 ml of Oil Red O working solution pipetted and incubated for 1h. As a next step cells 
were rinsed with water left wet and analysed on a phase contrast microscope where the 
lipids appeared red. 
 
4.2.8 Mitochondrial functions 
 
4.2.8.1 Membrane potential 
To evaluate the integrity of mitochondrial functions we used the cationic dye JC-1 
Assay Kit (Cat N# M34152; Molecular Probes, Eugene, OR, USA) following the 
manufactures procedure. JC-1 cationic dye (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide) signals the loss of the mitochondrial 
membrane potential. The normal potential is associated with bright red staining. The 
lipophilic dye, bearing a delocalized positive charge enters the mitochondrial matrix 
using the negative charge of the intact mitochondrial membrane potential and 
accumulates there. The red fluorescence appears when JC-1 reaches critical 
concentration and forms J-aggregates. When mitochondrial membrane potential 
collapses, JC-1 cannot accumulate within the mitochondria, remains in the cytoplasm in 
monomeric form and florescence is green. The absorption/emission maximum of the 
aggregate red form is 585/590 nm and of the green monomeric form is 510/527 nm. To 
stain for flow cytometry for each sample, cells were suspended in 1ml warm medium at 
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1 x 106 cells/mL. For the control tube, 1µl of CCCP were added and the cells incubated 
at 37°C/5min. Then 10µl of 200µM JC-1 were added and the cells incubated at 
37°C/5%CO2/ for 15-30min. As a next step cells were pelleted by centrifugation and 
ressuspend in 500µl PBS. Then cells were analysed on a flow cytometer with 488nm 
excitation using emission filters appropriate for Alexa Fluor 488 dye and R-
phycoerythrin. The cells were gated, excluding debris. Standard compensation was done 
using the CCCP –treated sample. 
 
4.2.8.2 Mitochondrial mass 
To evaluate the mitochondrial mass we used MitoTracker Red 580 (MTR, Cat N#M-
22425; Molecular Probes, Eugene, OR, USA) following the manufactures procedure. 
The reduced probes do not fluoresce until they enter an actively respiring cell, where 
they are oxidized to the corresponding fluorescent mitochondrion-selective probe and 
then sequestered in the mitochondria. These probes are well retained after fixation and 
permeabilization. To stain the cells for flow cytometry, the medium was removed and 
prewarmed medium containing MitoTracker Red 580 added. After 30-45 min 
incubation the loading medium was replaced with fresh medium and the cells pelleted 
by centrifugation. The pellet was ressuspend in 500µl PBS and analysed on a flow 
cytometer. The excitation/emission maximum of the MitoTracker® Red 580 is 581/644.  
 
4.2.9 Propidium iodide staining 
To evaluate cell death we used propidium iodide solution (Propidium iodide Cat N# 
P3566; Molecular Probes, Eugene, OR, USA) following the manufactures procedure. 
Propidium iodide is membrane impermeant and generally excluded from viable cells. It 
is commonly used for identifying dead cells. Propidium iodide binds to DNA by 
intercalating between the bases with little or no sequence preference and with a 
stoichiometry of one dye per 4–5 base pairs of DNA. Propidium iodide also binds to 
RNA, necessitating treatment with nucleases to distinguish between RNA and DNA 
staining. Once the dye is bound to nucleic acids, its fluorescence is enhanced 20- to 30-
fold. To stain cells for flow cytometry single cell suspension was prepared in buffer 
(e.g. PBS + 0.1% BSA), the cells were washed twice and pelletted. 1.5 mM propidium 
iodide staining solution was prepared by diluting the 1 mg/mL (1.5 mM) stock solution 
1:500 in PBS and 300 µL of this staining solution was directly pipetted onto the 
specimen. The specimen was incubated in the dark for 30 minutes at room temperature 
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and washed twice with PBS. Then propidium iodide fluorescence (FL2 on the FACS) 
was determined and signals compensated accordingly. Fluorescence excitation/ 
emission maximums for nucleic acids bound propidium iodide are 535/617 nm. 
Propidium iodide fluorescence is detected in the FL2 channel of flow cytometers. 
Double staining propidium iodide and hoechst or annexin V as well as trypan blue dye 
exclusion were performed according to the manufactures protocols. 
 
4.2.10 Enzyme activities 
The examination of enzyme activity has been done in control and NRTI treated cells. 
The cell lines and primary cultures used in these experiments were from early passages. 
Cells were plated to confluence on Petri dishes (diameter 30mm). For the performance 
of spectrophotometric measurement cells were washed twice with a Hepes buffer and 
then incubated in 1ml of buffer containing 10mM glucose for 15min at room 
temperature. Respiratory chain enzyme activities were assayed as described in (379-
383). Cells were subjected to sonication 2X10sec in a ‘bandelin-probe’ sonicator. The 
sonicater was set up at power 20W with 0.3sec duration of the single pulses and inter-
pulse duration of 0.7 sec. We determined complex I (NADH dehydrogenase), complex 
II+III (succinate-ubiquinone reductase and ubiquinol-cytochrome c reductase), complex 
IV (cytochrome c oxidase), complex V (ATP synthase) and citrate synthase activity 
(used as marker of mitochondrial content). Complexes I+III activity were measured 
spectrophotometrically at 37 °C using wavelength of 340nm. Rotenone was used to 
inhibit complex I (380). Complexes II+III activity was measured at wavelength 550 nm 
and antimycin A was used as inhibitor (384). Complex IV activity was measured at a 
wavelength of 550nm (381). Complex V was measured at 340nm (379;382) and 
oligomycine-was used as inhibitor. Enzyme activity was expressed in nmol/min/mg of 
cell protein for individual enzyme complexes of the MRC. The measurement was 
performed at 37°C in 1ml cuvette in appropriate medium. Enzyme activity of all 
complexes was calculated by subtracting the remaining residual activity after the 
addition of the complex specific inhibitor (rotenone for complex I, antimycin A for 
complex II+III activity; KCN for complex IV activity; and oligomycin for complex V). 
The photometric measurement and the calculation have been done using UV Visible 
Chemstation Software-Alien Technologies (HP 845xUV visible system). 
 
Complex I+III 
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The cuvettes were filled with 840µl modified buffer and 10µl NADH (stable for 3-4h). 
The photometer was set up at 340nm, y-scaling 0-2, run time 600s, cycle time 5, type 
Delta AU. 850µl modified buffer was used as a blank. Then the kinetic measurement 
was started at 340nm. Cytochrome C (5µl) was added and mixed well, and after 30 sec 
150µl cell suspension was added. After another 180 sec 10µl rotenone were added and 
measurement continued till the end of the 600 seconds. To analyse the data the 
photometer offline was used. For the calculation of respiration, analyses started from 
the first point of the straight line. Interval of 100 units was given and walk with this 
interval along the straight line with a step of 10 units performed in order to find the 
negative value that is most different from zero (A). For the calculation of inhibition, 
analyses started from the first point of the straight line after the addition of rotenone. 
Interval of 100 units was given and walk with this interval along the straight line with a 
step of 10 units performed in order to find the negative value closest to zero (B). The 
calculation was done using the formula: Enzyme activity (nmol/min/mg protein) = (-
1000*(A-B)*0.6)/(6.22*protein mg/ml*cell volume ml). 
 
Complex II+III 
The cuvettes were filled with 750µl KH2PO4 and 10µl NaN3. The photometer was set up 
at 550nm, y-scaling 0-2, run time 2000sec, cycle time 5, type Delta AU. 750µl KH2PO4 
and 10µl NaN3 was used as a blank. Then the kinetic measurement was started at 
550nm. 20µl Cytochrome C and 5µl rotenone were added and mixed well. After 30 sec 
200µl cell suspension was added and measurement performed for 15min. Then 20µl 
succinate was added and measured for another 6min. Finally 10µl antimycin was added 
and measured for another 12 min. To analyse the data the photometer offline was used. 
For the calculation of respiration, analyses started from the first point of the straight line 
after the addition of succinate. Interval of 100 units was given and walk with this 
interval along the straight line with a step of 10 units performed in order to find the 
positive value that is most different from zero (A). For the calculation of inhibition, 
analyses started from the first point of the straight line after the addition of antimycin. 
Interval of 100 units was given and walk with this interval along the straight line with a 
step of 10 units performed in order to find the positive value closest to zero (B). The 
calculation was done using the formula: Enzyme activity (nmol/min/mg protein) = 
(1000*(A-B)*0.6)/(18.5*protein mg/ml*cell volume ml)  
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Complex IV 
The cuvettes were filled with 650µl H2O and 100µl KH2PO4. The photometer was set up 
at 550nm, y-scaling 0-2, run time 2000sec, cycle time 5, type Delta AU. 650µl H2O and 
100µl KH2PO4 were used as a blank Then the kinetic measurement was started at 
550nm. 50µl D-Cytochrome C was added and mixed well. After 100 sec 200µl cell 
suspension was added and measurement performed for 10min. Then 10µl K-
ferricyanide was added and measured for another 1min. To analyse the data the 
photometer offline was used. For the calculation of respiration the first point of the 
straight line was taken. For the calculation of inhibition the lowest point of the straight 
line after the addition of K-ferricyanide was taken. The values for respiration and 
inhibition were summed, divided by 2 and the corresponding middle absorption was 
found. Next, calculation was performed to find how many seconds took the reaction to 
come to the middle absorption. The seconds were transferred in minutes (Z). Then the 
formula: 0,69/Z = K; Enzyme activity (nmol/min/mg protein) = (K x 38,36)/( protein 
mg/ml *cell volume ml) was used. 
 
Complex V 
The cuvettes were filled with 850µl from the following mixture: 5ml modified buffer, 
150µl ATP, 150µl PEP, 15µl NADH, 3µl PK, 15µl LDH, 200µl EGTA and 20µl KCN. 
The photometer was set up at 340nm, y-scaling 0-2, run time 600sec, cycle time 5, type 
Delta AU. 850µl modified buffer were used as a blank. Then the kinetic measurement 
was started at 340nm. After 30 sec 150µl cell suspension was added and measurement 
performed for 5min. Then 9µl oligomycin was added and measured for another 10 min. 
To analyse the data the photometer offline was used. For calculation of respiration, 
analyses started from the first point of the straight line. Interval of 100 units was given 
and walk with this interval along the straight line with a step of 10 units performed in 
order to find the negative value that is most different from zero (A). For the calculation 
of inhibition, analyses started from the first point of the straight line after the addition of 
oligomycin. Interval of 100 units was given and walk with this interval along the 
straight line with a step of 10 units performed in order to find the negative value closest 
to zero (B). The calculation was done using the formula:  Enzyme activity 
(nmol/min/mg protein) = (-1000*(A-B)*0.6)/(6.22*protein mg/ml *cell volume ml). 
 
Citrate Synthase  
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The quartz cuvettes were filled with 925µl Tris Buffer. The photometer was set up at 
232nm, y-scaling 0-2, run time 1200sec, cycle time 5, type Delta AU. Quartz cuvettes 
filled with 925µl Tris Buffer were used as a blank. Then the kinetic measurement was 
started at 232nm. After 30 sec 20µl oxaloacetate and 5µl acetyl-Co A were added. After 
10 min measurement 100µl cell suspension was added and measure for another 5min. 
To analyse the data the photometer offline was used. For calculation of respiration, 
analyses started from the first point of the straight line. Interval of 100 units was given 
and walk with this interval along the straight line with a step of 10 units performed in 
order to find the negative value that is most different from zero (A). The calculation was 
done using the formula: Enzyme activity (nmol/min/mg protein) = (-
1000*(A)*0.6)/(5.4*protein mg/ml *cell volume ml). 
 
Protein measurement 
Protein measurement was done using BCA™ Protein Assay Kit Cat# 23225 (PIERCE) 
following the manufactures procedure. The BCA™ Protein Assay is a detergent-
compatible formulation based on bicinchoninic acid (BCA) for the colorimetric 
detection and quantitation of total protein. This method combines the well-known 
reduction of Cu++ to Cu+ by protein in an alkaline medium (the biuret reaction) with the 
highly sensitive and selective colorimetric detection of the cuprous cation (Cu+) using a 
unique reagent containing bicinchoninic acid. The purple-colored reaction product of 
this assay is formed by the chelation of two molecules of BCA with one cuprous ion. 
This water-soluble complex exhibits a strong absorbance at 562 nm that is nearly linear 
with increasing protein concentrations over a broad working range (20-2,000 µg/ml). 
The BCA™ method is not a true end-point method; that is, the final colour continues to 
develop. However, following incubation, the rate of continued colour development is 
sufficiently slow to allow large numbers of samples to be assayed together. To analyse 
the total cellular protein of the probes 250µl cell suspension, 750µl Baker water and 
50µl 1% dissolved organic carbon (DOC) were mixed. For the DOC, 1000µl Baker 
water and 150µl DOC 1% were mixed. For the control, 250µl control solution, 50µl 
Baker water and 150µl DOC 1% were mixed. The probes, DOC and control were 
subjected to 5min incubation at room temperature, followed by addition of 200µl 50% 
trichloroacetic acid (TCA) and 15 min incubation on ice. Then the probes, DOC and 
control were subjected to 3 min centrifugation at 13500rpm, the supernatant was 
discarded and the pellet resuspended in 1000µl 0,2% DOC for Probes and DOC samples 
 69
and in 250µl DOC for control samples. From this point the protocol explained at: 
http://www.piercenet.com/files/ 1296dh4.pdf was followed. 
 
4.2.11 Cloning 
Cloning has been performed following the general recommendation from the cloning kit 
and from QIAGEN® PCR Cloning Handbook. TA Cloning® Kit with pCR®2.1 was 
used. This kit provides a quick, one-step cloning strategy for the direct insertion of a 
PCR product into a plasmid vector. Taq polymerase has a nontemplate-dependent 
activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. The 
linearized vector supplied in this kit has single 3´ deoxythymidine (T) residues. This 
allows PCR inserts to ligate efficiently with the vector. To clone a gene of interest, the 
PCR product was ligated into pCR®2.1 and transformed into competent cells. Since the 
PCR product can ligate into the vector in either orientation, individual recombinant 
plasmids were analyzed to confirm proper orientation. The correct recombinant plasmid 
was purified for further subcloning and characterization. Briefly, the PCR product was 
amplified using Taq polymerase and specially designed primers and parameters. Then 
the PCR product was ligated into pCR®2.1 and this ligation transformed into competent 
E. coli. Colonies were selected, plasmid DNA isolated and the plasmid DNA analysed 
for the presence and orientation of the PCR product by PCR using the plasmid and 
insert primers. DNA amount between 10 and100 ng was used as a template for the PCR 
and 30 cycles of amplification in order to achieve optimal ligation efficiencies. Total 
DNA was isolated from Hep G2 cell line (ATCC® Number: HB-8065) and the 
appropriate primers were used in the PCR for the creation of mtDNA and GH fragments 
to be cloned. The PCR reaction was performed using Taq PCR Core Kit (250 U) 
Cat. No 201223 (QIAGEN) and the following amplification conditions: 
 
72C 10 min Final Extension 
30 Number of Cycles 
72C 2 min Extension 
55C 30 sec Annealing 
94C 1 min Denaturation 
3-step cycling 
95C 15 minInitial activation step 
Time Temp 
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The PCR was optimized to eliminate multiple bands and smearing and a single, discrete 
band was obtained. Special care was taken to avoid sources of nuclease contamination 
and long exposure to UV light. For optimal ligation efficiencies, fresh (less than 1 day 
old) PCR products were used as the single 3´ A-overhangs on the PCR products may be 
degraded over time, reducing ligation efficiency. The amount of PCR product needed to 
ligate with 50 ng (20 fmoles) of pCR®2.1 vectors was calculated using the formula:  
X ng PCR product = ((Y bp PCR product)(50ng pCR® 2.1 vector))/(size in bp of the 
pCR® 2.1 vector~3900). 
Where X ng is the amount of PCR product of Y base pairs to be ligated for a 1:1 
(vector:insert) molar ratio. In general, 0.5 to 1.0 µl of a typical PCR sample with an 
average insert length (400-700 bp) gives the proper ratio of 1:1 (vector: insert). The 
ratio of 1:1 (vector: insert) gives the best efficiency of ligation. No more than 2-3 µl of 
the PCR sample was used in the ligation reaction as salts in the PCR sample may inhibit 
the T4 DNA Ligase. Ligation was performed at 14°C as higher or lower temperatures 
may reduce the ligation efficiency. One vial of pCR®2.1 was centrifuged to collect all 
the liquid in the bottom of the vial. The volume of PCR sample needed for the required 
amount of PCR product was determined (as explained above). The 10 µl ligation 
reaction was set up as follows (Fresh PCR product X µl; 10X Ligation Buffer 1 µl; 
pCR®2.1 vector (25 ng/µl) 2 µl; Sterile water to a total volume of 9 µl; T4 DNA Ligase 
(4.0 Weiss units) 1 µl; Final volume 10 µl. Then the ligation reaction was incubated at 
14°C for a minimum of 4 hours. After the ligation of the insert into pCR®2.1, the 
construct was transformed into competent E. coli. TOP10F´ does express the lac 
repressor ( lacIq), which represses transcription from the lac promoter. To perform blue-
white screening for inserts, isopropyl-β-D-thiogalactopyranosid (IPTG) was added to 
the plates to express LacZα. Kanamycin was used to select for transformants containing 
pCR®2.1 construct. To prepare for transformation, the water bath was equilibrated to 
42°C and S.O.C. medium brought to room temperature. For TOP10F´ cells, LB plates 
containing antibiotic were taken and equilibrated at 37°C for 30 minutes. 40 µl of 100 
mM IPTG and 40 mg/ml X-Gal were spread onto the plates and let to soak. Then the 
vials containing the ligation reactions were centrifuged briefly and placed on ice. One 
50 µl vial of frozen One Shot® Competent Cells was thawed for each transformation. 2 
µl of each ligation reaction were pipetted directly into the vial of competent cells and 
mixed by stirring gently with the pipette tip. The vials were incubated on ice for 30 
minutes. The cells were heat shocked for 30 seconds at 42°C without shaking and 
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immediately transferred on ice. Then 250 µl of room temperature S.O.C. medium was 
added to each vial and shacked horizontally at 37°C for 1 hour at 225 rpm in a shaking 
incubator. As a next step 10 µl to 50 µl from each transformation vial was spread on LB 
agar plates containing X-Gal and 50 µg/ml of kanamycin or 100 µg/ml ampicillin. IPTG 
was included for the TOP10F´ cells. The plates were incubated overnight at 37ºC and 
then shifted to +4°C for 2-3 hours to allow for proper colour development. On X-
Gal/IPTG plates, an average of 50-200 colonies per plate was obtained with 
approximately 80% white colonies. To analyse the positive clones at least 10 white 
colonies were picked for plasmid isolation and analysis. The colonies were grown 
overnight in 2-5 ml LB broth containing either 100 µg/ml of ampicillin or 50 µg/ml 
kanamycin. Plasmid was isolated and analyzed by PCR for orientation of the insert. 
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The next procedure was used for plasmid preparation from bacterial culture. For 
the starter culture, a single colony was inoculated from a fresh selective plate into 10 ml 
LB medium with appropriate antibiotic. The culture was shacked vigorously~300 rpm 8 
h at 37°C. As a next step the culture was diluted 1/500 - 1/1000 into LB medium and 
grown for 12–16 h at 37°C with vigorous shaking ~300 rpm. The cells were harvested 
by 15 min centrifugation at 6000 x g at 4°C and the supernatant was removed. E. coli 
was resuspended in Tris·Cl–EDTA buffer containing RNase A and lysis performed with 
NaOH/Sodium dodecyl sulphate (SDS) for 5 minutes. The lysate was neutralized with 
acidic potassium acetate and cleared from the debris by centrifugation. (Traditionally 
performed by cesium chloride (CsCl) ultracentrifugation). Concentration, desalting, and 
recovering of the nucleic acids was achieved using alcohol precipitation. Isopropanol in 
ratio 7/10 was added to the DNA solution at room-temperature and centrifugation 
performed for 15–30 min at 15,000 x g at 4°C. The supernatant was decanted and the 
pellet washed with 70% ethanol, followed by centrifugation for 5–15 min at 15,000 x g 
at 4°C. The supernatant was decanted and the pellet was air-dried for 5–20 min and 
redissolved in a suitable buffer (pH 8.0). 
DNA was quantified spectrophotometrically. Plasmid DNA concentration was 
determined through absorbance measurement at 260 nm (A260) using 
spectrophotometer and quartz cuvette. A260 readings was adjusted to be between 0.1 
and 1.0.A relationship A260 = 1 x 50 µg/ml, valid for measurements in neutral pH, 
(Tris·Cl, pH 7.0) was used.  
 
4.2.12 Animals 
Young male C57BL/6 mice weighing on average 23g at the six weeks of age were 
purchased from Charles River Laboratories. All the animals were fed ad libitum on a 
normal diet and were housed 5 or 10 mice per cage in an air conditioned facility with 12 
h light/dark cycle. At the end of one week of adaption, the animals were randomly 
divided into three groups (n=5 in the pilot and n=20 in the second experiment). For 
some experiments, mice were deprived of food for the last 18 h of the treatments. Food 
and water intake was monitored by weighing the pelleted diet every week and the water 
bottles every 72h in each cage and calculating the mean intake/mouse/day. All 
experiments were performed after ethics approval by the local animal ethics committee.  
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4.2.13 Drug administration 
Groups of mice were treated with d4T, AZT or vehicle (5-20 mice per group) for up to 
20 weeks with daily human doses adjusted for murine body surface area, 13.5 mg/kg of 
d4T and 100 mg/kg of AZT. The body area is 0.026 and 0.30 m2/kg of body weight in 
humans and mice, respectively (81). The plasma levels of d4T and AZT under such 
administration conditions have been reported by another group (74;81). d4T (Bristol-
Myers Squibb GmbH) and AZT (GlaxoSmithKline-GmbH) were extracted from 
capsules put in PBS and homogenized directly before being given, as they are poorly 
soluble in PBS. d4T and AZT were administered by gavage rather than in drinking 
water. The reasons for such administration were two: First the content of drug pills used 
to extract the drugs was practically insoluble in water and second the constant intake of 
the drug from the drinking water would not allow us to parallel the pharmacokinetics in 
human’s blood. Control mice received an equal volume of PBS. 
 
4.2.14 Assessment of body fat mass distribution 
The determination of subcutaneous mouse fat distribution (e.g. inguinal and axillary fat 
pads) was performed by macroscopic examination. In addition, pictures of the fat depots 
of the mice were evaluated by an independent person blinded for the respective 
treatment groups. This assessment was performed in male C57BL/6 mice on the last day 
of the 15 week treatment to compare the phenotypic body parameters at the end of 
treatments.  
 
4.2.15 Collection of tissues 
In anesthetised mice, blood was collected from the tail vain by bleeding in a 2ml tube. 
Serum was isolated by centrifugation and stored for analysis at -80°C. After sacrificing 
the mice subcutaneous adipose tissue, liver, heart, muscle and brain were excised, 
washed in PBS and aliquots immediately frozen at -80 for DNA analyses. 
 
4.2.16 Glucose tolerance test (GTT) 
Mice were fasted 18 hours before the GTT with free access to drinking water. Then the 
baseline glucose level for each mouse was recorded (before the GTT). At the beginning 
of the GTT the mouse was challenged with a glucose load of 1.5 g glucose/kg body 
weight. The glucose solution was injected intra-peritoneally using a syringe and a 25 
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gauge needle. The next glucose measurements were performed 30, 60 and 120 min after 
the injection using a glucometer. 
 
4.2.17 3H thymidine Assay 
Cells were incubated for 24 h in DMEM containing 10% FCS (DMEM-FCS) and 
100U/100mg/ml penicillin/streptomycin and the indicated drug. The labelled nucleotide 
was incubated for additional 24 hours with the cells, where only proliferating cells 
incorporate 3H thymidine during cell division. Cells were harvested and washed through 
a filter. The filters were placed into the β counter where the radioactivity and thereby 
the incorporated amount were measured. Assays were performed in eightplicates to 
build the arithmetic mean of the results. 
 
4.2.18 Statistical methods 
Statistics. All analyses represent at least triplicate experiments with triplicate plates in 
each experiment. The statistical analyses were done by unpaired and paired Student's t-
test. The level of significance was set at P < 0.05. All data ± SEM. All calculations were 
performed using GraphPad Prism version 2.01 
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5 RESULTS 
 
5.1 Relationship of mitochondrial DNA depletion and respiratory chain activity in 
preadipocytes treated with nucleoside-analogue reverse transcriptase inhibitors 
 
5.1.1 Influence of NRTI on adipocyte morphology, differentiation, and 
triglycerol accumulation. First we examined the longitudinal effects of NRTI on 
differentiating 3T3-L1 adipocytes in regard to their phenotype. Preadipocytes were 
induced to differentiate in the presence of AZT (6µM(Cmax) or 180µM), d4T 
(3µM(Cmax) or 90µM) and ddC (0.1µM(Cmax) or 3µM) under standard conditions. 
Adipocytes were treated with vehicle (DMSO) or the indicated drug concentrations 
from day -7 until day +15 (from differentiation). Adipocytes exposed to high AZT 
concentrations retained less Oil Red O stain when compared with vehicle-treated cells. 
No changes were observed at Cmax drug concentrations (data not shown). Surprisingly, 
cells exposed to d4T or ddC did not differ from control neither at Cmax (not shown) nor 
at high concentration in terms of acquisition of a spheric shape and lipid droplet 
accumulation (Figure 1). Microscopic examination confirmed decreased triacylglycerol 
droplets, increased numbers of non-differentiated cells and some patches devoid of cells 
due to loss of detached cells during the media changes in AZT-treated adipocytes 
(Figure 1). Trypan blue staining revealed that up to 50% of detached cells were dead. In 
contrast, adipocytes exposed to vehicle, d4T and ddC remained attached, contained 
normal lipid droplets, and demonstrated normal cell viability (Figure 1). 
 
5.1.2 Molecular analysis of adipocyte differentiation. To extend the above 
observations we examined important factors of differentiation including C/EBPα and 
PPARγ in differentiating 3T3-L1 adipocytes (338;385;386). Preadipocytes were 
induced to differentiate in the presence of vehicle or the indicated drugs. Measurement 
of C/EBPα and PPARγ expression on day nine demonstrated that AZT significantly 
inhibited the expression but only at high drug concentration (Figure 2C and D) 
corresponding to the inhibition of differentiation as described above. Similarly, d4T and 
ddC had no significant effect on C/EBPα and PPARγ expression at both concentrations 
(Figure 2). Taken together, none of the tested NRTI had a negative impact on adipocyte 
differentiation in vitro at therapeutic Cmax concentrations. Only AZT reduced adipocyte 
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maturation at high concentrations as indicated by increased preadipocyte numbers, 
premature cell loss, and reduced levels of crucial factors regulating adipogenesis. 
 
 
 
Figure 1. Impaired adipocyte differentiation after exposure to AZT 
3T3-L1 adipocyte phenotype (unstained cells) at day 15 after initiation of differentiation in the presence 
of AZT (180µM), d4T (90µm), ddC (3µM), or control. 3T3-L1 cells in the d4T and ddC treated culture 
have acquired a mature phenotype with round shape and multiple lipid droplets. AZT exposed cultures 
present decreased numbers of triacylglycerol droplets, increased numbers of non-differentiated cells 
(arrows) compared to control and some patches devoid of cells.  
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Figure 2. Molecular analysis of adipocyte differentiation 
The panels reflect the effects of therapeutic drug concentration (A and B) or high concentration of AZT 
(180µM), d4T (90µm), ddC (3µM) (C and D) on the expression of the important factors of differentiation 
PPARγ (A and C) and C/EBPα (B and D) in differentiating 3T3-L1. Preadipocytes were cultured in the 
presence of vehicle (black column) or the indicated drugs from day -7, induced to differentiate on day 0 
and differentiated until day + 9 when total RNA was isolated, reverse transcribed and expression levels 
measured with Real-Time PCR. Like in the morphological analysis (Figure 1), d4T and ddC had no 
significant effect on C/EBPα and PPARγ expression at both concentrations whereas AZT led to 
significant impairment only at high drug concentrations. Values are the mean ± SEM of three 
experiments. * p<0.05, ** p<0.01.versus control. 
 
5.1.3 Effect of NRTI on adiponectin production. We next examined an 
additional adipocyte function that depends on full adipocyte maturation and contribute 
to glucose homeostasis in vivo. The analysis of adiponectin in the supernatant after 
culture with different NRTI revealed that d4T reduced the adiponectin production by 
more than 50% with AZT having an even more pronounced effect (Figure 3A). Even 
after adjusting for the cell numbers of differentiated adipocytes as the only producers of 
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adiponectin, both drugs inhibited adiponectin production (Figure 3B). In contrast, 
adiponectin levels were unaffected by ddC. The substantial effect of d4T and AZT on 
adiponectin release was detectable using NRTI drug concentrations within the range of 
the plasma drug Cmax levels in HIV-patients (Figure 3C). 
 
 
 
Figure 3. Effect of NRTI on adiponectin production 
Preadipocytes were differentiated in the presence of AZT (180µM), d4T (90µm), ddC (3µM), or vehicle 
(black column) and at day +9 supernatant (A) or adipocytes (D) assessed for adiponectin by ELISA or 
mRNA. (B) After adjustment for matured adipocyte numbers (see Figure 1) of the AZT exposed cells, 
AZT still leads to significant reduced adiponectin release into the supernatant. Significant reduction in 
adiponectin production after AZT and d4T exposure was evident also at therapeutic drug concentrations 
as confirmed by ELISA (C) and mRNA (E). Values are the mean ± SEM of three to five experiments. * 
p<0.05, ** p<0.01.versus control. 
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All these observations were confirmed by analysis of adiponectin mRNA expression 
(Figure 3D+E). These data are in line with the idea that NRTI may have impact on 
adipocyte function in addition to mitochondrial toxicity.  
 
5.1.4 Effect of NRTI on mtDNA content in non-proliferating cells. We looked 
for NRTI-induced changes in the mtDNA content of adipocytes depending on their 
developmental stage and proliferation activity. First 3T3-L1 growth arrested (confluent) 
preadipocytes were incubated with AZT, d4T and ddC for 21 days and mtDNA content 
measured at the end of culture. Surprisingly, quantification by Real-Time PCR revealed 
no statistically significant differences in the mtDNA content even at the highest 
concentration tested compared to control (Figure 4A). In addition, analysis of cell 
viability excluded a toxic effect on resting preadipocytes (not shown). We next assessed 
the effect on mtDNA content in fully differentiated adipocytes. Preadipocytes were 
differentiated under the standard protocol and from day +8 incubated with AZT, d4T 
and ddC for 21 days. Similarly to the growth arrested preadipocytes, the Real-Time 
PCR measurements revealed no depletion of mtDNA at any drug concentration. 
Incubation with d4T even led to an increase in mtDNA copies in mature adipocytes 
(Figure 4B). Importantly, no profound effect on cell viability, attachment, triglyceride 
content, size or number of cell droplets per cell could be observed. Taken together, 
these results provide evidence that non-dividing preadipocytes or fully mature 
adipocytes clearly have a reduced susceptibility to NRTI-induced mtDNA depletion. 
 
5.1.5 Effect of NRTI on mtDNA content in differentiating or proliferating 
preadipocytes. We next wanted to evaluate the effect of NRTI on mtDNA in dividing 
and differentiating cells. By splitting the preadipocyte culture before reaching 
confluence every third day in the presence of drugs the cells were kept proliferating 
without differentiating into fully mature adipocytes. After 21 days of drug treatment 
with high levels of d4T a significant depletion (reduction by 80%) of mtDNA similar to 
the effects in the ddC culture could be observed (Figure 4C). In contrast, AZT treatment 
had no effect on mtDNA content in proliferating preadipocytes. Together with the 
results of the resting preadipocytes, these experiments provide evidence that only d4T 
and ddC but not AZT impair mtDNA synthesis in preadipocytes. No significant mtDNA 
depletion in preadipocytes was observed at therapeutic drug levels (data not shown). 
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Finally, we measured the mtDNA content of adipocytes differentiated in the presence of 
NRTI (Figure 4D). Culture with d4T led to a significant reduction of mtDNA under 
these conditions whereas ddC had no substantial effect. AZT reduced the mtDNA 
content but differences were not statistically significant. Considering the morphological 
changes in the AZT-treated adipocyte culture (Figure 1) and the lack of any AZT-
induced mtDNA depletion in resting or dividing preadipocytes, this mtDNA depletion is 
possibly a result of loss of maturing adipocytes and a proportional increase in immature 
preadipocytes. In contrast, the substantial mtDNA depletion by d4T in differentiating 
adipocytes was not accompanied by any detectable morphological alteration or 
increased apoptosis as compared to untreated cells. Experiments performed under 
similar conditions but at therapeutic drug concentrations revealed no mtDNA depletion 
(data not shown). In summary, d4T led to significant mtDNA depletion in both 
preadipocytes and adipocytes during differentiation whereas AZT had some effect only 
in the latter. In addition, NRTI-associated mitochondrial toxicity as measured by 
mtDNA depletion is evident only in adipocytes undergoing proliferation or 
differentiation. 
 
5.1.6 Effect of NRTI on mtDNA content in HUH 7 cell line. We next wanted to 
evaluate the effect of NRTI on mtDNA in human hepatoma (HUH 7) cell line in order 
to examine whether the effect of NRTI is cell line and cell type specific. By splitting the 
HUH 7 before reaching confluence in the presence of drugs the cells were kept 
proliferating. After 10 days of drug treatment, incubation with high levels of d4T led to 
a significant depletion (reduction by 40%) of mtDNA (Figure 5). In the ddC cultures for 
10 days the depletion observed was almost approaching 50% of the original content. 
(Figure 5). In contrast, AZT treatment led to increase in mtDNA content for 10 days. 
Similar results were obtained using Hep G2 cell line. These experiments provide 
evidence that d4T and ddC are able to impair significantly mtDNA synthesis in 
hepatoma cell lines. 
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Figure 4. Effect of NRTI on mtDNA content of non-proliferating cells and differentiating or 
proliferating adipocytes 
MtDNA content of growth arrested confluent preadipocytes (A) and fully differentiated adipocytes (B) 
was assessed 21 day after exposure to AZT (180µM), d4T (90µm), ddC (3µM), or vehicle (black 
column). The increase in mtDNA of fully matured adipocytes was statistically significant (p<0.05). 
MtDNA content measured by Real-Time PCR in (C) continuously proliferating preadipocytes and (D) 
preadipocytes differentiated in the presence of AZT (180µM), d4T (90µm), ddC (3µM), or vehicle (black 
column). Only d4T lead to a significant reduction of mtDNA in preadipocytes and preadipocytes 
undergoing maturation. Values are the mean ± SEM of three to five experiments. * p<0.05, ** 
p<0.01.versus control. 
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Figure 5. Effect of NRTI on mtDNA content of HUH 7 
MtDNA content of HUH 7 after 10 days exposure to AZT (180µM), d4T (90µm), ddC (3µM), or vehicle 
(black column). MtDNA content was measure by Real-Time PCR. After 10 days of incubation only d4T 
and ddC lead to a significant reduction of mtDNA content. On the contrary an increase in mtDNA was 
observed under AZT incubation. Values are the mean ± SEM of three experiments. * p<0.05, ** 
p<0.01.versus control 
 
5.1.7. Association of mtDNA depletion with respiratory chain function. Given 
the profound mtDNA depletion that we observed after d4T and ddC treatment we 
wanted to assess whether this translates into functional impairment of respiratory chain 
complexes. As depicted in Figure 6, in conditions leading to an approx. 80% reduction 
in mtDNA (d4T), we did not detect an impairment of respiratory chain complexes. 
Similarly, AZT treatment, which was not associated with mtDNA depletion under these 
conditions, did not reduce enzymatic complex activity but rather increased the activity 
of complex I and IV (Figure. 6). Even long term culture of preadipocytes with NRTI for 
2 months at therapeutic Cmax drug concentrations were not associated with any 
significant reduction in activities of the respiratory chain. Finally, citrate synthase 
activity as mitochondrial marker enzyme was not affected in NRTI treated cultures 
compared to control (not shown) indicating that the mitochondrial content in cells 
remained unchanged. The enzyme activity assays were tested using serial dilutions of 
the enzymes and demonstrated very good sensitivity to detect minor differences in the 
enzyme amount (data not shown). 
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Figure 6. Effect of NRTI on the respiratory chain complex activity in proliferating preadipocytes 
Preadipocytes were cultured for 21 days in the presence of AZT (180µM), d4T (90µm), ddC (3µM), or 
vehicle (black column). Cells were sonicated and individual substrates added to the cell lysates followed 
by photometric measurement of substrate metabolisation by the single respiratory chain complexes I, 
II+III, IV, and V. Values are the mean ± SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
 
5.1.8 Effect of NRTI on mtDNA content in human subcutaneous fibroblasts. 
We then evaluated the effect of NRTI on mtDNA in human subcutaneous fibroblasts in 
order to examine the effect in a system as close as possible to the in vivo situation. By 
splitting the fibroblasts culture before reaching confluence in the presence of drugs the 
cells were kept proliferating. After 21 and 42 days of drug treatment, incubation with 
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high levels of d4T led to a significant depletion (reduction by 60-70%) of mtDNA 
(Figure 7). Cultures with ddC for 42 days led to a depletion down to almost 10% of the 
original content (Figure 7). In contrast, AZT treatment had only slight effect on mtDNA 
content for 21 days. These experiments provide evidence that mainly d4T and ddC, and 
to a lesser extent AZT are able to impair significantly mtDNA synthesis in human 
primary fibroblast cultures. 
 
 
 
Figure 7. Effect of NRTI on mtDNA content of human primary fibroblasts 
MtDNA content of human primary fibroblasts after 21 days (A and B) and after 42 days (C and D) 
exposure to AZT (180µM), d4T (90µm), ddC (3µM), or vehicle (black column). MtDNA content was 
measure by Real-Time PCR. After 21 days of incubation only d4T and ddC led to profound reduction of 
mtDNA content. In order to induce substantial mtDNA depletion under AZT incubation we needed 42 
days exposure to high drug concentrations. Values are the mean ± SEM of three experiments. * p<0.05, 
** p<0.01.versus control. 
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chain. To this end, proliferating human primary fibroblasts were exposed for 42 days to 
NRTI at high concentrations. Cells were then sonicated, substrate of the individual 
respiratory chain complexes was added to the cell lysates and complex activity 
quantitated by photometric measurement. As depicted in Figure 8, in conditions leading 
to an approx 90% reduction in mtDNA (ddC), we did not detect a measurable 
impairment of any respiratory chain complexes. AZT treatment, which was associated 
with the weaker mtDNA depletion under these conditions, had a slight effect on 
enzymatic activity of complexes II+III and V (Figure 8). Finally, citrate synthase 
activity as a measurement for the overall content of mitochondrial function was not 
affected in NRTI treated cultures compared to control (Figure 8). 
 
5.1.10 NRTI effect on mitochondrial mass and function in primary human 
fibroblasts. As we were unable to associate the profound mtDNA depletion after 42 
days of d4T and ddC treatment with impairment of complex activity in the respiratory 
chain in primary human fibroblasts, we decided to examine whether this depletion 
translates into impairment of mitochondrial potential and mass. To this end, 
proliferating human primary fibroblasts were exposed for 42 days to NRTI at high 
concentrations, washed and in order to evaluate mitochondrial membrane potential and 
to measure mitochondrial mass incubated with the cationic dye JC-1 (5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethyl-benzimidazolo carbocyanine iodide) and MitoTracker 
Red 580 (MTR) respectively (387;388). None of the NRTI affected MitoTracker 
labelling (Figure 9B), indicating no effect of NRTI on mitochondrial mass. The 
mitochondrial membrane potential seemed to be preserved as shown by FACS 
fluorimetric quantification (Figure 9A) of JC-1 aggregates and monomers. The JC-1 
aggregate/monomer ratio, which is an index of mitochondrial potential (388) was not 
significantly affected by NRTI incubation and the subsequent mtDNA depletion. These 
results indicate that d4T, AZT and ddC affect neither the number of mitochondria nor 
the mitochondrial dysfunction under these experimental conditions.  
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Figure 8. Effect of NRTI on the respiratory chain complex activity in human primary fibroblasts 
Human primary fibroblasts were cultured for 42 days in the presence of AZT (180µM), d4T (90µm), ddC 
(3µM), or vehicle (black column). Cells were then sonicated and individual substrates added to the cell 
lysates followed by photometric measurement of substrate conversion by the single respiratory chain 
complexes I, II+III, IV, V and citrate synthase. Values are the mean ± SEM of three experiments. * 
p<0.05, ** p<0.01.versus control. 
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Figure 9. NRTI effect on mitochondrial mass and function in primary human fibroblasts 
Human primary fibroblasts were cultured for 42 days in the presence of AZT (180µM), d4T (90µm), ddC 
(3µM), or vehicle (black column). Cells were stained for mitochondrial membrane potential and 
mitochondrial mass. The mitochondrial membrane potential was not significantly affected by NRTI 
incubation and the subsequent mtDNA depletion (A). MitoTracker labelling demonstrated no difference 
in the amount of mitochondrial mass in comparison to vehicle treated cells (B). Values are the mean ± 
SEM of three experiments.  
 
5.1.11 Effect of NRTI on mtDNA content in human primary preadipocytes. 
In order to bring our model as close as possible to the in vivo species and tissue situation 
we evaluated the effect of NRTI on mtDNA in human primary preadipocytes. The cells 
were kept in a proliferating state. After 40 days of drug treatment, incubation with high 
levels of d4T and ddC led to a significant depletion of mtDNA (Figure 10). In contrast, 
AZT treatment had no significant effect on mtDNA content for 40 days. These 
experiments provide evidence that d4T and ddC are able to impair significantly mtDNA 
content in human primary preadipocytes. 
 
Figure 10. Effect of NRTI on mtDNA content of human primary preadipocytes 
MtDNA content of human primary preadipocytes after 40 days exposure to AZT (180µM), d4T (90µm), 
ddC (3µM), or vehicle (black column). MtDNA content was measure by Real-Time PCR. After 40 days 
of incubation only d4T and ddC lead to a significant reduction of mtDNA content. Values are the mean ± 
SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
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Figure 11. Effect of NRTI on the respiratory chain complex activity in human primary 
preadipocytes 
Human primary preadipocytes were cultured for 40 days in the presence of AZT (180µM), d4T (90µm), 
ddC (3µM), or vehicle (black column). Cells were then sonicated and individual substrates added to the 
cell lysates followed by photometric measurement of substrate conversion by the single respiratory chain 
complexes I, II+III, IV, V and citrate synthase. Values are the mean ± SEM of three experiments.  
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5.1.12 Association of mtDNA depletion with respiratory chain function in 
human primary preadipocytes. Given the profound mtDNA depletion that we 
observed after d4T and ddC treatment after 40 days of incubation we performed 
experiments to assess whether this translates into functional impairment of complex 
activity in the respiratory chain. To this end, proliferating human primary preadipocytes 
were exposed for 40 days to NRTI at high concentrations. Cells were then sonicated, 
substrate of the individual respiratory chain complexes was added to the cell lysates and 
complex activity quantitated by photometric measurement. As depicted in Figure 11, in 
conditions leading to an approx 60% reduction in mtDNA (d4T), we did not detect a 
measurable impairment of any respiratory chain complexes. Finally, citrate synthase 
activity as a measurement for the overall content of mitochondrial function was not 
affected in NRTI treated cultures compared to control (Figure 11). 
 
5.2 Zidovudine inhibits clonal expansion and adipogenic differentiation of 3T3-L1 
cells  
 
5.2.1 AZT perturbs adipocyte mass through an effect on differentiation-
dependent TG accumulation. Adipocyte size and number as well as the rates of 
preadipocyte differentiation and adipocyte loss determine the mass of adipose tissue. 
Alteration in any of these processes may result in changes in adipose tissue mass. The 
3T3-L1 cell line is a well characterized model for studying adipocyte differentiation and 
function. After stimulation 3T3-L1 preadipocyte change the pattern of gene expression 
and acquire adipocyte characteristics like spherical shape and accumulation of TG-rich 
lipid droplets as signs of differentiation. Therefore we aimed to determine whether AZT 
affects this process. Preadipocytes were induced to differentiate in the presence of AZT 
(6µM or 180µM) under standard conditions. Adipocytes were treated with vehicle, drug 
or TNF-α (250pM) as a positive control for differentiation impairment (140;141;389). 
Adipocytes exposed to high AZT concentrations failed to accumulate cytoplasmic TG 
compared to vehicle-treated cells, which was an effect of impaired differentiation 
(Figure 1). At low AZT doses the effect was less pronounced and they did not appear to 
differ noticeably from vehicle-treated cells. Microscopically AZT treated adipocytes 
revealed affected number of TG droplets and abundant patches devoid of cells (Figure 
1). The acquisition of adipocyte phenotype and cell density was affected already at day 
4, immediately after the completion of clonal expansion (Figure 12). Thus, under these 
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conditions AZT exerted a clear inhibitory effect on adipocyte differentiation. In 
contrast, 3T3-L1 adipocytes exposed to vehicle proceeded unaffected through the 
differentiation process (Figure 1 and 12). 
 
 
 
Figure 12. Impaired adipocyte differentiation after exposure to AZT 
3T3-L1 adipocyte phenotype (unstained cells) at day 4 after initiation of differentiation in the presence of 
AZT (180µM) and control. 3T3-L1 cells in the control culture have expanded properly started acquiring a 
mature phenotype with round shape and multiple lipid droplets. AZT exposed cultures present decreased 
numbers of cells, decreased amount of triacylglycerol droplets and retarded acquisition of mature 
phenotype compared to control. 
 
5.2.2 Mitotic clonal expansion is affected by AZT. The cascade of gene 
induction and the critical mitotic clonal expansion (390) are the first events 
characterizing adipogenesis. Mitotic clonal expansion takes place within the first three 
days of the in vitro adipogenic program. After roughly two divisions preadipocytes exit 
the cell cycle and continue with the expression of adipogenic cascade of transcription 
factors leading to the acquisition of adipocyte characteristics (Figure A). Given the 
known antiproliferative effects attributed to AZT (391-401) we were interested to 
determine whether AZT treatment affects mitotic clonal expansion. Preadipocytes were 
induced to differentiate in the absence or presence of different concentrations of AZT 
(6µM and 180 µM) and Rapamycin (10nM) as a positive control for impaired clonal 
expansion (402). Cell number was also determined from dishes of confluent 
preadipocytes without induction of differentiation, incubated with AZT and vehicle for 
an identical period of time. The number of vehicle-treated differentiating preadipocytes 
increased almost 3-fold, corresponding to roughly two rounds of mitosis (Figure 13A). 
The increase in cell number in preadipocytes induced to differentiate in the presence of 
AZT, and Rapamycin was significantly lower (Figure 13A). In case of confluent 
preadipocytes not induced to differentiate the number of cells remained almost the same, 
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with and without the presence of AZT. The very sensitive 3H-thymidine incorporation 
assay confirmed the inhibitory effect of AZT on the cell division during the phase of 
clonal expansion even at Cmax concentration (Figure 13B). Therefore, it appears that 
AZT significantly affects 3T3-L1 differentiation at the stage of mitotic clonal 
expansion, even without major difference in cell viability in comparison to control. 
 
 
 
Figure 13. Effect of AZT on mitotic clonal expansion 
Mitotic clonal expansion, takes place within the first three days of the differentiation program. 
Preadipocytes were induced to differentiate in the absence or presence of AZT (180 µM) and Rapamycin 
(10nM). Cell number increased almost 3-fold in vehicle-treated differentiating preadipocytes. 
Significantly diminished increase in cell number was observed in preadipocytes induced to differentiate in 
the presence of AZT, and Rapamycin. 3H-thymidine incorporation assay confirms the inhibitory effect of 
AZT on the cell division during the phase of clonal expansion even at Cmax concentration (Figure 13B). 
No inhibition has been observed in case of d4T (3µm), ddC (0, 1µM), or vehicle (black column) treated 
cells. Values are the mean ± SEM of five to ten experiments. * p<0.05, ** p<0.01.versus control. 
 
5.2.3 Precursors proliferation is affected by AZT. 3H-thymidine incorporation 
assay demonstrated AZT anti-proliferative effect on primary human and 3T3-Ll 
fibroblasts as well as on human preadipocytes suggesting that this effect is not restricted 
to the cell line and could be expected in an in vivo system. The effect was readily 
observed at physiological concentrations even after 3h incubation (Figure 14B) and was 
strikingly persuasive at higher concentrations (Figure 14). The AZT anti-proliferative 
effect on 3T3-Ll was also confirmed using a total cellular protein assay (Figure 15). 
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Figure 14. Effect of AZT on precursor proliferation 
Primary human (C) and 3T3-L1 (A and B) fibroblasts , human preadipocytes (D) as well as HUH 7 (E) 
and C2C12 (F) cell lines were cultured in absence or presence of different concentrations of AZT (6µM 
and 180µM) or vehicle (black column). 3H-thymidine incorporation assay demonstrated antiproliferative 
effect of AZT on all the cell lines as well as on the primary human fibroblasts and preadipocytes 
suggesting that this effect is not restricted to species, tissue or cell line specificity and could be expected 
in an in vivo system. The effect was readily observed at physiological concentrations (6µM) and was 
strikingly persuasive at higher concentrations (180µM). Values are the mean ± SEM of eight experiments. 
* p<0.05, ** p<0.01.versus control. 
 
 
 
Figure 15. Effect of AZT on cell proliferation measured through total cellular protein 
Equal number of 3T3-L1 preadipocytes were cultured in the presence of AZT (180µM), d4T (90µm), ddC 
(3µM), or vehicle (black column). Cells were then sonicated and total cellular protein measured at days 2, 
3, and 4. AZT affected the amount of total cellular protein in a progressive way speaking for an inhibition 
of cell proliferation. Values are the mean ± SEM of five experiments. * p<0.05, ** p<0.01.versus control. 
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5.2.4 Effects of AZT on adipogenic marker expression. A comprehensive 
examination of the effects of AZT on adipogenic transcription factors expression in 
3T3-L1 adipocytes was undertaken. We addressed the hypotheses that AZT inhibits 
differentiation-associated expression of these markers. Preadipocytes were induced to 
differentiate in the absence or presence of different concentrations of AZT (6µM and 
180µM), rapamycin and TNF-α. mRNA was isolated every second day starting from 
day +1 of the differentiation protocol. The mRNA was reverse transcribed and Real-
Time PCR analysis performed to assess expression levels of several transcription factors 
involved in a cascade during preadipocyte differentiation (Figure A). Increase in 
C/EBPβ expression starts from day one and peaks by day 2 (Figure A). To determine 
the very early effect of AZT on C/EBPβ induction before its complete effect on clonal 
expansion we measured C/EBPβ mRNA expression levels at day +1. Neither the 
cultures with AZT nor our positive control with TNF-α, showed statistically significant 
alteration in the expression of this factor at this time point under our experimental 
conditions (Figure 16). Expression levels of the adipogenic transcription factors PPARγ 
and C/EBPα after clonal expansion at days +3 and +5 respectively were markedly lower 
in AZT-treated cultures when compared to those in vehicle-treated ones (Figure 16). 
When considered together our Real-Time PCR analyses indicate that AZT treatment 
induces disruption of the expression patterns of the two main adipogenic factors 
C/EBPα and PPARγ, which expression normally picks after the successful completion 
of clonal expansion (Figure A). Our results are in line with a recent studies revealing 
trends towards reduced expression of adipogenic markers in 3T3-L1 and 3T3-F442A 
cell lines (349;403). The differentiation process, as measured by TG accumulation and 
expression pattern of adipogenic transcription factors, was disrupted by AZT. Similar 
results were obtained with rapamycin and TNF-α (Figure 16). 
 
5.2.5 Impaired differentiation is confirmed by decrease in adipokines 
expression and secretion. As we observed a decrease in the expression of C/EPBα 
during AZT incubation we decided to assess whether it affects the expression of 
downstream factors such as adiponectin, as C/EPBα is a key transcription factor for the 
complete activation of the expression of adiponectin gene in mature adipocytes through 
interaction with response elements in the intronic enhancer (404). At day +9 of the 
differentiation program there was a significant reduction in the expression and 
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production of adiponectin which is normally expressed by mature adipocytes and is a 
marker of successful differentiation and complete maturation (Figure 3). 
 
 
 
Figure 16. Molecular analysis of adipocyte differentiation 
The panels reflect the effects of high concentration of AZT (180µM), Rapamycin (10nM) and TNF-α 
(250pM) on the expression of the important factors of differentiation: C/EBPβ (A), PPARγ (B) and 
C/EBPα (C) in differentiating 3T3-L1. Preadipocytes were cultured in the presence of vehicle (black 
column) or the indicated drugs from day 0, induced to differentiate on day 0 and differentiated until day + 
9. Total RNA was isolated at days +1 (for C/EBPβ), +3 (for PPARγ) and +5 (for C/EBPα), reverse 
transcribed and expression levels measured with Real-Time PCR. Like in the morphological analysis 
(Figure 1), AZT led to significant impairment of C/EBPα and PPARγ expression at high drug 
concentrations. Values are the mean ± SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
 
5.2.6 AZT effect on adipocyte viability. At first we examined AZT effects on the 
viability of 3T3-L1, which were maintained in a nondifferentiated state. Preadipocytes 
cultured for 21 days in the presence of AZT (6µM) demonstrate neither morphological 
difference nor different trypan blue staining in comparison to vehicle treated ones. 
These results indicated that long-term AZT (6µM) treatment did not significantly affect 
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the viability of 3T3-L1 preadipocytes. Similar results were obtained even when we 
increased the AZT concentration up to 180µM for a period of 21 days. To confirm 
whether this lack of cell toxicity is something restricted to the cell line model we used, 
we incubated primary human fibroblasts for 42 days with 180µM and found no major 
cell death (Figure 17B). It appears that the observed changes in proliferation and 
differentiation are not due to the cellular toxicity of the drug as 3T3-L1 retained normal 
fibroblast morphology and were viable even after 21 days under supraphysiological 
concentrations. As apoptosis of subcutaneous adipocyte from lipodystrophic HAART 
treated patients has been reported (351), we tried to determine whether AZT induces 
signs of apoptosis in 3T3-L1 adipocytes. At first experiments with trypan blue dye 
exclusion were performed in order to determine whether differentiating adipocytes 
remain viable after AZT treatment. Exposure of differentiating adipocytes to high AZT 
concentrations during and after initiation of differentiation indicated no significant 
effect on cell viability and although 50% of the detached cells appeared to be dead as a 
percent of the total cell population we found only a slight increase in cell death in 
comparison to control (Figure 17A), which is unlikely to account for any of the other 
effects observed. Therefore we concluded that although high doses of AZT affect 3T3-
L1 proliferation and differentiation they have no effect on cell viability over the 
differentiation changes. Annexin V/ Propidium iodide staining demonstrated apoptosis 
levels which were in accordance with trypan blue staining. 
 
 
 
Figure 17. Effect of AZT on cell viability 
Primary human and 3T3-L1fibroblasts were cultured in the presence of AZT (180µM) or vehicle (black 
column) for 42 and 21 days respectively. Both cultures demonstrated only slight increase in cell death. 
Values are the mean ± SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
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5.3 Adipocyte viability and function but not preadipocyte differentiation is 
compromised by IDV 
 
5.3.1 IDV affects adipocyte mass but does not affect differentiation-
dependent accumulation of TG. The rates of preadipocyte differentiation and 
adipocyte loss as well as adipocyte size determine adipose tissue mass. Alteration in any 
of these processes may in theory bring changes in adipose tissue mass. 3T3-L1 
preadipocyte differentiation is induced by hormonal mixture (see the Introduction and 
Figure A) and appropriate culture conditions and they undergo specific pattern of gene 
expression and assume adipocyte characteristics like accumulation of cytoplasmic TG. 
We conducted experiments to determine whether the protease inhibitor IDV affects this 
process. Preadipocyte differentiation was induced as described above (see Methods). 
Drug incubation was initiated at days:-10,-5, 0, 8, adipocytes were exposed to different 
concentrations of IDV (5-100µM).  Adipocytes were treated with vehicle or drug. Every 
second day of the experimental protocol, cells were stained with Oil Red O. Adipocytes 
exposed to IDV retained less Oil Red O then vehicle-treated cells. That was more an 
effect of decreased cell number leading to decrease in total cytoplasmic TG per culture 
flask than decrease in total cytoplasmic TG per cell (Figure 18). This effect was most 
pronounced in adipocytes treated with higher doses of IDV. Cells incubated with low 
doses IDV did not appear to differ from vehicle-treated ones. The number of TG 
droplets per cell did not differ between adipocytes exposed to IDV and vehicle-treated 
ones, but in the treated cultures there were many patches devoid of cells (Figure 18). 
Thus the inhibitory effect of IDV on adipocyte differentiation was not observed in any 
of the experimental conditions. In the incubations with high IDV concentrations an 
increase in the number of floating cells was observed. A big proportions of these 
floating cells were dead.  In contrast, adipocytes exposed to vehicle were present in a 
continuous monolayer and were well attached to the culture dish (Figure 18). 
 
5.3.2 IDV does not affect mitotic clonal expansion. The initial cascade of gene 
induction and the critical mitotic clonal expansion are the main steps in determining 
adipogenesis. The clonal expansion takes place within the first three days of the 
differentiation program.  
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Figure 18. Adipocyte differentiation after exposure to IDV 
3T3-L1 adipocyte phenotype (unstained and Oil Red O stained cells) at day 9 after initiation of 
differentiation in the presence of IDV (100µM) or control. 3T3-L1 cells in the both IDV treated and 
control cultures have acquired a mature phenotype with round shape and multiple lipid droplets. IDV 
exposed cultures present neither decreased numbers of TG droplets nor increased numbers of non-
differentiated cells. The only difference compared to control is some patches devoid of cells. 
 
After expanding preadipocytes exit the cell cycle and the continuing adipogenic gene 
expression leads to the acquisition of adipocyte characteristics. Therefore, it was of 
interest to determine whether IDV treatment affects mitotic clonal expansion. 
Preadipocytes were induced to differentiate in the absence or presence of different 
concentrations of IDV (30 and 100 µM) and IDV incubation started at different time 
points: days -10, -5, 0 and starting at day 0 cell number was determined. Cell number 
was also determined from cultures of confluent preadipocytes which were not induced 
to differentiate, but were maintained in the absence or presence of IDV for an identical 
period of time. The cell numbers of preadipocytes not induced to differentiate, in the 
presence IDV or vehicle were similar. Cell number increased almost 3-fold in vehicle-
treated differentiating preadipocytes, corresponding to roughly approximately two 
rounds of mitosis (Figure 19). A similar expansion of cell numbers was observed also in 
preadipocytes induced to differentiate in the presence of IDV (Figure 19). At high IDV 
concentration the cell numbers were lower in comparison to control, but this was more a 
result of initial cell loss on day 1, followed by unaffected clonal expansion. The number 
of cells present under differentiating conditions with and without IDV has increased in 
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comparison to confluent preadipocytes that were not induced to differentiate. Therefore, 
it appears that IDV does not significantly affect the mitotic clonal expansion phase of 
preadipocyte differentiation despite its effects on cell viability. 
 
 
 
Figure 19. Effect of IDV on clonal expansion 
Preadipocytes were differentiated in the presence of IDV (30 and 100µM) or vehicle (black column) and 
cell numbers were counted every day till day +9. IDV leads to significant reduction in cell numbers on 
day +1, which seems to be preserved during the clonal expansion. Significant reduction in cell numbers 
after IDV exposure was evident also at therapeutic drug concentrations. Values are the mean ± SEM of 
five experiments. * p<0.05, ** p<0.01.versus control. 
 
5.3.3 Effects of IDV on adipogenic marker expression. Effects of IDV on 
adipogenic transcription factor expression in 3T3-L1 adipocytes were examined in 
details. The probable inhibitory effect of IDV on differentiation-associated expression 
was addressed.  Preadipocytes were induced to differentiate in the absence or presence 
of different concentrations of IDV (30 and 100µM) starting incubation at different time 
points: days -10,-5, 0 and mRNA was isolated every second day starting from day –1 of 
the differentiation protocol. To assess the expression levels of several markers involved 
in preadipocyte differentiation mRNA was reverse transcribed and Real-Time PCR 
analysis performed (Figure 20). The drug did not affect LPL expression in one day post 
confluent cells (Figure 20 A).  C/EBPβ mRNA expression levels at days +1 were similar 
in vehicle and IDV-treated cells demonstrating that IDV did not affect early induction of 
C/EBPβ (Figure 20 B). When compared to vehicle-treated cells IDV treated cells did not 
demonstrate different expression levels of the adipogenic transcription factors C/EBPα 
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and PPARγ (Figure 20 C and D). When considered together, our Real-Time PCR 
analyses indicate that IDV treatment does not disrupt the transcription factor cascade 
(C/EBPβ, C/EBPα, PPARγ) associated with preadipocyte differentiation (Figure 20). In 
other words, the differentiation process, as measured by the expression of adipogenic 
factors and by TG accumulation, was not disrupted by IDV. TNF-α a well known 
inhibitor of 3T3-L1 differentiation was used as a positive control for inhibition of 
adipogenic markers expression (Figure 21). 
 
Figure 20 Molecular analysis of adipocyte differentiation 
The panels reflect the effects of therapeutic (30µM) and high (100µM) IDV concentration on the 
expression of the important early and late factors of differentiation Lipoprotein lipase (LPL) (A), C/EBP 
β (B), PPARγ (C) and C/EBP α ( D) in differentiating 3T3-L1. Preadipocytes were cultured in the 
presence of vehicle (black column) or the indicated drugs from day -10, -5 and 0, induced to differentiate 
on day 0 and differentiated until day + 9. Total RNA was isolated on days -1, +1, +3, +5, reverse 
transcribed and expression levels measured with Real time PCR. Like in the morphological analysis 
(Figure 18), IDV had no significant effect on LPL, C/EBPβ, C/EBPα and PPARγ expression at both 
concentrations and in all time courses of incubation. Values are the mean ± SEM of three experiments. * 
p<0.05, ** p<0.01.versus control. 
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Figure 21. TNF-α as a positive control for inhibition of differentiation 
The panels reflect the effects of (250pM) TNF-α on the expression of the important late factors of 
differentiation PPARγ (A) and C/EBP α (B) in differentiating 3T3-L1. Preadipocytes were cultured in the 
presence of vehicle (black column) or TNF-α from day 0, induced to differentiate on day 0 and 
differentiated until day + 9. Total RNA was isolated on days +3, +5, reverse transcribed and expression 
levels measured with Real-Time PCR. TNF-α had significant effect on C/EBPα and PPARγ expression. 
Values are the mean ± SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
 
5.3.4 IDV perturbs adipocyte function. Although differentiation was not 
significantly affected at day +9 there was a significant reduction in the expression of 
adiponectin as evidence for impaired adipocyte function (Figure 22). To separate this 
effect of IDV from the differentiation processes we incubated fully differentiated 
adipocytes for 9 days and found that adiponectin expression was also decreased 
although not to the same extend like in cell at day +9 of differentiation protocol (Figure 
22).  
 
5.3.5 IDV promotes loss of adipocyte viability. In the first set of experiments, 
we examined IDV effect on the proliferation and viability of 3T3-L1, maintained in a 
nondifferentiated state. Short-term (24h) IDV (30 and 100µM) treatment affected 
neither the proliferation nor the viability of 3T3-L1. Even after 10 days of culture in the 
presence of 100µM IDV preadipocytes looked morphologically similar to vehicle 
treated ones and did not show differences in terms of trypan blue staining. The cell 
number was similar at confluence in both untreated and treated cells. These results 
suggest that neither short nor long-term IDV (up to 100µM) treatment affect growth and 
viability of 3T3-L1 preadipocytes. As 3T3-L1 preadipocytes proliferation was normal in 
preconfluence and during clonal expansion (Figure 19), and they maintained normal 
fibroblast morphology in the presence of IDV we can conclude that IDV is not generally 
toxic to them. These results correspond to earlier report by another group (347). 
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Samples from HIV-infected patients with lipodystrophy demonstrate subcutaneous 
adipocyte apoptosis (351). We therefore performed experiments to determine whether 
IDV induces signs of apoptosis in 3T3-L1 adipocytes by trypan blue dye exclusion 
experiments. When exposed to high doses of IDV during and after initiation of 
differentiation adipocytes exhibited trypan blue staining in comparison with vehicle 
treated cultures which exhibited little or no trypan blue staining, indicating that a part of 
the cells were either dead or dying. Therefore, high doses of IDV induce extensive loss 
of cell viability over a differentiation changes and in differentiated adipocytes 
eventually indicating that IDV induces cell death only after preadipocytes have been 
initiated to differentiate into adipocytes. Hoechst/ Propidium iodide staining 
demonstrate results in accordance with trypan blue staining.  
 
Figure 22. Effect of IDV on adiponectin production 
Preadipocytes were differentiated in the presence of IDV (100µM) and (30µm) or vehicle (black column) 
and at day +7 and +9 culture medium supernatant (A and B) or adipocytes (C and D) assessed for 
adiponectin by ELISA or mRNA. Another bunch of preadipocytes designated (diff) were differentiated 
prior to 9 days of IDV incubation and subjected to the same analysis. IDV leads to significantly reduced 
adiponectin release into the culture medium (after adjustment for cell numbers) no matter whether cells 
were differentiated prior or during the drug incubation. Significant reduction in adiponectin production 
after IDV exposure was evident also at therapeutic drug concentrations as confirmed by ELISA (A and 
B). Values are the mean ± SEM of three experiments. * p<0.05, ** p<0.01.versus control. 
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5.3.6 In vivo analyse of HAART on adiponectin production. After analyzing 
the AZT and d4T effects on adiponectin release in culture we wished to confirm these 
observations in vivo. We analyzed the frozen serum samples of 12 randomly selected 
HIV-patients from our outpatient clinic before and mean 9 months after initiation of 
HIV-therapy consisting of AZT, 3TC and IDV for levels of adiponectin. Interestingly, 
we found a reduction in adiponectin levels in all but one patient leading to a significant 
overall reduction of mean adiponectin values (7.3 µg/ml versus 5.4 µg/ml) after start of 
therapy and before clinical evidence for lipodystrophy (Figure 23). 
 
 
Figure 23. Adiponectin levels in patients before and after start of AZT, 3TC and IDV therapy 
Frozen serum samples from randomly selected patients receiving the same antiretroviral regimen were 
assessed for adiponectin levels before and mean 9 months after start of therapy. In all but one patient 
(dotted line) we observed a decrease in serum adiponectin levels leading to an overall significant 
reduction. 
 
5.4 Lipoatrophy and ubiquitous mtDNA depletion in mice following long-term 
NRTI traement 
6.4.1 Effects of AZT and d4T on fat amount and distribution in treated mice. 
The ex vivo determination of body fat mass and distribution was performed by 
dissection and macroscopic examination of different fat depots. Mice treated for 15 
weeks with therapeutic d4T or AZT doses similar to those used in humans presented fat 
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atrophy in axillary and inguinal subcutaneous fad pads as well as marked reduction in 
intra-abdominal fat.  
 
Figure 24. NRTI induced atrophy in murine model 
Effect of 15 weeks d4T (B and E) and AZT (C and F) or vehicle (A and D) treatment on axillary (A,B and 
C) and inguinal (D,E and F) fad pads. Arrows show the regions with fat depletion. Each picture is 
representative from 14 pictures per group. 
 
 
 
Figure 25. Effect of d4T and AZT on the body weight acquisition in C57BL/6 mice 
Over a time period of 15 weeks mice receiving d4T or AZT gained less weight (d4T 3.5 ± 0.3g; AZT 4.1 
± 0.4g) as compared to control animals (8.6 ± 0.5g). Values are the mean ± SEM of 17 to 20 mice per 
group. * p<0.05, ** p<0.01.versus control. 
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5.4.2 Effect of d4T and AZT on of body weight acquisition, in young male 
C57BL/6 mice. We assessed the acquisition of body mass in young male C57BL/6 
mice during 15 week treatment with pharmacological drug levels of d4T and AZT 
(Figure 25). A substantial increase in body weight was observed in mice treated with 
vehicle, but this increase was significantly attenuated in d4T and AZT treated mice 
(Figure 25). 
 
5.4.3 Effect of d4T and AZT on water and food consumption. Given the 
evident effect on body weight acquisition (Figure 25) and on both peripheral and central 
fat (Figure 24) that we observed after d4T and AZT treatment we wanted to assess 
whether this was due to differences in water and food consumption. We compared the 
weekly consumption of food and the 72h consumption of water during the treatment 
period and calculated the average daily consumption per mouse (Figure 26). 
 
 
 
Figure 26. Effect of d4T and AZT on the average daily water and food consumption 
d4T and AZT treatment resulted in no difference in daily water and food consumption. These results 
demonstrate that these drugs impair body weight acquisition without an effect on water and food intake. 
 
5.4.4 Effects of therapeutic drug levels d4T on mtDNA content in different 
tissues. MtDNA depletion has been proposed to be an important factor leading to 
peripheral lipoatrophy in HIV-patients receiving antiretroviral therapy and this factor 
could have accounted for the profound lipoatrophy observed in our murine model 
(Figure 24). We therefore wanted to evaluate the effect of therapeutic d4T levels on 
mtDNA content in subcutaneous fat. Tissue samples were taken from subcutaneous fat, 
liver, heart, muscle and brain, DNA isolated and mtDNA quantified using Real-Time 
PCR. Analysis of mtDNA content revealed that 5 months of treatment with therapeutic 
d4T levels caused depletion of mtDNA in organs including the brain (-20%) and fat 
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tissue (-27%; Figure 27 E and A), but the most profound and significant depletion was 
evident in muscle (-56%), liver (-64%), and heart (-45%, Figure 27 D, B, and C). 
Together with the results of the macroscopic examination, these experiments provide 
evidence that d4T exerts a wasting effect on subcutaneous fat with only limited effect 
on mtDNA content. These data expand earlier observations reported by Fromenty et al 
(405) and indicate that mtDNA depletion is an unspecific event during treatment with 
thymidine-analogues. 
 
 
Figure 27. Effect of d4T on mtDNA content of various mouse organs and tissues 
MtDNA content of subcutaneous fat, liver, heart, muscle and brain of 5 months treated mice with 
therapeutic drug levels d4T. Groups of mice were treated with d4T or vehicle (4 mice per group) for up to 
5 months with daily human doses adjusted for murine body surface area. The figure demonstrates 
tendency for depletion of mtDNA in organs such as brain (E) and fat tissue (A) and significant depletion 
in muscle (D), liver (B), and heart (C). Values are the mean ± SEM of four mice per group. * p<0.05, ** 
p<0.01.versus control. 
 
5.4.5 Effect of d4T on adipokine production. As adipose mass has been 
associated with adipokine production (406), and some studies reported decreased serum 
adiponectin in a murine model of lipoatrophy (407), we next examined blood 
adiponectin and leptin concentrations. The analysis of adipokine levels in mouse serum 
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revealed that d4T significantly reduced adiponectin production with an effect on leptin 
production as well (Figure A and B). 
 
Figure 28. Effect of a d4T on plasma leptin and adiponectin levels in C57BL/6 mice 
We measured plasma leptin and adiponectin in control and treated mice. Plasma adiponectin was 
significantly decreased by d4T (A). Leptin levels showed a decrease as well although statistically 
insignificant (B). Values are the mean ± SEM of 4 mice per group. * p<0.05, ** p<0.01.versus control. 
 
5.4.6 Effect of AZT and d4T on mouse insulin sensitivity. As disturbances in 
glucose homeostasis often accompany fat redistribution in HAART treated patients 
(149;365) we next wanted to assess whether decreased subcutaneous fat in our murine 
model (Figure 24) is accompanied by alteration in insulin sensitivity. After 15 weeks of 
NRTI treatment the GTT in mice did not demonstrate significant differences in plasma 
glucose levels of treated and control animals after the glucose challenge (Figure 29). 
 
 
Figure 29. Glucose tolerance test 
Mice were fasted for 18 hours with free access to drinking water. Then mice were challenged intra-
peritoneally with a glucose load of 1.5 g glucose/kg body weight. Blood glucose measurements were 
performed before injection and at 30, 60 and 120 minute after the injection. Values are the mean ± SEM 
and quartiles of 10 mice per group. 
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6 DISCUSSION 
 
Mitochondrial involvement has been suspected in the pathogenesis of HIV-
associated lipodystrophy. Several studies have shown decrease in mtDNA levels in 
subcutaneous adipose tissue in lipoatrophic patients taking NRTI (85;408). This 
depletion has been proposed to contribute to the pathogenesis of HIV lipodystrophy, 
although extent and specificity of this effect remain unknown. If indeed mtDNA 
depletion was a crucial pathogenetic factor we would expect the activity of complexes I, 
III, IV and V of the respiratory chain to be significantly reduced since they are partially 
encoded by mitochondrial genes.  
Adipose tissue has a very high plasticity potential. Its mass depends on the rate of 
preadipocyte proliferation and differentiation, adipocyte loss, and adipocyte size. 
Alterations in any of these processes can result in adipose tissue dys-/atrophy or 
hypertrophy (74;188;193;409). Using the 3T3-L1 cell line to study the effects of NRTI 
on the various differentiation forms of adipose tissue cells, we were able to show that 
mitochondrial toxicity as determined by mtDNA depletion depends on cell proliferation 
and cell differentiation. AZT and d4T were chosen as they have been most closely 
related to lipoatrophy and ddC has been shown to be one of the most powerful drugs 
leading to mtDNA depletion in cell culture systems (25;410). Significant mtDNA 
reduction occurred only if adipocytes were exposed to d4T or ddC before and during the 
differentiation process. Fully matured adipocytes, however, were resistant to mtDNA 
depletion showing even increased values for mtDNA content. The latter could reflect a 
compensatory responses in order to offset eventual cellular dysfunction (50;88). 
Similarly, growth arrested confluent preadipocytes showed no alteration in mtDNA 
after exposure to the NRTI tested. Our data imply that factors potentially promoting 
preadipocyte differentiation including insulin, cortisol or adipocyte cell death (observed 
in vitro and in vivo in association with protease inhibitor exposure (18;146;351;411) 
would render adipose tissue more susceptible to mtDNA depletion. We suspect that the 
mitochondrial proliferation during cell division and differentiation combined with an 
increased demand for energy supply during cell proliferation leads to a raised sensitivity 
for mtDNA depletion induced by d4T and ddC. Considering this, our data may have 
implications for HIV-therapy during pregnancy where proliferation-dependent NRTI-
toxicity could be of particular relevance (412;413). On the other hand, AZT had some 
effect on preadipocyte differentiation leading to decreased numbers of differentiated 
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cells, reduced lipid droplet accumulation and premature cell detachment as described by 
others (349). Our results using AZT concentration at around Cmax are in line with a 
recent study revealing no obvious morphological changes of fully mature 3T3-L1 cells, 
only a trend towards reduced markers of adipogenesis (CEBPβ, PPARγ), and no 
alteration in gene expression after differentiation in the presence of d4T (10µM) or ddC 
(0.2µM) (403). Given a known antiproliferative effect of AZT and the requirement of 
clonal expansion of preadipocytes for effective differentiation (338) we speculate that 
this mechanism contributes to impaired adipogenesis associated with AZT treatment. 
Although, to our knowledge, our study is the first to analyze mtDNA depletion in 
cultured adipocytes at different developmental stages, we were unable to quantitate any 
functional impairment of cell function solely due to mtDNA depletion. Several reports 
have indicated ddC to be a potent inhibitor of mitochondrial DNA polymerase-γ and 
mtDNA replication in other cell lines including hepatocytes (353;410;414). 
Surprisingly, we found ddC leading to mtDNA depletion only in proliferating 
preadipocytes but not differentiating adipocytes even at concentrations 30 times above 
Cmax values. In contrast, a recent study revealed a significant effect of ddC on 
mitochondrial mass and membrane potential measurements in the 3T3-F442A 
adipocytes cell line in vitro (349). Since mtDNA was not assessed in that study, this 
discrepancy may be due to differences in origins of cell lines or indicate mitochondrial 
dysfunction independent of mtDNA depletion.  
Efficient uptake and metabolisation of d4T and AZT within 3T3-L1 adipocytes 
have been shown as both are phosphorylated to their mono-, di-, and triphosphate 
anabolites with phosphate anabolites being the major intracellular component of AZT 
compared to the parent being the main component of d4T (350). Using therapeutic drug 
concentrations these authors did not detect any impairment in adipocyte function or 
viability, partially confirming our results.  
More importantly, however, our data argue that despite the significant mtDNA 
depletion after d4T incubation, 3T3-L1 adipocytes are able to differentiate and maintain 
central functions like fat storage. MtDNA depletion was not associated with impairment 
of the respiratory chain function as measured by individual enzymatic complex 
activities. Instead, there was even some evidence for an increased activity of complexes 
I and IV in AZT treated cell which could reflect a compensatory response to other 
mechanisms of mitochondrial toxicity or impaired energy production (89). Although 
there are numerous studies demonstrating an effect of NRTI therapy on mtDNA content 
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in various tissues, there are less data demonstrating this depletion as a relevant cause for 
mitochondrial and adipocyte dysfunction. This association, however, is relevant for the 
understanding of the pathogenesis of lipoatrophy as already pointed out by Brinkman et 
al (49) and is also crucial for therapeutic consequences. For example, interventions 
aimed to increase mtDNA levels might fail to improve subcutaneous fat loss, others, 
like uridine that improve peripheral fat content, may have no significant effect on 
mtDNA content. Thus, using a sensitive functional assay, our data provide evidence that 
severe mtDNA depletion might coexist with normal mitochondrial function and 
macroscopic integrity of adipocytes in vitro, at least for the time studied here. It is, 
however, reasonable to speculate that in vivo additional factors like the HIV-infection 
itself (59;415) or hepatitis C infection (57) could potentially exacerbate any effect on 
mitochondria and further decrease the mtDNA content. In HIV-patients other organs 
that are heavily depending on mitochondrial integrity including the liver and heart could 
be more susceptible to mtDNA depletion and resulting toxicity.  
The question arises what other effects of NRTI could lead to adipocyte 
dysfunction? Although we cannot exclude other mechanisms than mtDNA depletion 
leading to mitochondrial toxicity, our studies also emphasize the critical influence of 
AZT and d4T on adiponectin production. These effects were observed already at 
concentrations around therapeutic Cmax levels where no mtDNA depletion was 
detectable. Both NRTI have been often associated with the development of lipoatrophy. 
Impairment of pyruvatedehydrogenase activity as well as compromised fatty acid 
oxidation may be other factors contributing to cell dysfunction. Some studies reported 
decreased serum adiponectin in a murine model of lipoatrophy (407) or demonstrated 
that adiponectin levels are significantly lower in a sample of HIV-infected subjects with 
fat redistribution caused by HAART (416). In our experiments, adipocytes 
differentiated in the presence of around Cmax concentrations for d4T and AZT secreted 
significant less adiponectin while ddC had no effect. These data extend studies with 
3T3-L1 cells that did not address adiponectin production but revealed no effect of NRTI 
on adipogenesis, lipolysis, or protein synthesis (350). More recently, similar results 
have been published in a study using microarray analysis that revealed reduced 
adiponectin expression after treatment of 3T3-L1 cells with AZT+3TC (403). We 
speculate that loss off adiponectin could be a significant step in the development of 
lipoatrophy associated with NRTI treatment. Consequently, administration of 
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adiponectin might be a therapeutic option for improving IR and fat redistribution in 
HIV-infected patients in the future (169;407;417;418). 
Some important limitations of our study have to be considered. Employing a 
culture system aims at the principle evaluation of cellular mechanisms. Another benefit 
is to study cell differentiation under well characterized and standardized experimental 
conditions. Direct extrapolation to the human in vivo situation, however, is limited 
because of significant differences in time course of drug concentration (plasma levels of 
NRTI show a short half live time), time of drug exposure, cellular uptake and 
phosphorylation, and lack of secondary factors like cytokines and viral infection. 
Confirming the main results in primary preadipocyte culture give us a chance to exclude 
possible species-specific differences in enzymatic activity for drug-phosphorylation or 
dependency of adipocyte function on mtDNA content. This is relevant considering 
earlier observations that failed to find mitochondrial toxicity in animal models prior to 
clinical trail that later revealed fatal liver failure due to mitochondrial damage in 
humans (419). On the other hand, human therapeutic drug concentration may not be 
sufficient to generate a phenotype in vitro an therefore we chose drug levels of about 
Cmax values observed in HIV-patients and 30 time higher concentrations to allow for 
phenotypic changes during culture. Other systems like the murine 3T3-F442A 
adipocytes require even reduction (e.g. AZT) to enable experiments with NRTI because 
of cellular toxicity (349). Finally, although we extended the cell culture time up to 2 
months some long term toxicities might remain undetectable in vitro.  
In summary, our results suggest that adipocyte proliferation and/or differentiation 
is required for mtDNA depletion. Individual drugs may have distinct impact on 
preadipocytes and mature adipocytes and mtDNA depletion appears to be a poor 
predictor for mitochondrial dysfunction in our adipocyte cell model. However, the half 
life of respiratory chain complexes may be longer and reduced activities of respiratory 
chain complexes may develop later in cell life. Finally, we provide evidence that NRTI 
directly impair adipocyte function by reducing adiponectin production. These data have 
important implication of the understanding and treatment of the HIV-therapy associated 
lipodystrophy syndrome. 
The present study suggests that AZT may contribute to alteration in several of the 
processes determining adipocyte mass. In our fat ‘tissue’ model AZT contributes to 
atrophy through reduction of preadipocyte proliferation rate and inhibition of clonal 
expansion rate ultimately resulting in inhibition of the overall differentiation capacity. 
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It is believed that in both primary preadipocytes and preadipose cell lines, 
differentiation requires growth arrest (232). Preadipose cell lines undergo one or two 
rounds of DNA replication and cell division after growth arrest (232). It has been shown 
that inhibition of DNA synthesis at this stage inhibits the differentiation into fat cells 
(236-238). The drug rapamycin is able to inhibit the process of clonal expansion (402). 
This inhibition interferes with the subsequent adipocyte differentiation confirming the 
critical role of clonal expansion in 3T3-L1 differentiation model. Although primary 
human preadipocytes do enter the differentiation process after being isolated even 
without cell division (239) it is considered that these cells may have already undergone 
this critical cell division in vivo. A detailed analysis of the anti-adipogenic effects of 
AZT was performed in an attempt to identify potential mechanisms. Two families of 
transcription factors, C/EBPs and PPARs, involved in terminal differentiation by 
transactivation of adipocyte-specific genes, are induced early during adipocyte 
differentiation. After hormonal induction of differentiation expression of PPARγ 
becomes detectable around the second day, and peaks in mature adipocytes (246;250). 
PPARγ expression is preceded by a transient increase in the expression of C/EBPβ and 
C/EBPδ isoforms (246-248). C/EPBα is the next key player in adipocyte differentiation 
(242;246;248;251). Constitutive expression of C/EPBα alone induces 3T3-L1 cells 
differentiation (420;421). AZT appears to be able to inhibit preadipocyte differentiation 
at the point of mitotic clonal expansion most likely through inhibition of the early S 
phase, with subsequent effects on the cascade of differentiation markers C/EBPα, 
PPARγ expression. C/EBPβ activates the expression of both the C/EBPα and PPARγ 
genes during preadipocyte differentiation through the C/EBP regulatory elements in 
their promoter regions (422-424). Although C/EBPβ expression was not affected, we 
wish to emphasize the fact that C/EBPβ expression starts within 4h after the induction 
of adipocyte differentiation, but at this point this transcription factor is unable to bind to 
the C/EBP regulatory element in the C/EBPα promoter. Only when preadipocytes enter 
S phase at the beginning of mitotic clonal expansion, C/EBPβ begin to acquire the 
capacity to bind to the C/EBP regulatory element and concomitantly become centromere 
associated (425). Eventual effect on the above mentioned processes could account for 
the observed decrease in the expression of C/EBPα and PPARγ without detectable 
decrease in the C/EBPβ expression. Therefore, most likely a mechanism where AZT 
prevents the normal differentiation dependent expression of C/EBPα and PPARγ by 
 112
antagonizing the clonal expansion in connection with/or without C/EBPβ could be 
suggested. Although differentiation was impaired microscopically (acquisition of 
adipocyte morphology) and estimated through TG accumulation a mechanism where 
AZT may perturb molecular pathways, independent of but additional mechanisms to 
C/EBPβ, C/EBPα and PPARγ expression cannot be excluded.  
C/EPBα is expressed just before the transcription of most adipocyte-specific genes 
initiate. The promoters of adipocyte genes, like GLUT-4, leptin, adiponectin and the 
insulin receptor bind C/EPBα in order to be transactivated. In this case down-regulation 
in the expression of adipocyte secreted factor adiponectin is additional confirmation for 
impaired and incomplete differentiation. Adiponectin levels in HIV-infected men with 
lipodystrophy are approximately 50% of those without lipodystrophy, and 25% of those 
in uninfected controls (369). Adiponectin correlates with insulin sensitivity 
(369;416;426;427) and dystrophic fat demonstrates reduced expression of this adipocyte 
specific marker (151). 
Cell viability was slightly affected and only after long incubation and very high 
drug concentrations. Annexin V/ Propidium iodide staining demonstrated insignificant 
contribution of AZT treatment to level of apoptosis observed in control cultures. The 
molecular mechanism responsible for the anti-adipogenic effects of AZT is not known. 
MtDNA depletion has been suggested but in this model such depletion has not been 
observed even at highest concentrations and such an explanation would not explain the 
normal differentiation in presence of drugs like d4T and ddC, which are much stronger 
mtDNA depleters. Recent studies demonstrated that the presence of AZT inhibits the 
phosphorylation of dThd by TK2 suggesting that mitochondrial toxicity of some NRTI 
in adipocytes may be due to the depletion of normal mitochondrial dNTP pools (428). 
Whether or not such a mechanism can account for the observed inhibition remains to be 
shown. We conclude from our studies that AZT has strong influence on the proliferation 
capacity of primary human and 3T3-L1 fibroblasts as well as on human preadipocytes 
(Figure 14). In 3T3-L1 model it affects the differentiation process through inhibition of 
the critical clonal expansion. In vivo drug effect will be also determined by differential 
drug concentrations and drug penetration the site of action. 
In order to evaluate how PI affect preadipocyte proliferation, differentiation and 
the rate of adipocyte loss and adipocyte size, we examined the effect of IDV. Many in 
vitro studies prior to ours suggested that IDV inhibits differentiation process (38;347). 
The present study suggests that IDV may contribute to alteration in the mass of adipose 
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tissue. Data obtained from our murine adipocyte in vitro model, however, would not 
supprot that IDV contributes to atrophy by reducing preadipocyte proliferation rate or 
inhibiting clonal expansion rate with ultimate inhibition of the overall differentiation 
capacity. Our investigation into the mechanism of IDV contribution to the development 
of lipodystrophy syndrome suggests that IDV may promote adipocyte cell death and 
disturbance of the process of replacement of lost adipocytes through reduction of the 
viability of preadipocytes undertaking differentiation. Evidence for these effects were 
observe already at physiological concentrations and at concentration higher than those 
observed in plasma from patients treated with therapeutic doses of IDV. Considering the 
much shorter effect on adipocyte depletion in our model, it is possible that the effects of 
IDV on the 3T3-L1 cell line observed in vitro may also occur in vivo in a longer period. 
Our attempt to determine the eventual antiadipogenic effects of IDV, as confirmed by 
other in vitro studies (347), lead to the observation that IDV does not impair 
preadipocyte differentiation, the expression of the cascade of differentiation markers 
(C/EBPβ, C/EBPα, PPARγ) and mitotic clonal expansion. These results are in 
accordance with recently reported lack of effect of IDV on adipogenic transcription 
factors expression in healthy HIV-negative volunteers after four weeks IDV treatment 
(48). 
As we have already mentioned, C/EBPβ is known to activate the expression of 
both the C/EBPα and PPARγ in the process of preadipocyte differentiation through 
C/EBP regulatory elements in their promoter regions (342;423;424). In this regard we 
exclude a potential mechanism where IDV prevents the standard differentiation 
dependent expression of C/EBPα and PPARγ by eventual interference with C/EBPβ 
function.  
Differentiating 3T3-L1 preadipocytes exhibited a continuous loss in cell number 
(Figure 19) and demonstrated increased trypan blue staining after treatment with IDV. 
Surprisingly such an effect was restricted to differentiating 3T3-L1 preadipocytes, and 
in the absence of differentiation stimulus these precursors proliferated normally in the 
presence of IDV and showed no signs of cell death even when drug exposure was 
extended to up to 15 days. It is tempting to speculate that some cellular or molecular 
changes occur during differentiation and sensitize adipocytes to IDV-induced cell death. 
Down-regulation in the expression of adipokines such as adiponectin could be 
interpreted as either impaired adipocyte function or eventual induction of processes 
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leading to dedifferentiation. However, we believe that dedifferentiation alone is an 
unlikely scenario as there was a substantial percent of dead or dying adipocytes after 20 
days of IDV exposure. Although some degree of dedifferentiation can not be definitely 
excluded, the primary response of adipocytes to IDV appears to be their loss of cell 
viability and function (as hinted by the decrease in adiponectin expression and secretion 
(Figure 22). Hoechst/ Propidium iodide staining was in accordance with the results from 
trypan blue staining, and both methods demonstrated a clear loss of adipocyte viability 
in response to IDV. When considered together, there is a clear difference in the effects 
of IDV on proliferating and differentiating 3T3-L1 preadipocytes as well as on mature 
adipocytes. Although hypothesised by others (347) the precise molecular mechanism of 
IDV antiadipogenic effects is currently unknown. Inhibition of glucose transport has 
been demonstrated to cause apoptosis in some cell lines in in vitro experiments (429). In 
this regard it is important to note that IDV and RTV were found to inhibit insulin-
stimulated glucose uptake in 3T3-L1 adipocytes and the proposed mechanism was 
interference with the function of GLUT4 (342). Another interesting fact is the indirect 
inhibition of glucose uptake in obese (ob/ob) mice following antibody-mediated insulin 
depletion and the consequent adipose-specific cell death (195). Thus, IDV-dependent 
impairment of GLUT4 function and inhibition of insulin sensitizing by adiponectin in 
3T3-L1 adipocytes may provide a mechanistic explanation for the cell death. With this 
mechanism, it would be easy to explain the observation that IDV had significant effect 
on 3T3-L1 adipocyte viability under our experimental conditions. However, recent new 
results surprisingly demonstrated increased glucose uptake from subcutaneous adipose 
tissue (SAT) from lipoathrophic patients on a PI based regimen (367). This observation 
contradicts hypotheses in which lipoatrophy is induced through PI blocked insulin-
stimulated glucose uptake in adipose tissue. Alternatively, this increased glucose uptake 
in subcutaneous fat of lipoatrophic patients may even compensate for the fat loss and 
may reflect compensatory use of other glucose transporter (e.g. GLUT-1). Whatever the 
mechanism of IDV-induced inhibition of 3T3-L1 cell viability, common mechanism for 
PI-associated adipose tissue abnormalities could be applied to some other PI as a 
simplest explanation. Our initial studies with other PI (obtained form tablets) revealed 
some effects similar to those elicited by IDV. For example, RTV (30µM) significantly 
reduced the amount of cytoplasmic TG in 3T3-L1 adipocytes as measured by Oil Red O 
staining, with an effect on cell viability even stronger than that of IDV. Future studies 
are necessary in order to address the particular mechanisms and to examine the 
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hypothesis that PI-induced antagonism of adiponectin production is responsible for 
some of the symptoms of lipodystrophy syndrome. We conclude from our studies that 
IDV and perhaps other PI are able to affect cell viability of the 3T3-L1 cell line model 
of differentiation. Although we determined only the effect of IDV, different reports 
associate almost all PI with lipodystrophy syndrome in treated patients (430). In vivo 
drug effect will depend on differential drug concentrations and on the eventual rate of 
drug penetration at the site of action. The aetiology of lipodystrophy syndrome appears 
to be mutlifactorial, reflecting the effect of drug treatment to numerous biochemical 
pathways. The in vivo relevance concerning the in vitro effect of IDV on adipocyte 
differentiation has been recently confirmed by a study reporting lack of effect of IDV on 
adipogenic transcription factors expression in healthy HIV-negative volunteers after 
four weeks IDV treatment (48). Our findings do not exclude eventual atrophic effects of 
IDV on subcutaneous adipose tissue in relation to metabolic abnormalities. Additional 
in vitro and in vivo research will be necessary to test hypothetical mechanisms and to 
acquire a more complete understanding of the factors and mechanisms leading to the 
development of lipodystrophy syndrome. 
In HIV-associated lipodystrophy, the group of NRTI has been predominantly 
associated with the development of lipoatrophy (3;28). Several studies have shown 
decreased mtDNA levels in subcutaneous adipose tissue in lipoatrophic patients taking 
NRTI (85;408). This depletion has been proposed to contribute to the pathogenesis of 
HIV lipoathrophy, although extent and specificity of this effect remain unknown and 
definite prove for a unique role of mtDNA depletion in lipoatrophy is lacking (348). If 
indeed mtDNA depletion were a crucial pathogenetic factor we would expect this 
depletion to accompany the atrophy of adipose tissue. Our results demonstrated that 
both d4T and AZT are able to attenuate the acquisition of body fat mass in C57BL/6 
mice despite of similar water and food consumption in treated and control mice (Figure 
25 and 26). This effect was clearly observable after 15 weeks treatment with a daily 
dose corresponding to the human therapeutic dose and after macroscopic examination 
was predominantly contributed to atrophy of fat tissue. Interestingly these alterations 
occurred without significant depletion of mtDNA content in subcutaneous fat (Figure 
27A). 
Insulin resistance and impaired glucose tolerance are among the major metabolic 
abnormalities in HAART-lipodystrophy syndrome (362;363). Even diabetes has been 
reported in association with the therapy (149). Disturbances in glucose homeostasis very 
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often accompany fat redistribution in HAART-treated patients (149;365). Although a 
recent study demonstrated increased glucose uptake by subcutaneous adipose tissue 
(SAT) from lipoathrophic patients on a PI based regimen (367), it is generally believed 
that in situations of HAART-induced lipodystrophy, insulin resistance correlates with 
decrease in subcutaneous and increase in intra abdominal fat (368;369), and there are 
plenty of studies confirming such correlation (149;368;370;372;431). Even genetic 
forms of lipoatrophy (Beradinelli-Seip syndrome) present with insulin resistance (348). 
Under our experimental conditions the NRTI-induced atrophy of peripheral fat was not 
associated with altered insulin sensitivity (Figure 29) and would thus argue for only 
minimal contribution of NRTI to peripheral insulin resistance. It remains possible that 
this could be different in humans if one considers a more variable genetic background 
and different caloric intake, which are known factors to have an influence on peripheral 
insulin sensitivity. 
Plasma adiponectin, has been shown to inversely correlate with insulin sensitivity 
(432). Some studies reported decreased serum adiponectin in a murine model of 
lipoatrophy (407) or demonstrated that adiponectin levels are significantly lower in a 
sample of HIV-infected subjects with fat redistribution caused by HAART (416). Our 
results demonstrated that d4T is able to decrease adiponectin levels in C57BL/6 mice 
despite the similar insulin sensitivity in treated and control mice. We speculate that 
under these experimental conditions, NRTI reduce adiponectin production either 
directly through impairment of adipocyte function or indirectly through reduction of 
adipokine producing fat. It is highly probable that the effect on adipokine production 
comes from pure lack of adipocytes as we detected decrease in blood leptin which 
normally correlates well with the mass of adipose tissue (406). In the settings of HIV-
associated lipodystrophy, plasma levels of leptin have been found to be decreased as 
well (433). In summary, our murine model of lipodystrophy demonstrates that 15 weeks 
treatment with a therapeutic dose of AZT and d4T attenuates the acquisition of body fat 
mass, without significant effect on adipocyte mtDNA content and without alteration in 
insulin sensitivity. These results complement earlier study by Fromenty et al. where the 
authors used a much sorter period of treatment (6 week) and were unable to detect 
differences in body weight acquisition in d4T treated mice (405). These data have 
important implication of the understanding of the mechanism of HIV-therapy associated 
lipodystrophy syndrome suggesting that, besides mtDNA depletion in subcutaneous fat, 
other mechanisms could play a role in the development of this lipoatrophy. 
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In summary we propose that NRTI deplete with different potency mtDNA in vitro 
in our adipocyte models and in vivo in our murine model. NRTI induced mtDNA 
depletion is an unspecific event during treatment with thymidine-analogues as it 
occurred in almost all the cell lines and tissues analysed. The level of NRTI induced 
mtDNA depletion depends on the adipocyte developmental stage. Functionally, mtDNA 
depletion even with an extend up to 80% from the original does not correlate with 
detectable impairment of the respiratory chain enzyme activity and mitochondrial 
potential, neither does it correlate with detectable alterations in processes such as cell 
proliferation and differentiation in our adipocyte cell lines and primary cultures. In a 
search for the mechanism of NRTI antiadipogenic effects, AZT has been found to 
inhibit adipogenic differentiation of 3T3-L1 cells through inhibition of the critical step 
of clonal expansion. On the other hand IDV has been found to affect adipocyte viability 
and function without any detectable effect on preadipocyte differentiation. Some NRTI 
and PI are capable of affecting adiponectin expression and secretion in vitro and in vivo 
(patients and mice). 
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